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Summary 
CCX-CKR is an atypical chemokine receptor for the homeostatic chemokines CCL19, CCL21 
and CCL25. CCL19 and CCL21 are also ligands for CCR7 and are crucial for the induction of 
antigen specific immunity and tolerance, whereas CCL25 is the sole ligand for CCR9 and is 
involved in the recruitment of immune effector cells to the small intestine. CCX-CKR does 
not signal after binding its ligands, as determined by a failure to induce the rapid increase in 
intracellular calcium that is typical of G-protein mediated signalling. CCX-CKR also does not 
become desensitised to chemokine binding and therefore is proposed to act as a scavenger 
receptor that can regulate the activity of CCR7 and CCR9 by affecting the availability of their 
ligands in vivo. At the time of starting my project, there were no published reports describing 
the  biological  function  of  CCX-CKR  in  vivo  and  the  principal  aim  of  my  thesis  was  to 
characterise  the  immune  system  of  the  recently  generated  CCX-CKR  KO  mouse  with 
particular  focus  on  the  intestinal  immune  compartment  where  all  three  of  the  chemokine 
ligands are expressed.  
 
Firstly,  as  described  in  Chapter  3,  I  analysed  the  cellular  composition  of  the  secondary 
lymphoid  organs  of  CCX-CKR  KO  mice.  These  studies  revealed  normal  proportions  and 
absolute  numbers  of  lymphocytes,  CD11c
+  dendritic  cells  (DC),  macrophages  and  natural 
killer (NK) cells in the absence of CCX-CKR. The proliferative responses of lymphocytes to 
mitogenic  or  TCR  stimulation  in  vitro  were  also  normal,  although  there  was  a  decreased 
production  of  IFN!  by  CD4
+  T  cells  from  CCX-CKR  KO  mice.  Although  most  of  the 
phenotypic subsets of conventional DC were present in comparable numbers in the mesenteric 
lymph nodes (MLN) of CCX-CKR KO and WT mice, there was a consistent and dramatic 
reduction in the numbers of CD11c
loPDCA-1
+ plasmacytoid DC (pDC) in CCX-CKR KO 
MLN. In parallel, fewer CD11c
loB220
+ cells from CCX-CKR KO MLN than WT expressed 
CCR9,  despite  this  marker  being  expressed  normally  by  lymphocytes  in  these  mice.  The 
proportions of pDC in CCX-CKR KO inguinal lymph nodes (ILN) were also significantly 
reduced compared to WT and pDC from CCX-CKR KO MLN, ILN and spleen all appeared to 
express higher levels of class II MHC than WT pDC. These data suggest that CCX-CKR may 
play an important role in the recruitment and/or survival of pDC in the LN and that in its 
absence, pDC in secondary lymphoid organs may have a more mature phenotype. 
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In Chapter 4, I examined the cellularity of the intestinal immune compartment in resting CCX-
CKR KO mice, as well as the effects of Flt3L administration in vivo. Although CCX-CKR KO 
mice  displayed  no  histological  abnormalities  in  their  small  intestinal  architecture  and  had 
normal numbers of T cells in the lamina propria, they did have significantly reduced numbers 
of intra-epithelial lymphocytes (IEL) as well as decreased proportions of CD19
+ B cells and 
increased proportions of CD11c
+ cells in the lamina propria compared with WT mice. The 
proportions and absolute numbers of CD103
+ DC were normal in the lamina propria and MLN 
of CCX-CKR KO mice, suggesting that CCX-CKR has little to no role in regulating DC 
migration from the lamina propria to the MLN, a process that is critically dependent on CCR7. 
Although the proportions and absolute numbers of B cells and CD11c
+ cells were normal in 
CCX-CKR KO Peyer’s patches (PP), there were significantly decreased proportions of pDC 
compared with WT PP. In vivo treatment of CCX-CKR KO mice with the DC differentiation 
factor Flt3L, expanded CD11c
+ DC numbers dramatically in both CCX-CKR KO and WT 
small  intestinal  lamina  propria,  ILN,  spleen,  MLN  and  PP.  Although  Flt3L  abolished  the 
apparent defects in pDC populations in the ILN and PP, this was not the case for CCX-CKR 
KO MLN, which remained significantly deficient in pDC compared to WT MLN. Work in 
Chapter 6 examined parallel effects in the blood and bone marrow. 
 
As the CCX-CKR ligands CCL19 and CCL21 are involved in the development of all adaptive 
immune responses, and together with the other CCX-CKR ligand, CCL25, orchestrate immune 
responses to antigen encountered in the gut, I next investigated the development of antigen 
specific immunity and tolerance in CCX-CKR KO mice. There were no significant differences 
in  systemic  immune  responses  to  subcutaneous  immunisation  with  ovalbumin  (OVA) 
emulsified in complete Freunds adjuvant (CFA) between CCX-CKR KO and WT mice when 
assessed in vivo or in vitro. However, the development of oral tolerance in CCX-CKR KO 
mice was impaired, with no suppression of OVA specific delayed type hypersensitivity (DTH) 
responses or of serum OVA specific IgG2a as was seen in WT mice. In parallel with defective 
systemic tolerance after feeding OVA, CCX-CKR KO mice appeared to be more susceptible 
to priming of systemic and local antibody responses after feeding OVA with cholera toxin 
(CT) as a mucosal adjuvant. In addition, there was some evidence of priming of OVA specific 
antibody responses in CCX-CKR KO mice fed OVA alone, which was not seen in WT mice. 
Despite this evidence of abnormal mucosal immunity, CCX-CKR KO mice developed DSS 
colitis normally, with all indices of disease being identical in CCX-CKR KO and WT animals.   4 
Together,  these  data  suggest  that  there  are  selective  defects  in  the  regulation  of  antigen 
specific mucosal immune responses in the small intestine of CCX-CKR KO mice that may 
predispose these animals towards exaggerated active immune responses. 
 
Finally,  I  performed  some  preliminary  experiments  to  try  and  relate  DC  function  to  the 
immune dysregulation I observed in CCX-CKR KO mice and to explore the basis of the pDC 
defect in the MLN. Bone marrow derived and splenic DC from CCX-CKR KO mice showed a 
reduced ability to process and present intact protein antigens although endocytic activity was 
normal. MLN DC from normal and Flt3L treated CCX-CKR KO mice responded similarly to 
in  vitro  stimulation  with  the  synthetic  TLR7  agonist  R848,  showing  an  expansion  in  the 
numbers of CD11c
hiPDCA-1
+ cells that nearly all expressed CD40 and CD86. In addition, in 
vivo administration of R848 triggered identical migration of CD11c
hiclassIIMHC
hiCD103
+ DC 
into  the  MLN  of  CCX-CKR  KO  and  WT  mice,  suggesting  that  lamina  propria  pDC  can 
effectively  mobilise  local  DC  to  the  MLN  in  the  absence  of  CCX-CKR.  There  were  no 
differences in the proportions or absolute numbers of pDC in the liver of CCX-CKR KO and 
WT  mice  despite  the  fact  that  liver  pDC  have  been  implicated  in  other  studies  of  oral 
tolerance. Although the proportions of pDC were normal in the bone marrow of resting and 
Flt3L treated CCX-CKR KO mice, there did appear to be a defective recruitment of Flt3L 
expanded pDC into the blood of these animals. I used an adoptive transfer approach to study 
the in vivo localisation of pDC into lymphoid organs and although these experiments were not 
entirely conclusive, they indicated that WT pDC could enter the MLN and other lymphoid 
tissues of CCX-CKR KO mice normally and that pDC from CCX-CKR KO mice may have a 
defect in their ability to enter WT MLN. 
 
Taken together, my data suggest that CCX-CKR is involved in the entry and/or survival of 
pDC in secondary lymphoid organs, a process that normally involves migration across high 
endothelial venules (HEV). This was associated with impaired oral tolerance induction and 
heightened  immune  responses  to  antigen  delivered  orally,  indicating  that  CCX-CKR 
contributes  to  the  regulation  of  mucosal  immunity  and  tolerance  by  an  as  yet  unclear 
mechanism.  Further  study  of  these  animals  will  hopefully  better  define  the  relationship 
between pDC and the regulation of mucosal immune responses.  
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Abbreviations 
 
The following abbreviations are used throughout this thesis: 
 
7-AAD    7-amino-actinomycin D 
APC     allophycocyanin 
APC      antigen presenting cells 
BM      bone marrow   
BMDC  bone marrow derived dendritic cells 
CCL       CC-chemokine ligand 
CCR     CC-chemokine receptor 
CCX-CKR   Chemocentryx chemokine receptor 
CD       cluster of differentiation 
cDC      conventional dendritic cell 
CFA      complete Freund’s adjuvant 
CMF-HBSS   calcium/magnesium free Hank’s buffered salt solution 
CP       cryptopatch 
Con A   Concanavalin A 
CXCL   CXC-chemokine ligand 
CXCR   CXC-chemokine receptor 
CX3CL   CX3C-chemokine ligand 
CX3CR   CX3C-chemokine receptor 
DAG     diacylglycerol 
DARC   Duffy antigen receptor for chemokines 
DC       dendritic cell 
DNA     deoxyribonucleic acid 
DP       double positive 
DSS      dextran sulphate sodium 
DTH     delayed type hypersensitivity 
EAE      experimental autoimmune encephalitis 
EDTA   ethylenediaminetetraacetic acid 
ELISA   enzyme-linked immunosorbent assay 
EMA    ethidium monoazide   17 
FACS    fluorescence activated cell sorting 
FAE      follicle associated epithelium 
FCS      foetal calf serum 
FDC      follicular dendritic cell 
FGF      fibroblast growth factor 
FITC    fluorescein isothiocyanate 
FRC      fibroblastic reticular cell 
FSC      forward scatter 
Flt3      FMS-like tyrosine kinase 3 
Flt3L    FMS-like tyrosine kinase 3 ligand 
GAG     glycosaminoglycan 
GALT   gastrointestinal associated lymphoid tissue 
GC       germinal centre 
GDP       guanosine diphosphate 
GM-CSF   granulocyte macrophage colony-stimulating factor 
GRK     G-protein coupled receptor kinase 
GTP      guanosine triphosphate 
HAO     heat aggregated ovalbumin 
HBSS    Hank’s buffered salt solution 
HEV     high endothelial venule 
IBD      inflammatory bowel disease 
IDO      indoleamine-2,3-deoxygenase 
IEL      intra-epithelial lymphocyte 
IFN      interferon 
Ig       immunoglobulin 
IL       interleukin 
ILF      isolated lymphoid follicle 
ILN      inguinal lymph node 
i.p.       intraperitoneal 
IP3        inositol triphosphate 
IRF      interferon regulatory factor 
i.v.       intravenous 
kD       kilodaltons   18 
KO       knock-out 
LN       lymph node 
LP       lamina propria 
LPS      lipopolysaccharide 
LT       lymphotoxin 
LTi       lymphoid tissue inducer 
LTin     lymphoid tissue initiator 
LTo      lymphoid tissue organiser 
M       microfold 
MACS   magnetically activated cell sorter 
MAPK   mitogen-activated protein kinase 
MFI      mean fluorescence intensity 
MHC    major histocompatibility complex 
MLN    mesenteric lymph node 
mRNA   messenger RNA 
NK       natural killer 
NKT     natural killer T  
OD       optical density 
OVA     ovalbumin 
PAMP   pathogen associated molecular pattern 
PBS      phosphate buffered solution 
PCR      polymerase chain reaction 
pDC      plasmacytoid dendritic cell 
PE       phycoerythrin 
PI3K     phosphatidylinositol biphosphate 
PIgR     polymeric immunoglobulin receptor 
PLC      phospholipase C 
plt/plt    paucity of lymph node T cells 
PMA     phorbol 12-myristate 13-acetate 
Poly I:C   polyinosinic-polycytidylic acid 
PP       Peyer’s patches 
PRR     pattern recognition receptor 
R848     resiquimod   19 
RA       retionic acid 
RALDH    retinaldehyde dehydrogenase 
RNA     ribonucleic acid 
RPMI    Roswell Park Memorial Institute-1640 medium 
RT-PCR   reverse transcriptase polymerase chain reaction 
SA       streptavidin 
SD       standard deviation 
SP       spleen 
SPF      specific pathogen free 
SSC      side scatter 
Tcm      central memory T cell 
TEC      thymic epithelial cell 
Tem      effector memory T cell 
TGF      transforming growth factor 
Tfh       follicular helper T cell 
Th1       T helper 1 
Th2       T helper 2 
Th17      T helper 17 
TLR      Toll-like receptor 
TMB     3,3,5,5-tetramethylbenzidine peroxides 
TNF      tumour necrosis factor 
TPA      12-O-tetradecanoylphorbol-13-acetate 
TSLP    thymic stromal lymphopoietin  
T reg    regulatory T cell 
SED      sub-epithelial dome 
VEGF   vascular endothelial growth factor 
WT      wild type 
XCL       XC-chemokine ligand 
XCR     XC-chemokine receptor 
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Introduction 
The  innate  and  adaptive  arms  of  the  immune  system  co-operate  to  discriminate  between 
harmless and pathogenic antigens, tolerating and eradicating them respectively. Our immune 
systems are in a constantly dynamic state, employing growth factors to nurture and develop, 
cytokines  to  activate  and  polarise,  and  chemotactic  molecules  to  guide  and  assemble 
leukocytes. Cells of the innate immune system respond to conserved microbial constituents 
and  products  of  tissue  damage,  whereas  lymphocytes  of  the  adaptive  immune  system 
recognise specific epitopes so that targeted immunity can be implemented.  
 
During an inflammatory immune response, antigen loaded dendritic cells (DC) are licensed at 
peripheral sites of infection and mature as they migrate via the afferent lymphatics to draining 
secondary lymphoid organs and alert circulating lymphocytes to the presence of their cognate 
antigen.  Activated  T  cells  and  plasmablasts  are  then  disseminated  to  the  original  site  of 
antigen  encounter  to  complement  the  innate  effector  mechanisms  already  in  place,  and 
memory T and B cells are generated to allow rapid antigen specific responses in the case of 
subsequent challenge.  At all stages of these responses, cells must be motile and receptive to 
the  directional  cues  provided  by  the  combinational  display  of  adhesion  molecules  and 
chemokines that allow their appropriate temporal and spatial positioning.  
 
Chemokines regulate leukocyte organisation under homeostatic basal conditions and direct 
their recruitment and activation during infection and inflammation. The differential expression 
of chemokines and their receptors contributes to the strategic positioning of cells within their 
particular niches and directly influences whether immunity or tolerance ensue. As a result, 
chemokines must be tightly regulated to ensure appropriate immune activation and tolerance. 
 
 
 
 
 
 
 
 
   22 
1.1 Chemokines – a superfamily of cytokines 
Chemokines are small proteins between 8 and12 kDa in size that are best known for their 
ability  to  induce  chemotaxis  of  leukocytes,  allowing  for  the  strategic  positioning  of  cells 
during immune responses. Their sequence homology is variable, but their tertiary structure is 
highly  conserved,  comprising  an  N-terminus  of  6-10  amino  acids  that  serves  as  a  crucial 
signalling domain (1). Most chemokines are secreted from the cell, with the exceptions of 
CX3CL1 and CXCL16 that can also be tethered to extracellular surfaces by mucin-like stalks 
(2,  3).  Chemokines  and  their  receptors  can  vary  dramatically  in  their  homology  between 
species,  suggesting  that  there  has  been  rapid  and  divergent  evolution,  and  reflecting  the 
ongoing “arms race” between hosts and their specific pathogens (3). Although best known as 
mediators of cell migration, chemokines are also involved in the processes of angiogenesis, 
fibrosis, cell proliferation and apoptosis (4). Chemokines can function as monomers, dimers, 
oligomers and even as hetero-oligomers, although oligomers appear to be needed to elicit cell 
migration, which is termed “haptotaxis” when movement is directional (1, 5). “Chemokinesis” 
is the random movement of cells in response to soluble chemokine, whereas “chemotaxis” is 
the directed movement of cells in response to chemokine gradients (6).  
 
Classification of chemokines  
The  recent  expansion  in  bioinformatics  and  gene  discovery  has  heralded  the  rapid 
characterisation  of  numerous  chemokines  and  their  receptors.  Such  a  boom  in  chemokine 
biology  called  for  a  consistency  in  their  nomenclature,  as  many  chemokines  have  several 
alternative names, often based on how they were originally defined functionally. Chemokines 
are now classified on the basis of the arrangement of four cysteine motifs in their amino acid 
sequence (2, 3). Approximately fifty chemokines have been characterised and they can be 
broadly categorized into four families. The CC chemokines (CCL1-28) comprise most of the 
chemokine superfamily and have the first two of their four cysteine molecules adjacent to each 
other. CXC chemokines (CXCL1-16) constitute the second family, and have a single amino 
acid between their first two cysteine residues. Three non conserved amino acids separate the 
first two cysteine residues of CX3CL1, the sole member of the third family of chemokines. C 
chemokines (XCL1 and hXCL2) lack one of the first two cysteine residues and comprise the 
fourth family (3, 4, 7). The chemokine family members are summarised in Table 1.1. 
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Table 1.1: Systematic nomenclature of chemokines  
CC Family 
Systematic Name 
Alternative Name(s)  Systematic Receptor Name(s) 
CCL1  (h)I-309 (m)TCA-3  CCR8 
CCL2  (h)MCP-1 (m)JE  CCR2 
CCL3  (h)MIP-1"  CCR1, CCR5 
CCL4  (h)MIP-1#  CCR5 
CCL5  (h)RANTES  CCR1, CCR3, CCR5 
mCCL6  (m)C10  CCR1 
CCL7  (h)MCP-3  CCR1, CCR2, CCR3, CCR5 
CCL8  (h)MCP-2  CCR3 
mCCL9  (m)MIP-1!  CCR1 
mCCL10  (m)MIP-1!  CCR1 
CCL11  Eotaxin  CCR3 
mCCL12  (m)MCP-5  CCR2 
hCCL13  (m)MCP-4  CCR2, CCR3 
hCCL14  (h)HCC-1  CCR1 
hCCL15  (h)HCC-2  CCR1, CCR3 
hCCL16  (h)HCC-4  CCR1, CCR2, CCR5 
CCL17  TARC  CCR4 
hCCL18  (h)DC-CK1/PARC  unknown 
CCL19  ELC/MIP-3#/exodus3  CCR7 
CCL20  MIP3"/LARC/exodus1  CCR6 
CCL21  SLC/6Ckine/exodus2  CCR7 
CCL22  (h)MDC (m) ABCD-1  CCR4 
hCCL23  (h)MPIF-1  CCR1 
CCL24  Eotaxin-2/MPIF-2  CCR3 
CCL25  TECK  CCR9 
hCCL26  (h)Eotaxin-3  CCR3 
CCL27  C-TACK (m)Eskine  CCR10 
CCL28  (h)MEC  CCR10 
 
C Family Systematic 
Name 
Alternative Name(s)  Systematic Receptor Name(s) 
XCL1  Lymphotactin/(h)SCM-1"   XCR1 
hXCL2  (h)SCM-1#  XCR1 
 
CX3C Systematic 
Name 
Alternative Name(s)  Systematic Receptor Name(s) 
CX3CL1  Fractalkine/ 
(m)Neurotactin 
CX3CR1 
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CXC Family 
Systematic Name 
Alternative Name(s)  Systematic Receptor Name(s) 
CXCL1  (h)GRO" (m)GRO/MIP-
2/KC  
CXCR1, CXCR2 
CXCL2  (h)GRO# (m)GRO/MIP-
2/KC  
CXCR2 
CXCL3  (h)GRO! (m)GRO/MIP-
2/KC  
CXCR2 
CXCL4  PF4  CXCR3B 
CXCL5  (h)ENA-78 (m)GCP-2/LIX  CXCR2 
CXCL6  GCP-2  CXCR1, CXCR2 
hCXCL7  (h)NAP-2  CXCR2 
hCXCL8  (h)IL-8  CXCR1, CXCR2 
CXCL9  Mig  CXCR3 
CXCL10  IP-10  CXCR3 
CXCL11  I-TAC  CXCR3, CXCR7 
CXCL12  SDF-1  CXCR4, CXCR7 
CXCL13  (h)BCA-1 (m)BLC  CXCR5 
CXCL14  BRAK (h)Bolekine  unknown 
mCXCL15  (m)Lungkine/WECHE  unknown 
CXCL16  SCYB16, SR-PSOX  CXCR6 
 
Preceded with (h) = applicable to humans only 
Preceded with (m) = applicable to mice only 
Not specified= applicable to both humans and mice 
 
 
Glycosaminoglycans (GAGs) bind and localise chemokines 
Most chemokines are produced as soluble molecules in vivo, although they are also found 
tethered to cell surface glycosaminoglycans (GAGs) that concentrate chemokines in localised 
areas and so help position cells bearing cognate chemokine receptors. GAGs are negatively 
charged polysaccharides attached to core proteins forming proteoglycans that interact with 
several circulating proteins. These are important in several complex processes such as blood 
coagulation  and  angiogenesis,  as  well  as  in  modulating  the  signalling  transduction  events 
involved in cell development and proliferation (8, 9). Their electrostatic interactions with basic 
chemokines mean that GAGs such as heparan sulphate present and immobilise proteins in 
defiance  of  the  shear  forces  found  in  blood  vessels,  allowing  for  the  local  retention  of 
chemokines and development of putative chemokine gradients in vivo (8). The importance of 
this strategic display of chemokines as directional cues for migrating cells is apparent from 
observations that mice deficient in GAGs or their oligermization show impaired migration of 
leukocytes, as well as an inability to trigger adhesion of leukocytes to vascular endothelium in 
response to chemokines (5, 10, 11).  
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Chemokines mediate leukocyte extravasation and migration in interstitial spaces 
The most familiar role of chemokines is to drive the movement of leukocytes out of blood 
vessels and through tissues. Leukocyte recruitment from the vasculature into lymphoid tissues 
is mediated via a multi-step sequential process involving selectin mediated rolling, chemokine 
dependent integrin activation, integrin induced arrest and cellular trans-migration across the 
endothelium (8, 12). This process is summarised in Figure 1.1. The co-ordinated efforts of 
selectins, chemokines and adhesion molecules can also result in tissue selectivity, depending 
on the combination and mode of molecules expressed (13). The essential role of chemokine 
receptors is emphasised by the fact that integrin activation, integrin mediated signalling and 
cellular extravasation can all be blocked using pertussis toxin to inhibit G-protein-signalling 
(14). Chemokine binding induces cytoskeletal rearrangements in responding cells via actin 
polymerisation that casues the formation of a polarised cellular morphology with chemokine 
receptor  expression  concentrated  at  the  leading  edge  (6,  15,  16).  This  accounts  for  the 
directional  movement  of  a  cell  towards  chemokine  and  triggers  a  series  of  co-ordinated 
integrin activations that propel the cell onwards (17, 18). The directional movement of cells in 
response to chemokines has been extensively documented in vitro although it is not yet clear 
whether true chemokine gradients exist in organised lymphoid tissues in vivo. Lymphocytes 
can negotiate these sites in the absence of any such gradient, using chemokine immobilised on 
fibroblastic  reticular  cells  (FRC)  as  a  scaffolding  to  guide  their  migration  (19-26). 
Nevertheless,  it  has  been  proposed  that  chemokine  gradients  may  prevail  at  sites  of 
inflammation, with evidence suggesting the formation of solid phase chemokine gradients on 
the GAGs of extracellular matrix of human rheumatoid synovium (27).    26 
 
 
Fig 1.1 Role of chemokines in the extravasation of lymphocytes 
Naïve circulating lymphocytes exit the blood via specialised high endothelial venules (HEV) 
into lymph nodes (LN) and Peyer’s patches (PP) in search of dendritic cells (DC) presenting 
their  cognate  antigen.  This  is  a  multi-step  process  beginning  with  selectin  mediated 
tethering that slows lymphocytes to roll along the endothelium. Rolling lymphocytes are 
activated via CCR7 by CCL19 and/or CCL21 presented by glycosaminoglycans (GAGs) on the 
luminal  surface  of  HEV.  This  induces  conformational  changes  in  lymphocyte  integrin 
molecules leading to their clustering in a high affinity state encouraging their firm arrest 
via  interactions  with  endothelial  expressed  intracellular  adhesion  molecule  1  (ICAM  1). 
Lymphocytes then undertake paracellular or transcellular translocation between or across 
endothelial  cells  respectively,  possibly  in  response  to  CCR7  ligands  within  the  awaiting 
parenchyma.  
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1.2 Chemokine receptors 
Chemokine  receptors  are  part  of  the  wider  family  of  G  protein  linked  coupled  receptors 
(GPCR).  GPCR  are  seven  trans-membrane  receptors  that  comprise  the  largest  family  of 
membrane  associated  receptors  to  have  been  characterised  and  are  involved  in  several 
physiological processes such as neurotransmission, blood pressure maintenance and smooth 
muscle contraction (1, 5, 28). Despite no obviously conserved structural signature, chemokine 
receptors show up to 80% sequence homology, suggesting a common ancestor. Chemokine 
receptors are 340 to 370 amino acids in length, have an acidic N-terminal segment and a 
cysteine residue in each of their four extracellular domains. The sequence DRYLAIVHA, or a 
variation of it, lies in the second intracellular loop and is essential for the signal transduction 
events following chemokine receptor ligation (2). 
 
In keeping with chemokine nomenclature, chemokine receptors are classified systematically 
based  on  the  chemokine  class  they  bind  followed  by  a  number.  Thus,  CXCR  bind  CXC 
chemokines, CCR bind CC chemokines, XCR1 binds the C chemokines XCL1 and hXCL2, 
and CX3CR1 binds CX3CL1 (3). 
 
Chemokine receptor signal transduction 
GPCR classically initiate signalling events via the activation of their associated G protein 
heterotrimer complexes that contain G", # and ! subunits. In the resting state, the G" subunit 
has  GDP  bound  rendering  the  G  protein  complex  inactive.  There  are  four  families  of  " 
subunits, G"s, G"q, G"i and G"12. Each family consists of several members, thus contributing 
to the complexity of chemokine receptor mediated signalling events. Chemotaxis is regulated 
primarily  via  the  G"i  sub-family  (29).  After  chemokine  receptor  ligation,  the  G"  subunit 
becomes phosphorylated, exchanges GDP for GTP and releases activated # and ! subunits 
which remain bound together. The targets of the now dissociated G protein components are 
usually enzymes or ion channels in the plasma membrane that ultimately lead to intracellular 
signalling events including activation of phosphatidylinositol 3-kinase (PI3K), phospholipase 
C  (PLC),  RAS  and  RHO  GTPases  and  the  mitogen-activated  protein  kinase  (MAPK) 
pathways. In the case of most chemokine receptors, these processes induce cytoskeletal re-
arrangement and migration (18). After signalling, the G" subunit then hydrolyses its bound 
GTP back to GDP and re-associates with the #! complex to re-form the inactive G protein   28 
heterotrimer ready for further stimulation (17). These signalling pathways are summarised in 
Figure 1.2. 
 
 
 
Fig 1.2 Schematic representation of chemokine receptor signalling cascades 
In a resting state (top) the G" subunit has GDP bound, rendering the G protein complex 
inactive. Chemokine binding (bottom) induces a conformational change, releasing the G" 
protein a n d  a l l o w i n g  t h e  t r a n s d u c t i o n  o f  s e v e r a l  s i g n a l l i n g  c a s c a d e s .  A r r o w s  i n d i c a t e  
downstream  target  signalling  pathways  that  culminate  in  integrin  activation,  actin 
polymerisation and cell migration (15, 17, 18, 30).  
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The chemokine system can be characterised as one of redundancy, with several chemokines 
within the same sub-class binding multiple chemokine receptors (2). Further complexity is 
generated by the ability of chemokine receptors to function as homodimers and heterodimers 
(5).  
 
Chemokine receptor desensitisation 
GPCR become de-sensitised after prolonged ligand interactions and re-sensitise to binding 
when denied ligand exposure. G protein coupled receptor kinases (GRK) contribute to this 
mechanism by recognizing the activated GPCR, binding to and phosphorylating it and creating 
an arrestin binding substrate. #-arrestin binding effectively silences the GPCR even in the 
presence of chemokine ligand stimulation and targets the GPCR for recycling to endocytic 
pathways  via  clathrin  coated  pits.  This  allows  for  receptor  degradation  or  re-sensitisation. 
Alternatively  or  in  addition,  arrestin  binding  can  initiate  additional  intracellular  signalling 
cascades independent of GPCR signalling events (28, 31). GRK themselves can also activate 
PI3K,  MAPK  and  the  Ezrin/Radexin/Moesin  cascades,  leading  to  cell  migration  events 
rivalling those induced by classical GPCR signalling (30). 
 
1.3 Homeostatic versus inflammatory chemokines 
Chemokines can be divided into two main functional groups. Those which co-ordinate cell 
trafficking throughout resting tissues and secondary lymphoid organs (homeostatic) and those 
which recruit cells to sites of inflammation (inflammatory) (12, 15). CCL19, CCL21, CXCL13 
and CCL25 are examples of chemokines that are expressed constitutively within lymphoid 
tissues. However, it is a misconception to assume that homeostatic chemokines simply keep 
things  “ticking  over”,  as  they  underpin  extremely  active  processes  that  determine  the 
development of the immune system and allow naïve lymphocytes to survey the enormous 
antigen  load  delivered  constantly  to  secondary  lymphoid  organs.  In  addition,  homeostatic 
chemokines direct tissue tropic effector cells back to the original sites of their cognate antigen 
encounter,  allowing  for  site  specific  and  targeted  immune  responses.  Inflammatory 
chemokines include CCL2, CCL3, CCL4 and CCL5.  They are inducible during inflammatory 
responses and serve to activate and direct effector cells to and within peripheral tissues. This 
division of chemokines into homeostatic and inflammatory groups is becoming less clear, as 
increasing  evidence  suggests  that  homeostatic  chemokines  such  as  CCL19,  CCL21  and 
CXCL13 can also be induced in peripheral tissues during inflammatory responses (32, 33).     30 
Homeostatic chemokines in thymus organisation 
CCR7 and its two ligands, CCL19 and CCL21, as well as CCR9 and its ligand CCL25 are 
involved at several stages of T cell development in the thymus. Proceedings begin after the 
CCR9 dependent entry of bone marrow derived haematopoietic precursors into the thymus via 
blood  vessels  in  the  cortico-medullary  junction  in  response  to  the  only  known  ligand  for 
CCR9, CCL25. These cells then migrate through the cortex to the sub-capsular zone as double 
negative (DN) CD4
-CD8
- thymocytes undergoing pre-T cell receptor mediated selection and 
maturing into double positive (DP) CD4
+CD8
+ cells (34-39). CCR7 and CCR9, along with 
CXCR4 and its ligand CXCL12, all appear to be involved in this outward migration, with 
CCR7 and CCR9 KO mice showing poor accumulation of DN thymocytes in the subcapsular 
zone (34, 40). At this point, DP thymocytes undergo positive selection by recognising self-
peptides  presented  in  MHC  molecules  on  cortical  thymic  epithelial  cells  (TEC),  before 
reversing their migration and returning to the cortico-medullary junction in response to CCL19 
and CCL21 expressed by TEC in the medulla (34, 41). Once in the medulla, the developing 
thymocytes are exposed to tissue specific self-antigens presented by DC and AIRE expressing 
TEC leading to the deletion of self-reactive T cells. The surviving T cells then become single 
positive (SP) and migrate from the medulla to peripheral lymphoid organs (34, 42, 43). The 
importance of CCR7 in these latter processes is shown by the lack of migration towards the 
medulla and failed negative selection in CCR7 KO mice and in paucity of lymph node T cell 
(plt/plt) mice that are deficient for CCL19 and CCL21-Ser (43-45). These effects may partly 
account for the spontaneous autoimmunity seen in CCR7 KO mice (34, 46). Interestingly, 
CCL19 KO mice show no defects in cellular composition and architecture of the thymus, 
suggesting that as CCL19 and CCL21 are not compartmentalised in their expression, CCL21 
may offer a compensatory role (12, 23).  
 
Homeostatic chemokines in secondary lymphoid organ development 
As well as organising cells within the thymus, homeostatic chemokines are also essential for 
the  positioning  of  the  progenitor  cells  that  establish  secondary  lymphoid  organs  during 
embryogenesis.  The  development  of  secondary  lymphoid  organs  occurs  through  the 
interactions between haematopoietic CD4
+CD3
-IL-7R"
+"4#7
+ lymphoid tissue inducer cells 
(LTi), and CD4
-CD3
-IL-7R"
-CD11c
- lymphoid tissue initiator (LTin) cells and mesenchymal 
lymphoid  tissue  organiser  (LTo)  cells  that  are  positioned  at  designated  sites  of  future 
lymphoid organ development. The homeostatic chemokines CCL19, CCL21 and the CXCR5   31 
ligand, CXCL13, attract LTi cells to these sites and promote their expression of lymphotoxin-
"# (LT"#) (47). The ligation of LT#R on mesenchymal cells by LT"# on LTi cells promotes 
the expression of the vascular addressins MAdCAM, VCAM-1 and PNAd as well as inducing 
further production of CCL19, CCL21 and CXCL13. These homeostatic chemokines recruit 
more LTi cells, as well as mature lymphocytes that are required to establish T and B cell zones 
within  secondary  lymphoid  organs.  In  addition  to  orchestrating  the  spatial  and  temporal 
positioning of LTi cells and lymphocytes, the CCR7 ligands CCL19 and CCL21 promote 
LT"# expression by both LTi and mature CD4
+ T cells, triggering further chemokine release 
by mesenchymal and stromal cells. This in turn recruits further LT"# producing cells and 
forms a powerful positive feedback loop that sustains lymphoid organ development (47). The 
importance of homeostatic chemokines in the development of secondary lymphoid organs is 
shown by findings that CXCL13 and CXCR5 KO mice fail to develop PP and most LN while 
CCL19 and CCL21 deficient plt/plt mice have small and poorly organised lymphoid organs 
(48-50).  
 
Inflammatory chemokines and innate immune responses  
Homeostatic  chemokines  regulate  the  development  of  secondary  lymphoid  organs  and  the 
thymic  differentiation  of  the  T  cells  that  populate  them,  providing  the  infrastructure  for 
antigen specific immunity. However, pathogenic organisms tend to invade at peripheral sites 
that  are  distant  from  these  specialised  lymphoid  structures.  Therefore  mechanisms  have 
evolved to alert lymphocytes in secondary lymphoid tissues to the presence of their cognate 
antigens in the periphery. The presence of invasive organisms at these peripheral sites induces 
local inflammatory responses that include chemokine production by stromal and parenchymal 
cells, recruiting innate effector cells from the blood as a first line of immune defence. These 
cells are alerted to the presence of microbes via activation of different families of conserved 
pathogen recognition receptors (PRR). Toll like receptors (TLR) comprise a major family of 
PRR and their activation results in the production of chemokines and inflammatory cytokines 
such as IL-1, TNF" and IL-6 that recruit and activate effector immune cells (15). Chemokines 
typically  produced  in  response  to  pathogens  include  the  ligands  of  CCR1,  CCR2,  CCR3, 
CCR5, CXCR2 and CXCR3 that recruit granulocytes, monocytes, DC, natural killer (NK) 
cells  and  effector  T  cells  to  their  source.  As  a  consequence,  mice  deficient  in  these 
chemokines  or  their  chemokine  receptors  are  often  compromised  in  their  immunity  to 
pathogens  (15,  51,  52).  The  inflammatory  chemokine  milieu  at  sites  of  infection  and   32 
inflammation can also play a role in polarising effector T cell responses, with CCL2 and 
CCL3  appearing  to  induce  Th1  and  Th2  differentiation  respectively  (15,  53,  54).  Innate 
immune responses of this kind are rapid, but are often aggressive and indiscriminate. The 
development of antigen specific adaptive immunity allows more targeted responses and is 
highly dependent on chemokines and other mediators produced during the innate response. 
  
Chemokines and DC in the link between innate and adaptive immunity  
One of the most important of these processes is the carriage of antigen by DC from the site of 
infection  to  the  naïve  lymphocytes  congregated  in  secondary  lymphoid  organs.  DC  are 
professional antigen presenting cells (APC) that are recruited to peripheral tissues from blood 
derived  precursors  by  inflammatory  chemokines.  Circulating  Ly6C
+CCR2
hiCX3CR1
lo 
monocytes recruited to inflamed tissues by the CCR2 ligand, CCL2, give rise to a variety of 
conventional DC (cDC) subsets (55). CCR2 expression by monocytes also facilitates their 
release  from  the  bone  marrow  during  inflammation  (56).  Immature  DC  express  the 
inflammatory chemokine receptors CCR1, CCR2, CCR5, CCR6, CXCR1 and CXCR2 and 
only moderate levels of class II MHC and co-stimulatory molecules (57). Some immature DC 
also  express  inflammatory  chemokine  receptors  particular  to  their  local  environment.  For 
instance immature CCR6
+ DC are recruited to Peyer’s patches (PP) and intestinal mucosa in 
response to CCL20 produced by epithelial cells under resting and inflamed conditions (58, 
59). When tissues are inflamed, resident DC secrete potent immune enhancing cytokines such 
as TNF", IL-6, IL-12 and IFN" to activate other innate effector cells including NK cells and 
natural killer T (NKT) cells. Activated DC then down-regulate their inflammatory chemokine 
receptors and tissue anchoring adhesion molecules such as E-cadherin, whilst concomitantly 
up-regulating CCR7. These processes promote their exit from tissues via afferent lymphatics 
towards  the  subcapsular  sinus  of  the  draining  LN  (60,  61).  In  parallel,  the  DC  mature, 
assuming a dendritic like morphology and up-regulating class II MHC and co-stimulatory 
molecule expression so that they may activate and polarise T cells upon their arrival in the LN. 
They  also  secrete  CCL19,  which  assists  in  their  differentiation  and  contributes  to  the 
recruitment of naïve T cells and further activate DC once they have arrived in the LN (62, 63).  
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1.4 Chemokines and the generation of adaptive immune responses 
Antigen  specific  immune  responses  are  initiated  in  secondary  lymphoid  organs  where 
lymphocytes are organised into a distinct T cell zone and B cell follicles under control of the 
CCR7 ligands, CCL19/CCL21 and the CXCR5 ligand, CXCL13. CCR7 and L-selectin co-
expression  on  naïve  lymphocytes  directs  their  entry  from  the  blood  via  specialised  high 
endothelial venules (HEV) which punctuate the T cell zone (58, 64, 65). NK, NKT and !$ T 
cells also co-express CCR7 and L-selectin suggesting that they too enter LN via HEV (65). 
The spleen is devoid of HEV and instead lymphocytes and DC enter the red pulp via terminal 
arterioles and migrate into the T cell zone of the white pulp via the marginal sinus (63, 64, 66). 
Interestingly, some T cells can access LN from peripheral tissues via the afferent lymphatics 
in a CCR7 dependent manner reminiscent of DC (67, 68). The LN of CCR7 KO mice are 
lymphopaenic and deficient in DC, and the T cell areas in all secondary lymphoid organs are 
grossly disrupted, emphasising the indispensable role for CCR7 and its ligands in leukocyte 
recruitment  to  and  positioning  within  these  structures  (40,  69).  Once  in  the  T  cell  zone, 
lymphocytes migrate around randomly under the control of CCL19 and CCL21 produced by 
radiation  resistant  stromal  cells  (58,  70).  Interestingly,  CCL21  protein  levels  are 
approximately 100 fold higher than of CCL19, and it remains to be clarified exactly why the 
two ligands for CCR7 are expressed together. However, this property is conserved across 
mammalian species, and so it would appear to be of biological importance (12, 66, 71). In 
mice there are two genetic variants of CCL21 distinguishable by the amino acid at position 65 
of their sequence. CCL21-Ser is expressed by HEV and fibroblastic reticular cells (FRC) in T 
cell areas of secondary lymphoid organs, whereas CCL21-Leu is restricted to the lymphatic 
vessels in non-lymphoid organs such as the lung, colon and skin (12). Whereas CCL21 is 
produced directly by cells lining the HEV, CCL19 is not, and instead it is transcytosed from 
the basolateral region to the luminal endothelial surface. As described above, the presentation 
of the CCR7 ligands, CCL19 and CCL21 on HEV facilitates lymphocyte trans-migration by 
enhancing the affinity state of endothelial integrins such as LFA-1 and triggering increases in 
the expression of integrin ligands on lymphocytes (63, 66, 72, 73). Unlike CCL19, CCL21 has 
a  long  C-terminal  tail  that  avidly  binds  to  GAGs,  in  particular  podoplanin  expressed  by 
lymphatic endothelial cells and reticular stromal cells. The expression of podoplanin might 
regulate  CCL21  availability  and  thus  contribute  to  the  kinetics  of  leukocyte  entry  into 
secondary lymphoid organs (12). The need for such regulation is emphasised by findings that   34 
transgenic over-expression of CCL21 correlates with a dramatic down-regulation of CCR7 on 
T cells and immune deficiency (74).  
 
CCL19 and CCL21 introduce naïve T cells to DC 
Naïve  lymphocytes  recirculate  continuously  between  the  blood  and  secondary  lymphoid 
organs in search of DC bearing their cognate antigen. T and B cells spend approximately 12-
18 and 24 hours respectively surveying any given secondary lymphoid organ and especially in 
the case of T cells, undertake a rapid and random migration guided by FRC under the control 
of CCR7 ligands. If unfulfilled in their search, lymphocytes exit LN and PP via the efferent 
lymph or from the spleen directly into the venous circulation. Efferent lymph collects in the 
thoracic  duct  and  then  returns  lymphocytes  to  the  blood  where  they  continue  their  re-
circulation and search for antigen (66, 75). As described above, activated DC loaded with 
antigen filter into the LN via the subcapsular sinus and then migrate deeper into the paracortex 
under the control of CCR7 ligands produced by and around the HEV. There the DC can greet 
as many T cells entering the LN as possible. As discussed above, DC within the paracortex 
produce CCL19 themselves, attracting even more DC and increasing the chances of any given 
lymphocyte to locate a DC bearing its cognate antigen (22, 76). The importance of CCL19 and 
CCL21 in this DC localisation is shown by findings that afferent lymph borne DC do not exit 
the sub-capsular sinus of CCL21-Ser and CCL19 deficient plt/plt mice and that CCR7 KO 
mice have reduced DC numbers in their LN paracortex, as well as defective development of 
antigen specific immunity and tolerance (69, 77, 78). T cells spend approximately 15 hours 
associated with DC presenting their cognate antigen, engaging co-stimulatory molecules and 
receiving signals from DC derived cytokines. CCL22 or CXCL16 secretion by DC maintains 
such  contacts  by  binding  to  recently  activated  T  cells  expressing  CCR4  or  CXCR6 
respectively (58).  
 
Adaptable expression of CXCR5 and CCR7 allow T and B cells to interact 
With adequate TCR affinity thresholds met, CD4
+ T cells proliferate and differentiate into 
effector Th1, Th2, Th17 or regulatory T cells (T regs), depending on the context of antigen 
presentation. A proportion of activated T cells migrates to the interface of the T and B cell 
zones  and  becomes  follicular  helper  T  cells  (Tfh)  that  interact  with  and  activate  B  cells 
possessing the same antigen specificity. Concurrently, naïve B cells encounter and internalise 
their  cognate  antigen  by  routes  that  remain  controversial,  but  may  involve  subcapsular   35 
macrophages, DC in the T cell dependent area or follicular dendritic cells (FDC) in the B cell 
follicles (79). The encounters between antigen specific T and B cells are prompted by the 
TCR-induced expression of CXCR5 and BCR-induced expression of CCR7, leading to the 
translocation of activated T and B cells to the boundary separating the CCL19/CCL21 rich T 
and CXCL13 rich B cell zones (63, 65). Up-regulation of CXCR5 accompanied by a down-
regulation of CCR7 allows CD4
+ T lymphocytes to enter B cell follicles and interact with B 
cells specific for the same antigen, presented as peptides on surface class II MHC molecules. 
As  the  B  cell  follicle  matures  into  a  germinal  centre  (GC),  the  production  of  IL-4  and 
expression of co-stimulatory molecules such as ICOS and CD40L by T helper cells drives the 
differentiation of a proportion of B cells into CXCR4 expressing plasmablasts that migrate in 
response to CXCL12 to the red pulp of the spleen or the medulla of LN and ultimately enter 
the bloodstream. In addition, T cell help drives the affinity maturation and class switching of 
plasmablasts  within  the  GC  so  that  high  affinity  antibody  can  be  produced  upon  their 
deployment to effector sites (66, 80). Other T cells differentiate into an effector phenotype in a 
process  accompanied  by  down-regulation  of  CCR7  and  concurrent  up-regulation  of  the 
inflammatory chemokine receptors CCR3, CCR5 and CXCR3, allowing for their recruitment 
to peripheral sites of inflammation (81). Activated T cells can also express tissue specific 
chemokine  receptors  and  adhesion  molecules,  guiding  the  effector  T  cells  to  the  site  of 
original antigen encounter. For instance, T cells activated in cutaneous draining LN acquire 
expression of CCR4 and CCR10 for which the ligands, CCL17 and CCL27 are expressed in 
the skin. Similarly, CCR9 expression is induced on T cells primed in the MLN, for which the 
ligand, CCL25 is produced in the small intestine (82) . The organisation of T and B cells in 
LN is briefly summarised in Fig 1.3. 
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Fig 1.3 Schematic representation of lymph node organisation 
The  LN  is  made  up  of  a  T  cell  zone  and  B  cell  follicles.  CCR7  expressing  lymphocytes 
arriving from the blood via the HEV move around the T cell zone rapidly using CCL19 and 
CCL21 immobilised on stromal cells and meet up with CCR7 expressing antigen loaded DC 
that have arrived via the afferent lymphatics. CCR7 expression is down-regulated by T cells 
upon their activation and a proportion of cells then up-regulate CXCR4 and migrate towards 
the  medulla  to  be  released  into  the  circulation.  Other  T  cells  up-regulate  CXCR5  and 
migrate to the T/B cell boundary in response to CXCL13 secreted by FDC and stromal cells. 
Here  they  become  Tfh  and  interact  with  CCR7  expressing  B  cells  activated  by  antigen 
presented on FDC. B cells that receive T cell help then differentiate into plasmablasts, up-
regulate CXCR4 and migrate to the medulla in response to CXCL12 for their release into the 
circulation.    37 
Chemokines and the development of immunological memory 
In addition to this immediate deployment of effector cells, a proportion of activated T and B 
cells contribute to immunological memory so that rapid responses to pathogen re-exposure can 
be implemented. Antigen specific memory T cells persist after the resolution of infection and 
can be divided into central memory (Tcm) and effector memory (Tem) subsets based on their 
differential expression of CCR7. Tcm express CCR7 and re-circulate throughout secondary 
lymphoid  organs  scanning  DC  for  the  presence  of  their  cognate  antigen,  so  that  upon 
secondary encounter they can provide a rapid source of fresh effector T cells (83, 84). The 
importance of CCR7 in this re-circulation is demonstrated by the impaired homing of Tcm to 
secondary lymphoid organs in CCR7 KO mice (85). In contrast, Tem do not express CCR7 
and so are denied access to secondary lymphoid organs. Instead, Tem express inflammatory 
chemokine  receptors  and  localise  preferentially  in  peripheral  tissues,  so  that  during  re-
infection they can activate local innate effector responses immediatey (86).  
 
Memory T cell responses are also complemented by memory B cell responses generating high 
affinity antibody quickly in the event of re-infection. As described, during adaptive immune 
responses, B cell follicles can develop into germinal centres (GC) that are split into CXCL12 
rich dark and CXCL13 rich light zones. Within GC, B cell derived centroblasts accumulate 
somatic mutations in their BCR affinity, driving affinity maturation and selection of B cells 
with high affinity and class switched BCR. Some of these B cells remain in the GC as memory 
cells, meaning that in the event of subsequent infection by the same pathogen, high affinity 
class  switched  antibody  is  available  rapidly  (77).  Class-switched  memory  B  cells  express 
CCR7, CXCR4, CXCR5 and CCR6 that are thought to assist in their recirculation between the 
blood and secondary lymphoid organs (87). In addition, long-lived plasma cells that have 
already undergone differentiation to produce high affinity class switched antibody, accumulate 
in the bone marrow so that they may maintain serum antibody levels. This persistence is 
thought to be dependent on CXCR4 expression by plasma cells (88).  
 
Chemokines and regulatory T cells 
The immune system is designed to be a formidable adversary for pathogens, but it is important 
to  remember  that  these  responses  also  need  to  be  regulated  to  ensure  resolution  of 
inflammation. In addition, tolerance has to be maintained against self-antigens and harmless 
antigens  such  commensal  organisms  and  foodstuffs.  Regulatory  T  cells  (T  regs)  are  key   38 
players in tolerance, suppressing immune responses through their secretion of the cytokines 
TGF# and IL-10, or by cell-cell contact dependent mechanisms. “Natural” T regs develop in 
the  thymus  under  control  of  the  forkhead  family  transcription  factor,  FoxP3  and  are 
FoxP3
+CD4
+CD25
+. Similar cells, known as “adaptive’ T regs can differentiate from naïve T 
cells in the periphery and these may be either FoxP3
+CD4
+CD25
+ or FoxP3
-CD4
+CD25
+ (89). 
Circulating T regs express CCR7 and although CCR7 deficient T regs are suppressive in vitro, 
they cannot function in vivo due to their inability to access LN via HEV (85, 90).  After 
encountering  antigen,  T  regs  express  a  variety  of  inflammatory  chemokine  receptors, 
including CCR1, CCR2, CCR4 and CCR5 allowing them to enter tissues and assist in the 
resolution of inflammation at peripheral sites (91).  
 
1.5 Dendritic cells shape immune responses 
As discussed above, DC are specialised APC, dedicated to sampling antigens in tissues and 
processing and presenting them as peptides in class II MHC molecules after migrating to meet 
T cells in draining secondary lymphoid organs. DC are the only APC that can do this and so 
provide the sole means of alerting naive T cells to the presence of their cognate antigen, DC 
also alert T cells to the presence of dangerous pathogenic organisms by up-regulating co-
stimulatory molecules in response to PRR activation. The co-expression of peptide bound 
MHC and co-stimulatory molecules induces antigen specific naïve T cells to undergo IL-2 
dependent clonal expansion. Although macrophages and B cells also express class II MHC 
and can process and present antigen with this molecule, DC are the only APC that can induce 
clonal expansion of naïve CD4
+ T cells directly. DC also instruct the development of the 
resultant effector T cells via the secretion of cytokines such as IL-12 and, IL-6 and IL-23 
which  instruct  Th1  and  Th17  type  responses  respectively  (89,  92).  IL-4  is  required  for  the 
polarisation of Th2 responses but as DC do not produce this cytokine themselves, its source is 
unclear although, basophils have been suggested (93, 94). Several subsets of DC have now 
been  characterised  based  on  their  surface  markers  and  anatomical  positioning  and  are 
summarised  in  Table  1.2  (55).  Broadly,  these  can  be  divided  into  conventional  and 
plasmacytoid  DC,  although  some  controversy  surrounds  the  division  of  tissue  resident 
mononuclear antigen sampling cells into conventional DC (cDC) and other CD11c expressing 
subsets such as activated macrophages (95, 96).  
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Table 1.2: DC subsets  
 
Differentiated  
DC Subset 
 
 
Cell Surface Marker Phenotype 
CD8"
+ DC  CD8"
+, class II MHC
+, CD11c
+, CD4
-, CD205
+ SIRP-1"
-  
pDC  B220
+, CD11c
lo, Ly6C
+, class II MHC
lo, CD4
-/+, CD8"
-/+, PDCA-1
+ 
Langerhan’s Cells  Langerin
+, class II MHC
+, Dectin-1
+, CD1a
+, CD11b
+, CD11c
+, 
CD24a
+, CD205
+, CD45
lo, CD8"
+/-, CD103
- 
Dermal DC 
(Langerin
+ subset) 
Langerin (CD207)
+, class II MHC
+, CD103
+, CD11b
lo, CD11c
int, 
CD45
hi, CD8"
- 
Dermal DC 
(Langerin
- subset) 
Langerin (CD207)
-, class II MHC
+, CD11c
+, CD4
-, DEC205 
(CD205)
+, CD24a
- 
CD8"
- DC  CD8"
-, class II MHC
+, CD11c
+, CD11b
+, CD4
-, SIRP-1"
+, DCIR2
+ 
CD8"
-CD4
+ DC  CD8"
-, CD4
+, CD11b
+, class II MHC
+, DCIR2
+ 
Lung DC 
Conducting airways  CD11b
hi, CD11c
+, CD103
- 
Lung interstitium  CD11b
lo, CD11c
+, CD103
+ 
Lamina propria DC 
  CD11c
int, CD11b
int, CD205
-, CD103
- 
CD11c
int, CD11b
+, CD205
-, CD103
- 
CD11c
hi, CD11b
-, CD205
+, CD103
+ 
CD11c
hi, CD11b
+, CD205
+, CD103
+ 
Peyer’s patch DC 
  CD11c
+ CD8"
- CD11b
- 
CD11c
+ CD8"
+ CD11b
- 
CD11c
+ CD8"
- CD11b
+ 
 
Conventional DC subsets 
DC develop from myeloid precursors in the bone marrow and in mice, all DC express CD11c 
integrin and class II MHC molecules to some extent. In mammalian species, several subsets of 
DC can be distinguished by their surface markers and cytokine secretion profiles and in mice 
there are two main subsets of conventional DC, CD8"
+ and CD8"
- (97). CD8"
- DC usually 
express CD11b and/or CD4 and are the principal DC found in non-lymphoid tissues. These are 
derived from myeloid precursors, are under control of the transcription factor IRF4 and seem 
to be closely related to monocytes. CD8"
- DC are proficient in the capture of antigens and in 
presenting them with class II MHC to CD4
+ T cells after migrating to LN (93, 98, 99). In 
contrast, CD8"
+ DC are generally found in the T cell zones of secondary lymphoid organs and 
were once believed to be derived from a lymphoid precursor. However, it is now clear that like 
CD8"
-CD11b
+ DC, CD8"
+ DC develop from a common myeloid precursor, but differ in that 
they are under the control of Batf3 and IRF8 transcription factors (100, 101). CD8"
+ DC are   40 
also thought to enter LN directly from the bloodstream via HEV and generally do not migrate 
from tissues in afferent lymph. Initial studies suggested that CD8"
+ DC and CD8"
-CD11b
+ 
DC primed different subsets of CD4
+ T cells, but it is now clear that they can both produce IL-
12 and other polarising mediators under appropriate circumstances (93, 99, 102). However, 
one  striking  difference  is  that  CD8"
+  DC  are  the  only  DC  capable  of  cross  presenting 
exogenous  antigen  in  class  I  MHC  to  CD8
+  T  cells,  making  them  important  in  the 
development of adaptive immune responses to viral and tumour antigens (101, 103-105). 
 
Plasmacytoid DC  
Plasmacytoid DC (pDC) are a subset of DC that are the principal sources of type 1 IFN in viral 
infections in most species. In mice, pDC are CD11c
lo and co-express B220, PDCA-1 and 
Ly6C  and  they  are  functionally,  genetically  and  morphologically  distinct  from  the 
conventional DC described above. pDC are thought to migrate from the bone marrow to the 
periphery  as  fully  matured  cells  and  recognise  unmethylated  cytosine  phosphate  guanine 
(CpG) motifs and single stranded (ss) RNA from viruses via TLR9 and TLR7 respectively. 
Upon activation via these TLR, pDC become potent secretors of type 1 IFN and contribute 
significantly to the development of anti-viral immunity (106-112). Moreover, IFN" and IFN# 
promote  CD8
+  T  cell  and  natural  killer  (NK)  cell  cytotoxicity,  Th1  polarisation  and  the 
differentiation  of  B  cells  into  antibody  secreting  plasma  cells.  In  addition  to  type  1  IFN, 
activated pDC also secrete the pro-inflammatory chemokines CCL3, CCL4, CCL5, CXCL8 
and CXCL10, that can recruit activated T cells and NK cells. Activated pDC can also secrete 
IL-12 and are capable of presenting antigen in class II MHC to T cells (113-117). In addition, 
pDC have been reported to have tolerogenic properties in a variety of inflammatory disease 
models (118-120). pDC are scarce in resting non-lymphoid tissues with the exception of the 
small intestine, but are readily detectable in the blood, bone marrow and secondary lymphoid 
organs. pDC enter LN via HEV using L-selectin which they constitutively express (106). pDC 
numbers are dramatically increased in non-lymphoid organs during inflammatory responses, 
but unlike conventional DC, pDC do not exit tissues via the afferent lymphatics (29). Instead it 
is proposed that pDC serve to activate and mobilise tissue DC, directing their migration into 
afferent lymphatics (121). pDC express CCR7 and CCR9 and although the former seems to be 
only upon activation, the expression of CCR9 is thought to account for their presence in the 
resting small intestinal lamina propria where there are high levels of the CCR9 ligand, CCL25 
(29, 121-124). As a result, CCR9 KO mice are devoid of lamina propria pDC (121).    41 
DC mediate immunological tolerance 
Although DC are potent activators of adaptive immune responses, together with T regs they 
also play crucial roles in the maintenance of immunological tolerance. This is partly due to 
their role in negative selection of self-reactive T cells in the thymus and may involve resident 
CD8"
+ DC. However, recent studies suggest that circulating immature CD8"
- DC can enter 
the thymus carrying self-antigens from peripheral tissues (55). DC are also crucial in the 
maintenance of peripheral tolerance where their role is to minimise activation of any mature T 
cells in the periphery that might recognise self-antigens or innocuous foreign antigens. This is 
particularly important at sites of chronic exposure to harmless environmental antigens such as 
the airways and gut. Peripheral tolerance relies on DC to present antigen to T cells and as for 
the  induction  of  active  immunity,  requires  CCR7  dependent  interactions  between  antigen 
loaded  DC  and  antigen  specific  T  cells  in  secondary  lymphoid  organs  (125-128).  Recent 
studies have revealed that tissue derived DC constitutively enter the afferent lymph under 
resting conditions (129, 130). The precise mechanisms governing the migration of these non-
inflammatory steady state DC are yet to be elucidated, but the continuous migration of steady 
state  DC  from  the  lungs,  skin  and  small  intestine  is  CCR7  dependent  as  is  the  ensuing 
development of T cell tolerance (125, 131-133). 
 
There are a number of ways in which DC can induce peripheral tolerance. Autoreactive T cells 
can be deleted directly by DC especially those specific for antigens targeted to endocytic 
pathways via DEC-205 (CD205) (126, 134). Antigen presentation by immature DC in the 
absence of co-stimulation can lead to impaired clonal expansion and T cell anergy or to the 
induction  of  T  regs  (92,  126,  135,  136).  DC  can  also  direct  the  differentiation  of  T  regs 
through  the  secretion  of  IL-10,  TGF#  or  retinoic  acid  (RA).    This  is  a  particular  trait  of 
CD103
+  DC  from  the  gut  and  respiratory  tract,  where  chronic  exposure  to  environmental 
antigen may lead to preferential production of IL-10 that inhibits secretion of IL-12 (60, 89, 
128).  A  further  mechanism  by  which  DC  can  induce  tolerance  is  via  indolamine-2-3-
deoxygenase (IDO), a tryptophan metabolising enzyme that depletes this essential amino acid, 
which is required by activated T cells for their proliferation and function. As well as  depleting 
local tryptophan, IDO leads to the accumulation of toxic metabolites and together these effects 
encourage cell cycle arrest and anergy in T cells and the generation of T regs (92, 137, 138). 
IDO production by DC may be induced by IFN!, TNF" or PGE2 and by ligation of CD80 by 
CTLA-4 on T regs (139-142). Whether or not a specialised subset of tolerogenic DC exists is   42 
controversial. Initially, CD8"
+ LN resident DC were believed to be dedicated to tolerance 
induction  but,  as  described  above,  these  DC  can  actively  prime  T  cells  and  more  recent 
evidence shows that constitutive CCR7 dependent migration of CD11b
+ DC from tissues is 
critical for inducing and maintaining peripheral tolerance (92, 126, 143-147). In the intestine, 
this function is associated specifically with DC expressing CD103 (the "E component of "E#7 
integrin). As DC are so plastic in their function, whether or not priming or tolerance occurs 
probably  reflects  the  local  environment  at  the  time  of  antigen  sampling  as  opposed  to 
dedicated lineages of DC.  
 
1.6 Regulation of chemokine function 
As I have discussed, chemokines have many crucial roles in the organisation of innate and 
adaptive  immune  responses,  and  so  they  must  be  regulated  stringently  to  avert  the 
development of aberrant immune responses and a number of mechanisms exist to achieve this. 
The  bioactivity  of  chemokines  can  be  regulated  by  post-translational  modifications  of  the 
amino acid terminus and this provides a means of regulating chemokine function more rapidly 
than  transcriptional  control,  as  it  allows  targeting  of  pre-formed  biologically  active 
chemokines  that  have  already  been  secreted.  After  secretion,  chemokine  bioactivity, 
distribution and bioavailabilty can also be regulated by enzymatic cleavage and glycosylation 
(7, 148).  
 
In  addition,  chemokine  receptors  can  be  antagonised  directly  (148,  149).  CCL7  naturally 
antagonises CCR5, while CCL11 and CCL26 antagonise CCR2 mediated chemotaxis (150-
153). CCR3 ligands can antagonise CXCR3 and vice versa, suggesting that as CXCR3 and 
CCR3 are associated with opposing types of Th responses, this antagonism may play a role in 
polarising  immune  response  (153-156).  Soluble  chemokine  receptors  can  also  antagonise 
chemokine responses, a phenomenon that has been exploited by several viruses and parasites 
that produce soluble decoy cytokine and chemokine receptors (157).  
 
The  immune  system  itself  produces  cytokine  and  chemokine  receptor  homologues  that 
regulate the responses of their relevant ligands. For instance, atypical TNF and IL-1 receptors 
exist as soluble and membrane bound forms that do not conduct signals following ligand 
engagement, but are thought to scavenge these pro-inflammatory cytokines, promoting the 
resolution of inflammatory responses. Several atypical chemokine receptors have now also   43 
been identified and are proposed to function as scavenging decoy receptors (7). One of these, 
CCX-CKR, is the focus of this thesis. 
 
Atypical chemokine receptors 
Over  the  last  decade,  a  number  of  atypical  chemokine  receptors  with  hypothesised  decoy 
functions have been identified. Such receptors do not couple to the typical G protein signalling 
pathways and so generally do not induce chemotaxis or calcium flux within cells. Atypical 
chemokine receptors of this kind include DARC, D6, CXCR7 and CCX-CKR (149, 157-162). 
The distribution and ligands of these atypical chemokine receptors are summarised in Table 
1.3.  Atypical  chemokine  receptors  have  been  proposed  to  function  as  decoy  receptors  or 
“sinks” in a manner somewhat similar to the IL-1 receptor type II which binds to IL-1# with 
high affinity and specificity without triggering signal transduction (163). However with the 
increasing characterisation of atypical chemokine receptors, mounting evidence suggests that 
their function may be more complex than simply to remove chemokine.  
 
Table 1.3: Atypical chemokine receptor ligands and distribution 
Atypical Chemokine 
Receptor 
Chemokine Ligands  Receptor Expression Sites 
DARC  CCL2, CCL5, CCL7, CCL11, 
CCL13, CCL14, CCL17, 
CXCL5, CXCL6, CXCL8, 
CXCL11 
Erythrocytes, endothelial cells, 
Purkinjie cells, kidney epithelial 
cells, type II pneumocytes 
D6  CCL2, CCL3, CCL3L1, CCL4, 
CCL5, CCL7, CCL8, CCL11, 
CCL13, CCL17, CCL22, 
CCL23, CCL24 
Lymphatic endothelium, lungs, 
innate B cells, trophoblasts 
CXCR7  CXCL11, CXCL12  Somatic cells during development, 
adult tumour cells 
CCX-CKR  CCL19, CCL21, CCL25, 
hCXCL13, mCCL1 
Lymph nodes, thymus, spleen, skin, 
heart, small intestine  
CCRL2 (aka CRAM in 
humans) 
CCL19, (also binds the 
chemo-attractant 
molecule, chemerin) 
Mast cells, macrophages, T cells 
(humans only), bronchial 
epithelium, astrocytes, microglia 
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Duffy antigen receptor for chemokines (DARC) 
Duffy  antigen  receptor  for  chemokines  (DARC)  was  originally  characterised  as  an  entry 
receptor  for  malarial  parasites  on  erythrocytes  (149,  157,  158,  162).  It  is  a  seven  trans-
membrane spanning receptor lacking the DRY motif on the second intracellular loop that is 
essential for G protein coupling and signal transduction by conventional chemokine receptors 
(162). Thus, ligand binding does not cause detectable signalling events or chemotaxis (149). 
As well as being expressed by erythrocytes, DARC is found on venular endothelial cells, and 
binds to most inflammatory CC and CXC chemokines, but not to homeostatic chemokines 
(164, 165). This promiscuity in ligand binding has been attributed primarily to the amino 
terminal  extracellular  domain  (166).  Upon  chemokine  binding  and  internalisation,  DARC 
associates with caveolae vesicles that are usually involved in trans-cellular transport. Thus it 
has been suggested that DARC is involved in transcytosis of chemokines on to the luminal 
surface of endothelium, a notion supported by evidence that DARC can transcytose intact 
ligand  from  basal  to  apical  endothelial  cell  surfaces  (149,  164).  Interestingly,  DARC  can 
hetero-oligeromize with CCR5 and prevent chemotaxis and calcium flux in response to CCR5 
ligands,  indicating  that  DARC  can  directly  and  specifically  over-rule  CCR5  mediated 
chemotactic activity (167). 
 
An  inhibitory  role  for  DARC  is  supported  by  the  findings  that  DARC  KO  mice  develop 
exaggerated inflammatory responses and leukocyte infiltrates into tissues in response to LPS, 
as well as accumulating elevated levels of DARC chemokine ligands in the blood (168, 169). 
Such reports have led to suggestions that DARC expression on erythrocytes may serve to 
buffer plasma chemokine levels (149, 164). In parallel, transgenic over-expression of DARC 
is associated with reduced angiogenesis and tumourogenesis, as well as reduced levels of 
CCL2 (149). Thus, DARC appears to play an important role in the recruitment of leukocytes 
to sites of inflammation by regulating local concentrations and distribution of its chemokine 
ligands.  
 
D6, an inflammatory chemokine receptor 
D6  is  an  atypical  chemokine  receptor  expressed  by  lymphatic  endothelium,  placental 
trophoblasts and some leukocytes. It binds inflammatory CC chemokines, sharing most of its 
ligands  with  CCR1-5  and  is  proposed  to  function  as  a  “decoy”  chemokine  receptor  that 
resolves inflammation by scavenging chemokines (149, 157, 159, 160, 162, 170).  D6 is a   45 
close structural homlogue of CCR1 and CCR5, but does not couple to the major signalling 
pathways normally induced by ligand engagement of chemokine receptors and so does not 
induce chemotaxis. This is thought to be due to an altered DRYLAIV motif in the second 
intracellular loop of D6 that is instead present as DKYLEIV. D6 constitutively binds and 
internalises ligand into clathrin-coated pits before entering recycling endosomes in a #-arrestin 
dependent manner and then returning to the cell surface. This process prevents de-sensitisation 
of D6 and occurs in the absence of ligand binding, allowing constitutive expression of D6 on 
the  cell  surface.  Any  bound  chemokines  dissociate  readily  from  internalised  D6  receptors 
during vesicle acidification and are then targeted for degradation (171-173). Unlike DARC, 
D6 expressed on lymphatic endothelium does not appear to transcytose its chemokine ligands 
in vivo (174). Taken together with its continual recycling and ligand degradation, chemokine 
scavenging seems the most likely role for D6.  
 
D6  KO  mice  have  been  shown  to  have  heightened  inflammatory  responses  in  the  skin, 
together with increased leukocyte infiltrates and delayed clearance of D6 chemokine ligands 
from the tissue and draining LN (175, 176). D6 KO mice are also more susceptible to lethal 
Mycobacterium  tuberculosis  infection,  with  exaggerated  local  and  systemic  inflammatory 
responses and elevated levels of the D6 ligands, CCL2-5. Importantly, these effects of D6 
deletion could be reversed by blocking the inflammatory chemokines (177).  
 
However, some studies have reported opposite effects of D6 deletion on inflammation, with 
resistance  to  the  induction  of  experimental  autoimmune  encephalomyelitis  (EAE)  and  to 
dextran  sodium  sulphate  (DSS)  induced  colitis  (178,  179).  As  the  latter  finding  has  been 
contradicted recently by another study, it would appear that the exact biological role of D6 in 
inflammation requires more investigation (180).  
 
CXCR7 
CXCR7  is  expressed  on  somatic  cells  during  development  and  has  been  implicated  in 
regulating the trans-endothelial migration of cells, as well as angiogenesis (158, 181). Adult 
mice appear to lack CXCR7, although it is expressed by some tumours, suggesting it may 
support the rapid angiogenesis necessary for tumour survival (182). CXCR7 lacks a canonical 
DRYLAIV  motif,  instead  expressing  DRYLSIT  and  consequently,  does  not  signal 
conventionally following binding of its ligands, CXCL11 and CXCL12 (183).    46 
CCRL2 and CRAM 
CCRL2 is a further atypical receptor that binds the chemoattractant molecule, chemerin and 
has recently been identified on a variety of leukocytes and non-haematopoietic cells such as 
mast cells, macrophages, human T cells, astrocytes, microglia and bronchial epithelial cells. 
CCRL2  is  thought  to  present  and  concentrate  chemerin,  enhancing  the  attraction  of  cells 
expressing the chemerin receptor, ChemR23 which is also known as CMKLR1 (184). CCRL2 
KO mice have reduced IgE responses to allergen sensitisation, but its exact biological roles 
remain  unknown  (184-186).  Confusingly,  the  literature  also  cites  CRAM  as  an  atypical 
chemokine receptor encoded by the CCRL2 gene and existing as the splice variants CRAM-A 
and CRAM-B. CRAM is expressed by human peripheral blood and bone marrow derived B 
cells and binds CCL19 with a similar affinity to CCR7, constitutively recycling via clathrin-
coated pits to the cell surface (187, 188). 
 
CCX-CKR, a homeostatic chemokine receptor 
ChemoCentryx  chemokine  receptor  (CCX-CKR)  was  originally  named  CCR11  and  first 
identified from a screen of orphan receptors transfected into human embryonic kidney (HEK) 
cells.  Upon  interrogation  with  immobilised  chemokines,  CCX-CKR  showed  high  affinity 
binding to the murine and human forms of the CCR7 ligands CCL19 and CCL21, as well as 
the CCR9 ligand CCL25. mCCL9/CCL10 and hCXCL13 also bound to CCX-CKR transfected 
HEK cells, but with far weaker affinity (189).  
 
As there is no antibody available for CCX-CKR, its expression has only been investigated 
using molecular approaches. Initial RT-PCR studies suggested that CCX-CKR mRNA was 
expressed in human primary T cells and monocyte derived DC, as well as in whole spleen, 
LN, heart, kidney, placenta, trachea and brain (189). Northern blot analysis then revealed 
expression in the mouse lung and heart as well as lower levels in the spleen and skeletal 
muscle.  Equivalent analysis in humans also revealed abundant expression in the heart, lung, 
small intestine, colon and skeletal muscle, but no CCX-CKR RNA was detectable in human 
leukocytes (190). In mice, CCX-CKR exists as a single gene, whereas two CCX-CKR genes 
have  been  identified  in  humans,  one  on  chromosome  3  and  the  other  on  chromosome  6. 
Northern blot analysis showed the chromosome 6 hCCX-CKR gene to be primarily expressed 
in the heart (190).  
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The only published studies of CCX-CKR protein expression have used CCX-CKR1-EGFP 
knock-in mice and they suggested that CCX-CKR was expressed by non-haematopoietic cells 
of the thymus, intestine, LN and epidermis. Specifically these cells were identified as TEC, 
intestinal  lymph  vessels  and  the  marginal  sinus  of  LN.  However,  no  CCX-CKR  protein 
expression was found in the heart, kidney, liver, spleen or brain (191). As these findings 
contradict the original analyses of CCX-CKR mRNA expression, they emphasise the need for 
reliable methods of detecting CCX-CKR protein in vivo. 
  
The discovery that CCX-CKR binds the same chemokines as CCR7 and CCR9 led to the idea 
that  CCX-CKR  may  act  as  a  scavenger  receptor  that  might  regulate  the  activity  of  these 
receptors  by  affecting  the  availability  of  their  ligands  in  vivo.  This  is  supported  by  the 
available evidence that demonstrates that CCX-CKR does not signal after binding its ligands 
or  induce  a  rapid  increase  in  intracellular  calcium.  Instead  it  appears  to  target  bound 
chemokine for degradation after internalisation (191, 192). This process is extremely efficient, 
allowing  scavenging  and  degradation  of  around  80%  of  biotinylated  CCL19  from  culture 
medium after 24 hours. This is quite distinct from when CCR7 binds CCL19, which as one of 
two  ligands  of  CCR7,  selectively  leads  to  receptor  desensitisation  after  prolonged  ligand 
exposure and impaired clearance of exogenous CCL19 from culture medium (12, 192-194). 
The  uptake  and  sequestration  of  CCL19  by  CCX-CKR  occurs  via  a  caveolae  dependent 
mechanism that does not appear to require #-arrestin-1 or clathrin mediated endocytosis (192).   
 
At the time my project started, very little was known about the biological role of CCX-CKR in 
vivo, although the Nibbs group had generated a CCX-CKR KO mouse and their preliminary 
findings suggested that CCX-CKR KO mice developed normally, with no gross abnormalities 
in the architecture of secondary lymphoid organs, although the ILN were found to be smaller 
in CCX-CKR KO mice compared to WT. However, there were no significant differences in 
the proportions of T cells and B cells in the spleens or ILN of CCX-CKR KO mice. In parallel, 
CCX-CKR KO ILN failed to enlarge normally in response to the skin irritant, PMA.  
 
Subsequent published studies have confirmed a trend towards lower cell numbers in CCX-
CKR KO lymphoid tissue, with lower numbers of migratory CD11c
+MHCII
hi DC in the skin 
draining  LN  of  resting  CCX-CKR  KO  mice  compared  with  WT  animals.  However,  the 
numbers of CD11c
+MHCII
hi isolated from epidermal sheets and their mobilisation into skin   48 
draining LN upon FITC skin sensitisation were normal. Although CCX-CKR is expressed in 
the thymus and all of its ligands play important roles in T cell development, this process 
appears  to  be  normal  in  CCX-CKR  KO  mice.  Transgenic  over-expression  of  CCX-CKR 
targeted to thymic epithelial cells revealed no alterations in the expression levels of thymic 
chemokines,  or  in  the  expression  pattern  of  CCL25  in  the  embryonic  thymic  anlagen. 
However, there were significantly reduced numbers of haematopoietic precursors entering the 
thymus, consistent with disruptions to these normally CCR9 dependent processes although T 
cell  development  in  adult  CCX-CKR  transgenic  mice  was  normal  (191).  In  addition,  a 
separate  study  has  reported  that  the  over-expression  of  CCX-CKR  by  cancer  cell  lines 
inhibited their proliferative and invasive capacity (195). 
 
Thus, no clear role for CCX-CKR in vivo has been elucidated and there have been no studies 
of the intestinal immune compartment, a site where all three ligands of CCX-CKR are known 
to play crucial roles in the regulation of immunity and tolerance. Therefore, investigating these 
tissues in CCX-CKR KO mice was the principal aim of my project. 
 
1.7 The intestinal immune system 
The physiological role of the intestinal epithelium requires that it is selectively permeable to 
nutrients and water, but not permissive to invasion by potentially pathogenic luminal microbes 
(196). The intestinal mucosa is exposed to the greatest antigenic burden of the whole body, 
which  includes  dietary  proteins,  commensal  flora  and  self-antigens  as  well  as  pathogenic 
organisms. As discussed above, these different types of antigens must be distinguished, so that 
active tolerance or immunity are induced accordingly. As in the rest of the immune system, 
CCL19 and CCL21 are critical for these processes, as is the other CCX-CKR ligand, CCL25.  
 
The layout of the intestinal immune system 
The immune apparatus of the intestine can be divided into organised and scattered lymphoid 
tissues. The organised tissues comprise the PP, MLN and isolated lymphoid follicles (ILF), 
and are the sites where immune responses are initiated. PP are macroscopic structures lying in 
the wall of the small intestine and like other secondary lymphoid organs, have a distinct T cell 
zone and B cell follicles, but differ by lacking afferent lymphatics. Instead, luminal antigens 
gain access to PP by specialised epithelial cells known as microfold (M) cells, found in the 
follicle associated epithelium (FAE) overlying the lymphoid compartments of the PP. Antigen   49 
from M cells is delivered to DC in the underlying sub-epithelial dome (SED) area, which then 
interact with T and B cells deeper in the PP or migrate to MLN (197). ILF are microscopic 
cellular aggregates that are structurally very similar to PP, with FAE and M cells, but consist 
of only one or two B cell follicles. Although ILF are smaller than PP, they can increase 
dramatically in size in response to local antigen burden. There are many hundreds of them in 
both the small and large intestine, and thus they can make a substantial contribution to local 
immune responses (198). MLN are the draining LN of the intestine and are connected to PP 
and the intestinal mucosa by lymphatics. In keeping with the enormous load of antigen in the 
gut, MLN are the largest LN in the body. Cryptopatches (CP) are a further group of organised 
lymphoid tissues found in the intestinal mucosa. Once thought to be sites of extra-thymic T 
cell differentiation they are now seen as immature ILF, containing CCR9
+ LTi recruited by 
CCL25 producing DC (197). The scattered lymphoid tissues comprise the lamina propria and 
epithelium, where effector leukocytes are found. In the lamina propria, there are macrophages, 
plasma cells, DC, CD4
+ T cells, CD8
+ T cells and eosinophils. The epithelium contains mostly 
CD8
+ T cells, which are found immediately above the basement membrane and are known as 
intra-epithelial lymphocytes (IEL). IEL express CCR9 and have been shown to up-regulate 
CD103  in  response  to  CCL25,  which  is  secreted  by  intestinal  epithelial  cells.  CD103 
expression mediates IEL adhesion to E-cadherin, a molecule that is abundant on intestinal 
epithelium, and such interactions appear to be important in the localisation of IEL, as CD103 
KO and CCR9 KO mice have reduced numbers of these cells (199-201). With its constant 
leukocyte  infiltrate  arising  from  a  bombardment  of  luminal  antigen,  the  healthy  intestinal 
mucosa could be described as being in a chronic state of inflammation. However, symptomatic 
inflammatory bowel disease is a rare occurrence thanks to stringent regulatory mechanisms. 
 
The induction of intestinal immune responses 
As  described  above,  invasive  antigens  such  as  bacteria  are  delivered  directly  from  the 
intestinal lumen to PP DC which then mature and migrate to the T cell zone of the PP, or to 
the  MLN  where  they  prime  effector  T  and  B  cells  (202).  As  in  all  mucosal  tissues,  the 
antibody response in the intestine is dominated by IgA which is produced by plasma cells in 
the  lamina  propria.  IgA  secreted  as  a  J  chain  linked  dimer,  interacts  with  polymeric 
immunoglobulin receptors (pIgR) expressed on epithelial cells and is transcytosed across them 
into the lumen where it can neutralise pathogens and their products (203). IgA class switching 
occurs in the GC of PP and MLN under the influence of T cells, TGF# and RA production   50 
from  mucosal  DC.  In  mice  but  not  humans,  there  is  also  a  significant  production  of  T 
independent IgA induced by direct interactions between DC and B1 B cells (203-206).  
 
Homing of small intestinal effector cells 
An essential component of mucosal immunity is the homing of effector T cells, T regs and 
plasmablasts from inductive sites to the mucosal surface. In the small intestine, this is directed 
by  the  expression  of  CCR9  and  "4#7  integrin  on  lymphocytes.  These  recognise  CCL25 
secreted by small intestinal epithelial cells and MadCAM-1 expressed selectively by vascular 
endothelial cells at mucosal surfaces. Evidence suggests that the induction of these receptors 
on naive lymphocytes occurs in the MLN and is controlled by RA production by a population 
of  CD103
+  DC  that  is  unique  to  the  intestine  (133,  197,  205,  207-215).  Although  CCR9 
controls T cell and IgA plasma cell migration into the small intestine, it is not involved in the 
colon or other mucosal sites. The specific factors controlling entry to these tissues are yet to be 
elucidated, but in the case of the colon, CCR10 and CCL28 may be important (82, 216-218). 
CCR9 KO mice have decreased numbers of IgA plasma cells in the small intestinal lamina 
propria and show decreased IgA responses after oral immunisation with antigen, although they 
do have normal numbers of "4#7 expressing CD4
+ and CD8
+ T cells in the lamina propria. 
Intriguingly, CCR9 deficient T cells can retain some ability to migrate into the lamina propria 
(219).  Together, these data suggest that the requirement of CCR9 expression for T cell entry 
into  the  small  intestine  is  not  absolute  and  that  it  is  the  combined  display  of  chemokine 
receptors and integrins that affords tissue specific localisation (82).  
 
Intestinal DC 
PP are not the sole source of mucosal DC as these are also abundant in the lamina propria, 
MLN and ILF. Several DC subsets have been characterised in the intestine, including CD103
+, 
CD8"
+ and CD8"
-CD11b
+ DC, as well as pDC (133, 208, 209). However there has been much 
debate recently over the definition of DC in the gut. This is particularly so in the lamina 
propria,  where  the  majority  of  CD11c
+CD103
-  cells  originally  classed  as  DC  are  in  fact 
CX3CR1
+ cells derived from inflammatory monocytes and are genetically and morphologically 
identical  to  tissue  resident  macrophages.  As  a  result,  many  workers  consider  that  only 
CD11c
+CD103
+  cells  and  pDC  are  genuine  DC  in  the  intestinal  mucosa.  However,  the 
situation is different in the PP and MLN, where conventional CD103
- DC are found (95, 96).   
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CD103
+ DC 
CD103
+ DC are found throughout the intestinal immune compartment and in some peripheral 
secondary lymphoid organs although in much fewer numbers. They are the dominant DC in 
the lamina propria, have several unique functional properties and are the only population of 
DC to migrate from the lamina propria to the MLN. Under resting conditions, CD103
+ DC 
generally promote tolerance and appear to be conditioned to be anti-inflammatory by soluble 
factors  such  as  thymic  stromal  lymphpoietin  (TSLP)  secreted  by  intestinal  epithelial  cells 
(205). CD103
+ DC contribute to peripheral tolerance to innocuous proteins within the small 
intestine by driving the development of antigen specific FoxP3
+ T regs from naïve T cells 
during antigen presentation in the MLN in a TGF-# and RA dependent manner (220). CCR7 
KO mice have defective migration of CD103
+ DC to MLN and fail to develop peripheral 
tolerance to orally administered antigens (125, 132). 
 
As CD103
+ DC are also the only APC to induce the expression of CCR9 and "4#7 on T cells 
including FoxP3
+ T regs, they play a crucial role in instructing antigen experienced T cells to 
return to the mucosa. This property also requires the production of retinoic acid (RA) by 
CD103
+ DC, which is generated from the metabolism of dietary vitamin A by the retinal 
dehydrogenase  (RALDH)  and  ALDH  families  of  enzymes.  Consequently,  the  long-term 
withdrawal  of  vitamin  A  from  the  diet  of  mice  results  in  a  selective  reduction  in  "4#7 
expressing CD4
+ T cells in secondary lymphoid organs and a defect in total lamina propria T 
cell numbers (212, 221). Other intestinal DC cannot produce vitamin A metabolising enzymes 
and  neither  can  CD103
+  DC  from  peripheral  secondary  lymphoid  organs.  Although  it  is 
suggested that CD103
+ DC are intrinsically capable of generating RA while in the mucosa, 
other recent work suggests this property may be induced in DC by stromal cells in the MLN. 
Intriguingly, this effect appears to be unique to MLN stroma, as peripheral LN transplanted 
into the intestinal mesentery are unable to promote the expansion of gut tropic effector T cells 
(222). Although it now appears that many CD11c
+CD103
- cells in the lamina propria may be 
inflammatory macrophages, conventional CD11c
+CD103
- DC are also present in the MLN and 
are thought to develop from blood derived DC precursors that have not been exposed to non-
inflammatory conditioning in the gut. As a result they have potent immunogenic potential and 
in contrast to CD103
+ DC, these CD11c
+CD103
- DC possess high levels of mRNA coding for 
TLR, so are more sensitive to activation by PAMPs and inclined to produce pro-inflammatory 
cytokines driving Th1 and Th17 type immune responses (206). However as CD103
- DC cannot   52 
induce the expression of gut homing molecules on the effector T cells, it brings into question 
how they can instruct the appropriate migration of T cells to the lamina propria which would 
be required for protective immunity.  
 
Intestinal pDC 
pDC can be found in the MLN, PP and small intestinal lamina propria. CCR9 expressing pDC 
are thought to migrate to the small intestinal lamina propria in response to CCL25 and are 
largely absent from the small intestine of CCR9 KO mice. Competitive transfers confirm that 
CCR9 deficient pDC are impaired in their ability to seed the small intestine of WT recipients. 
In contrast, pDC are present in normal numbers in the lung, liver and secondary lymphoid 
organs of CCR9 KO mice (121). pDC do not themselves migrate in lymph to MLN, but appear 
to  control  the  mobilisation  of  CD103
+  DC  from  the  mucosa  via  type  1  IFN  and  TNF" 
dependent mechanisms (121, 223, 224). In addition, CCR9
+ pDC have been reported to be 
capable of inducing T regs in vivo and in vitro, whereas CCR9
- pDC fail to induce T cell 
tolerance (118). Recent work also suggests that pDC in the liver play a direct role in oral 
tolerance by virtue of their ability to delete CD8
+ T cells or drive the differentiation of T regs 
(225,  226).  Thus,  pDC  may  play  a  central  but  as  yet  not  fully  defined  role  in  regulating 
mucosal immune responses. 
 
Oral tolerance  
Many  of  the  antigens  encountered  by  the  gastrointestinal  tract  are  harmless,  such  as  the 
commensal  bacteria  and  dietary  antigens  that  are  essential  to  our  existence.  It  would  be 
wasteful  to  induce  active  immunity  against  such  antigens  and  in  fact  this  can  lead  to 
inflammatory bowel disease (IBD) and coeliac disease. Therefore the default response to these 
antigens is the induction of peripheral tolerance. Oral tolerance is the phenomenon by which 
immunological tolerance is induced by oral administration of an innocuous antigen such as 
soluble protein or commensal bacteria. In the case of proteins, this is manifest as a systemic 
hypo-responsiveness upon challenge with the same antigen in an immunogenic form (146, 
227-235). It can also affect local immune responses such as IgA responses and in the case of 
commensal bacteria, local tolerance may be the only aspect of immunity that is altered, while 
the systemic immune system remains ignorant to these antigens (236). The mechanisms of oral 
tolerance remain unclear, although initial studies reported that high doses of a protein antigen 
induced  T  cell  anergy  and/or  deletion,  whereas  lower  doses  of  proteins  induced  active   53 
suppression by expanding T regs and enhancing TGF#, IL-4 and IL-10 release (227, 237-240). 
More recently, this distinction has become less accepted and most work has focussed on the 
role of T regs which may be FoxP3
+ or FoxP3
- (146, 235). Irrespective of the mechanism, the 
MLN appear to be the main site of oral tolerance induction, as deletion of PP has no consistent 
effect on the phenomenon, whereas removal of MLN ablates tolerance to both bacteria and 
proteins. Preventing cell emigration from the MLN also prevents the development of systemic 
tolerance to orally administered proteins by as yet undefined mechanisms (241, 242). 
      
Thesis Aims 
The  homeostatic  chemokines  CCL19,  CCL21  and  CCL25  are  all  crucial  for  immune 
development and function. In particular the development of adaptive immunity and tolerance 
are dependent on CCR7 and its ligands CCL19 and CCL21, while CCL25 is important in the 
recruitment of CCR9 expressing pDC and effector cells to the gut. With such integral roles in 
immune  activation  and  suppression,  the  regulation  of  these  chemokines’  bioavailability  is 
essential. The atypical chemokine receptor CCX-CKR binds all three of these chemokines and 
has been proposed to assist in this regulation by scavenging excess chemokine. 
 
At  the  time  of  starting  my  project,  studies  of  CCX-CKR  function  were  limited  and 
characterisations of the CCX-CKR KO mouse were in their infancy. The aims of this thesis 
were therefore to characterise the immune system of CCX-CKR KO mice and to determine the 
effects of CCX-CKR deletion on mucosal immunity in particular. 
 
I began my investigations by examining the cellularity of secondary lymphoid organs in CCX-
CKR KO mice and this work is described in Chapter 3. Subsequently, in Chapter 4, I describe 
my  characterisation  of  the  intestinal  immune  compartment  and  in  Chapter  5,  I  detail  my 
investigations of antigen specific immune responses and tolerance in CCX-CKR KO mice 
after systemic and oral challenge, and explore the development of oral tolerance and intestinal 
inflammation.  Finally  in  Chapter  6,  I  describe  some  preliminary  investigations  into  DC 
function in CCX-CKR KO mice.  
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Chapter 2 
Materials and Methods 
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2.1 Mice 
CCX-CKR knock-out (KO) and CCR9 KO mice (CD45.1
-CD45.2
+) were bred and maintained 
on a C57Bl/6 genetic background (H-2
b) under specific pathogen free (SPF) conditions in the 
Central  Research  Facility,  University  of  Glasgow.  C57Bl/6  (B6)  wild-type  (WT)  mice 
(CD45.1
-CD45.2
+)  (originally  littermates  of  the  CCX-CKR  KO  mice)  were  bred  and 
maintained in these conditions as a separate colony. C57B1/6 SJL mice (CD45.1
+CD45.2
-) and 
OT2  CD4  T-cell  receptor  (TCR)  transgenic  mice  (CD45.1
-CD45.2
+)  specific  for  the 
ovalbumin (OVA) peptide sequence 323-339 complexed to the I-Ab class II MHC molecule 
were bred under SPF conditions at the Veterinary Research Facility, University of Glasgow.  
All mice used were female and first used between 6-8 weeks of age. All procedures were 
performed in accordance with United Kingdom Home Office regulations. 
 
2.2 Flt3L mediated expansion of dendritic cells in vivo 
In vivo expansion of DC was achieved by the administration of 10µg human recombinant 
CHO derived Flt3L (kind gift of Amgen Corp, Seattle, USA) in 0.2ml sterile PBS (Invitrogen, 
Paisley,  UK)  i.p.  for  10  consecutive  days.  Mice  were  sacrificed  the  day  after  the  final 
administration.  
 
2.3 R848 administration 
10µg or 100µg of the synthetic TLR7/8 agonist R848 (Enzo Life Sciences UK Ltd, Exeter, 
UK) were administered via gavage in 0.2ml sterile PBS (Invitrogen) as a single dose. 18 or 24 
hours  later,  mice  were  sacrificed  and  their  MLN  and  small  intestines  removed  to  assess 
CD11c
+ cell content. 
 
2.4 Induction of systemic immune responses in vivo 
Mice were immunized in the right hind footpad with a single 50µl subcutaneous injection of 
100µg  ovalbumin  (OVA)  (Sigma,  Poole,  UK)  dissolved  in  sterile  PBS  (Invitrogen)  and 
emulsified  in  Complete  Freund’s  Adjuvant  (CFA)  (Sigma)  in  a  1:1  ratio  of  antigen  to 
adjuvant.  
 
2.5 Measurement of antigen specific delayed type hypersensitivity responses 
DTH responses were assessed three weeks after immunisation in the footpad with OVA/CFA 
by measuring the increase in thickness of the opposite footpad 24 hours after challenge with   56 
100µg heat aggregated OVA (HAO) in 50µl sterile PBS (Invitrogen) using callipers. HAO 
was prepared by heating a 2% solution of OVA (Sigma) in sterile PBS at 70°C for an hour. 
The precipitated OVA formed was then centrifuged for 10 minutes at 400G at 4°C and the 
supernatant  discarded.  HAO  pellets  were  suspended  in  sterile  PBS  (Invitrogen)  at  a 
concentration of 20mg/ml until further use.  
 
2.6  Measurement  of  antigen  specific  antibody  production  and  total  serum 
antibody titres 
Serum was separated from blood by centrifugation at 13000g for 20 minutes and was stored at 
-20°C until use. Immulon-4 ELISA plates (Corning, Amsterdam, the Netherlands) were coated 
overnight  at  4°C  either  with  50µl  per  well  10µg/ml  OVA  (Sigma)  or  purified  capture 
antibodies for the detection of OVA specific IgA, IgG, IgG1 and IgG2a and total IgA and IgG 
respectively. The next day, plates were washed a minimum of five times with PBS 0.05% 
Tween  20  (Sigma)  before  blocking  with  PBS  3%  BSA  (Sigma)  for  1  hour  at  room 
temperature.  Plates  were  washed  and  50µl  of  diluted  serum  samples  added  in  doubling 
dilutions in duplicate before leaving overnight at 4°C. The next day, plates were washed and 
75µl biotin conjugated detection antibodies added and incubated at room temperature for 1 
hour. Plates were then washed and incubated with 1:1000 extravidin-peroxidase (Sigma) for 1 
hour at room temperature before washing and being developed using TMB substrate (KPL, 
Middlesex, UK) and read at 630nm using a MRX II microplate reader (Dynex, West Sussex, 
UK). A list of the capture and detection antibodies used are shown in Table 2.1. 
 
2.7 Isolation and measurement of intestinal IgA antibodies  
Faeces were removed from the colon and transferred to Eppendorfs containing ice cold PBS 
(Invitrogen)  with  0.1mg/ml  soybean  trypsin  inhibitor  type  II  (Sigma)  and  50mM  EDTA 
(Sigma). Tubes were centrifuged at 1500g for 10 minutes and the supernatants collected into 
fresh Eppendorfs, to which 10µl of 100mM phenylmethylsulfonyl (PMSF) (Sigma) in 95% 
ethanol solution was added before being centrifuged at 14000g for 30 minutes at 4°C. 10µl 
PMSF solution, 10µl of 1% sodium azide (Sigma) solution and 50µl FCS (Invitrogen) were 
then added to the resulting supernatants which were stored at –20°C until required. The total 
protein  content  of  these  preparations  was  determined  using  a  BCA  assay  kit  (Pierce, 
Loughborough, UK) according to the manufacturer’s guidelines and using two-fold dilutions 
of BSA as standards. Samples were added neat and in duplicate. Immulon-4 ELISA plates   57 
(Corning) were coated overnight at 4°C either with 50µl per well 10µg/ml OVA (Sigma) or 
purified rat anti-mouse IgA (BD Biosciences, Oxford, UK) for the detection of OVA specific 
IgA and total IgA respectively. The next day, the plates were washed a minimum of five times 
with PBS 0.05% Tween 20 (Sigma), before blocking with PBS 3% BSA for 1 hour at room 
temperature.  Plates  were  washed  and  50µl  of  neat  faecal  samples  preparations  added  in 
duplicate before leaving overnight at 4°C. The next day, the plates were washed and 75µl 
biotin conjugated rat anti-mouse IgA (BD Biosciences) was added before being incubated at 
room temperature for 1 hour. Plates were then washed and incubated with 1:1000 extravidin-
peroxidase (Sigma) for 1 hour at room temperature before washing and were developed using 
tetramethylbenzidine (TMB) substrate (KPL) and read at 630nm using a MRX II microplate 
reader (Dynex). 
 
2.8 Induction of tolerance or priming by oral administration of antigen  
To induce tolerance, mice were fed OVA, either as a single high dose feed of 25mg or as five 
daily  feeds  of  1mg  dissolved  in  0.2ml  sterile  PBS  (Invitrogen)  using  a  rigid  steel  curved 
gavage tube. Control mice received 0.2ml sterile PBS alone. One week after feeding, all mice 
were immunized in the right hind footpad with 100µg OVA/CFA and 2 weeks later, OVA 
specific DTH and antibody responses were assessed.  To induce oral priming, mice received 
three feeds of 10mg OVA (Sigma) together with 10µg cholera toxin (CT) (Sigma) in 0.2ml 
sterile PBS ten days apart. Control mice received either 10mg OVA in 0.2ml sterile PBS or 
0.2ml  sterile  PBS  alone.  Ten  days  after  the  final  feed,  OVA  specific  DTH  and  antibody 
responses were assessed. 
 
2.9 Isolation of lymphocytes from secondary lymphoid organs 
Single cell suspensions were prepared from the spleen (SP), inguinal lymph nodes (ILN) and 
mesenteric  lymph  nodes  (MLN)  by  mashing  through  sterile  50µm  Nitex  mesh  (Cadisch, 
London,  UK)  in  RPMI  1640  medium  (Invitrogen).  Cells  were  subsequently  washed  by 
centrifugation at 400g for 5 minutes at 4°C and re-suspended in complete medium (RPMI 
1640, 2mM L-glutamine, 100µg/ml penicillin, 100µg/ml streptomycin, 1.25µg/ml Fungizone 
and 10% foetal calf serum (FCS) (all Gibco)). Red blood cells were removed from spleen cell 
preparations by re-suspending cell pellets in 1ml Red Blood Cell Lysing Buffer Hybri-Max 
(Sigma) for 1 minute at room temperature followed by washing in RPMI 1640 (Invitrogen) for 
5  minutes  at  4°C  prior  to  re-suspension  in  complete  medium.  Viable  cell  counts  were   58 
performed  using  a  Neubauer  haemocytometer  and  phase  contrast  microscope  (Nikon 
Labophot, UK). Cell suspensions were kept on ice until required.   
 
2.10 Isolation of dendritic cells (DC) and macrophages from secondary lymphoid 
organs 
Lymphoid  tissues  were  chopped  up  using  a  sterile  scalpel  blade  and  digested  in  1mg/ml 
collagenase D and 30µg/ml DNase I (both Roche, Hertfordshire, UK) calcium-magnesium 
free (CMF) HBSS (Invitrogen) for 30 minutes in a 37°C cell shaker. Cells were subsequently 
homogenised into a single cell suspension as outlined above. 
 
2.11 Isolation of Peyer’s patch (PP) leukocytes 
PP were removed from the small intestine and cells were isolated from PP as for secondary 
lymphoid  organs  with  an  additional  step  prior  to  collagenase  digestion  comprising  an 
incubation with CMF-HBSS (Invitrogen) 2mM EDTA (Sigma) in a 37°C cell shaker for 15 
minutes to remove surface epithelium. 
 
2.12 Isolation of small intestine lamina propria leukocytes 
Whole small intestines were removed, soaked in CMF-HBSS (Invitrogen), placed on a CMF-
HBSS  soaked  paper  towel  and  stripped  of  Peyer’s  patches  and  fat  by  careful  dissection. 
Intestines were opened longitudinally, cut into 1cm sections and placed in 20ml CMF-HBSS 
(one intestine per tube) in a 37°C shaker for approximately 10 minutes to remove mucus and 
intestinal content. To remove the epithelial cell layer, the CMF-HBSS was aspirated from the 
tissue before being replenished with 20ml fresh CMF-HBSS supplemented with 2mM EDTA 
(Sigma). Following 15 minutes incubation in the 37°C shaker, the EDTA CMF-HBSS was 
removed and discarded. 20ml fresh CMF-HBSS was added, the tube shaken vigorously by 
hand and then aspirated before addition of 20ml fresh 2mM EDTA CMF-HBSS for a further 
incubation. A total of four EDTA incubations and washes were performed. Tissue was then 
washed in 20ml sterile PBS and aspirated before addition of 20ml CMF-HBSS containing 
100U/ml  collagenase  type  V111  from  Clostridium  histolyticum  (Sigma),  30µg/ml  DNase 
(Roche) and 20% FCS. Tissues were digested for 45 minutes to an hour at 37°C in a shaker. 
Resultant suspensions were passed through cell strainers to generate a single cell suspension, 
washed for 5 minutes, re-suspended in complete medium and placed on ice until use. 
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2.13 Isolation of liver leukocytes 
Livers were chopped into approximately 5mm
2 pieces and incubated in a shaker at 37°C for 30 
minutes with 1mg/ml type IA collagenase (Sigma) and 0.1mg/ml DNase I (Roche) in CMF-
HBSS (Invitrogen). Following digestion, the solution and any remaining tissue were mashed 
through a 40µm cell strainer to generate a single cell suspension. 
 
2.14 Purification of CD4
+ lymphocytes 
Cells were purified by negative selection using a CD4
+ T cell isolation kit according to the 
manufacturer’s instructions (Miltenyi Biotec Ltd, Surrey UK).  Briefly, single cell suspensions 
of LN cells were prepared as described and up to 10
7 total cells were suspended in 40µl 
MACS buffer (2mM EDTA, 0.5% BSA PBS).  10µl of biotin-antibody cocktail was then 
added per 10
7 total cells and incubated for 10 minutes at 4°C. 30µl of MACS buffer and 20µl 
of  anti-biotin  magnetic  microbeads  were  then  added  per  10
7  total  cells,  mixed  well  and 
incubated for 15 minutes at 4°C. Cells were then washed by centrifugation at 300g for 10 
minutes and re-suspended in 500µl of MACS buffer per 10
8 cells and passed through a MACS 
column placed within the magnetic field of the MACS separator. Magnetically labelled cells 
were  retained  there  and  the  effluent  containing  the  fraction  of  unlabelled  CD4
+ c e l l s  w a s  
collected.    
 
2.15 Generation of bone marrow derived dendritic cells (BMDC) 
To obtain bone marrow cells, mouse femurs and tibias were flushed out with RPMI 1640 
(Invitrogen) using a syringe and 21G needle. Cells were filtered through sterile Nitex and 
suspended at 3x10
6 cells/ml. 1ml of cells were seeded into 90cm low-adherence Petri dishes 
(Sterilin, UK) along with 8ml complete medium and 1ml GM-CSF derived from the filtered 
supernatant of the X-63 fibroblast GM-CSF transfected cell line. Cells were incubated at 37°C 
in  5%  CO2  and  after  3  and  6  days  of  culture,  the  medium  was  supplemented  with  5ml 
complete medium and 0.5ml GM-CSF supernatant. BMDC were harvested by gentle washing 
of the Petri dishes after 7 to 9 days of culture and were typically >70% CD11c
+ as determined 
by flow cytometry. 
 
2.16 Assessment of endocytic activity of BMDC 
BMDC were cultured in complete medium with 1mg/ml FITC dextran (MW 4400; Sigma) in 
ultra low adherence 24 well flat-bottomed plates (Corning) for 0-60 minutes at either 4°C or   60 
37°C. Cells were then washed twice in ice-cold FACS buffer (PBS 2% FCS 5mM EDTA) 
before staining with anti-CD11c-PE (BD Biosciences) for 30 minutes at 4°C in the dark and 
analysis  by  flow  cytometry.  The  uptake  of  FITC  dextran  was  expressed  as  the  %MFI, 
calculated by subtracting the FITC specific mean fluorescent intensity of cells cultured at 4°C 
from that of cells cultured at 37°C.  
 
2.17 Activation of BMDC in vitro 
1x10
6 BMDC per well were cultured overnight in 24 well flat bottom low adherence plates 
(Corning) in either complete medium alone or with 2µg/ml Escherichia coli LPS (Sigma). 
Cells were harvested by aspiration of supernatants, washed in complete medium and stained 
for CD11c and a selection of co-stimulatory molecules and class II MHC for analysis by flow 
cytometry. 
 
2.18 Assessment of antigen presenting activity of DC 
B6  BMDC  or  spleen  cells  were  pulsed  with  5mg/ml  OVA  (Sigma)  by  incubating  in  low 
adherence 24 well plates (Corning) at 3x10
6 cells per well at 37°C in 5% CO2 for 2 hours. 
Excess OVA was then washed off by centrifugation at 4°C for 5 minutes at 400g and the cells 
irradiated at a dose of 3000Gy to inhibit proliferative capacity. The pulsed cells were then 
cultured with OVA specific OT2 LN cells in a 1:1 or 1:5 ratio in flat-bottomed 96 well plates 
at 2x10
5 cells per 200µl T cell medium per well.  Unpulsed BMDC or spleen cells were also 
cultured with T cells and 1µg/ml OVA peptide 323-339 (Genosys, Sigma). Cells were cultured 
for 120h and pulsed with 1µCi/well tritiated thymidine (
3H-TdR) for the final 18 hours of 
culture and harvested as above.  
 
2.19  Proliferative  responses  of  lymphocytes  to  Concanavalin-A  and  anti-
CD3/CD28 
Aliquots of 2x10
5 lymphoid cells were cultured in 200µl of T cell medium (complete medium 
supplemented with 1% non-essential amino acids (NEAA), 1mM sodium pyruvate and 50µM 
2-ME (all Gibco, Invitrogen)). Cells were either cultured alone or in the presence of 1µg/ml 
anti-CD3 and 1µg/ml anti-CD28 (both from BD Biosciences), or with 5µg/ml concanavalin-A 
(ConA) (Sigma). Cells were cultured in triplicate for 48-120h at 37°C in 5% CO2 in 96-well 
flat-bottomed  tissue  culture  plates  (Corning).  After  48h  of  culture,  cell  supernatants  were   61 
removed  and  stored  at  –20°C  for  measurement  of  cytokines  by  ELISA  and  the  wells 
replenished  with  fresh  medium.  To  assess  proliferation,  cells  were  pulsed  with  1µCi/well 
tritiated thymidine (
3H-TdR) (West of Scotland Radionucleotide Dispensary) for the final 18 
hours of culture. Cellular DNA was harvested on to glass fibre filter mats (Wallac, Perkin-
Elmer, Cambridge, UK) and 3H-TdR uptake was measured by a Betaplate scintillation counter 
(Wallac) using the Microbeta programme. 
 
2.20 Assessment of antigen specific cell proliferation and activation in vitro  
Aliquots  of  2x10
5  lymphoid  cells  were  cultured  in  200µl  of  T  cell  medium.  Cells  were 
cultured in the presence of 1mg/ml, 500µg/ml or 100 µg/ml OVA, or with 1µg/ml OVA 
peptide  323-339  (Genosys,  Sigma)  to  assess  antigen  specific  proliferation  and  cytokine 
production. Cells cultured in medium alone or in the presence of 1µg/ml anti-CD3 and 1µg/ml 
anti-CD28  (both  from  BD  Biosciences)  were  used  as  negative  and  positive  controls 
respectively. Cells were cultured in triplicate for 96h at 37°C in 5% CO2 in 96-well flat-
bottomed tissue culture plates (Corning). After 48h of culture, cell supernatants were removed 
and stored at –20°C for measurement of cytokines by ELISA and the wells replenished with 
fresh medium. To assess proliferation, cells were pulsed with 1µCi/well tritiated thymidine 
(
3H-TdR) for the final 18 hours of culture as above. 
 
2.21 Stimulation of MLN cells with R848 in vitro 
Single cell suspensions were prepared from the MLN of normal resting or Flt3L treated mice 
by mashing through sterile 50µm Nitex mesh (Cadisch) in RPMI 1640 medium (Invitrogen). 
Cells  were  subsequently  washed  by  centrifugation  at  400g  for  5  minutes  at  4°C  and  re-
suspended in complete medium. Aliquots of 1x10
6 viable MLN cells were cultured in 1ml of T 
cell medium alone, or in the presence of 1µg/ml R848 (Alexis Biochemicals). Cells were 
cultured in triplicate for 24h at 37°C in 5% CO2 in 24-well flat-bottomed tissue culture plates 
(Corning). After 24 hours, cells were harvested and stained for expression of CD11c, PDCA-1 
and CD40 or CD86 for analysis by flow cytometry.  
  
2.22 Flow cytometry 
Cells were washed by centrifugation at 400g at 4°C for 5 minutes in ice cold FACS buffer, 
suspended  at  1x10
6  cells  per  tube  in  5ml  round-bottomed  tubes  (BD  Biosciences)  and   62 
incubated with 1:200 anti-CD16/CD32 (BD Biosciences) in FACS buffer for 15 minutes at 
4°C to block non-specific binding. Cells were washed in FACS buffer and stained for a further 
30-60  minutes  with  fluorescein  isothiocyanate  (FITC),  phycoerythrin  (PE), 
allophycophycoerythrin  (APC)  or  biotin-conjugated  antibodies  specific  for  selected  cell 
markers  (Table  2.2).  Biotin-conjugated  antibodies  were  detected  by  the  addition  of 
streptavidin allophycophycoerythrin (SA-APC) (BD Biosciences). All FACS antibodies were 
used at 1:200 in FACS buffer with the exception of anti-PDCA-1 which was used at 1:11. All 
incubations were performed in 200µl at 4°C in the dark. After washing, dead cell exclusion 
was carried out by addition of 10µl 7-AAD (BD Biosciences) to each tube immediately prior 
to acquisition and analysis using a dual laser (488nm argon laser, 635nm red diode laser) 
FACSCalibur flow cytometer and CELLQuest software (BD Biosicences). Data were analysed 
using FlowJo software (Tree Star Inc, OR, USA). 
 
2.23 Chemokine receptor staining for flow cytometry 
Surface CCR9 was detected using monoclonal antibodies kindly provided by Dr Oliver Pabst 
(Institute  of  Immunology,  Hannover  Medical  School,  Hannover,  Germany).  Non  specific 
binding by cells was blocked by incubating in PBS 2% FCS 10% mouse serum for 1 hour at 
4°C, then cells were washed by centrifugation in PBS 2% FCS three times before staining for 
a further hour at 4°C with 5µg/ml anti-CCR9 antibody or purified ratIgG2b (as an isotype 
control). Cells were washed three times, stained with biotinylated polyclonal anti-rat IgG (BD 
Biosciences)  for  30  minutes  at  4°C,  washed  again  and  then  stained  with  SA-APC  (BD 
Biosciences) for 15 minutes at 4°C before washing three times.  
 
2.24 Assessment of intracellular cytokine production  
To assess cell specific IFN! production, 2x10
6 LN and spleen cell suspensions were stimulated 
for 4 hours with 0.1µM PMA and 1µM ionomycin (both Sigma) per well in 6 well tissue 
culture plates (Corning) in complete medium. 1µM monensin and 10µg/ml Brefeldin A (both 
Sigma) were added to the culture to prevent protein secretion by blocking the Golgi apparatus. 
Cells were harvested and re-suspended in 200µl “Block Wash” solution (PBS 0.1% sodium 
azide (Sigma), 1% heat inactivated FCS (Invitrogen) and 0.1% BSA (Sigma)). To allow for 
dead cell exclusion, 800µl 0.11µg/ml ethidium monoazide (EMA; Molecular Probes, Paisley, 
UK) was added to the tubes before their incubation for 10 minutes in the dark, followed by 
exposure to bright light for a further 10 minutes all at room temperature. Cells were stained for   63 
surface markers as described above then washed in “Block Wash” solution. 250µl of 1% 
formaldehyde (BDH Laboratory Supplies, Poole, England) in PBS was then added for 10 
minutes at 4°C to fix cells. Cells were then permeabilised in “Perm Wash” solution (PBS 0.1% 
saponin (Sigma) 0.1% sodium azide, 0.2% heat inactivated FCS and 0.1% BSA) before their 
incubation with purified anti-mouse CD16/CD32 (Fc block) (BD Biosciences) at 4°C for 15 
minutes to block intracellular Fc receptor binding. Cells were then suspended in “Perm Stain” 
solution (PBS 0.1% saponin (Sigma) 0.1% sodium azide, 1% heat inactivated FCS and 0.1% 
BSA) with anti-cytokine antibodies or appropriate isotype controls added at 1:200 dilutions 
and incubated in the dark at 4°C for 30 minutes. Finally, cells were washed in “Perm Wash” 
and analysed by flow cytometry.  
 
2.25 Assessment of intracellular FoxP3 staining by flow cytometry 
Cells were stained for intracellular expression of the regulatory T cell specific transcription 
factor FoxP3 using an APC-anti mouse/rat FoxP3 staining kit according to the manufacturer’s 
instructions (Ebioscience). Briefly, 1x10
6 cells were added per tube in 100µl FACS buffer and 
stained with EMA as above to exclude dead cells. Surface markers were stained for as above 
and  cells  washed  in  the  flow  cytometry  buffer  provided.  1ml  of  freshly  prepared 
fixation/permeabilisation  working  solution  was  then  added  to  the  cells  which  were  then 
incubated in the dark at 4°C for 30 minutes. Cells were then washed in the permeabilisation 
buffer provided and blocked with 100µl Fc block in permeabilisation buffer at 4°C for 15 
minutes. Without further washing, anti-FoxP3 antibody or the isotype control antibody was 
added at 0.5µg per 100µl of sample and incubated in the dark at 4°C for 30 minutes. Cells 
were then washed twice in permeabilisation buffer before re-suspension in FACS buffer and 
analysis by flow cytometry as above. 
 
2.26 Measurement of cytokine production by ELISA 
IFN! levels in culture supernatants were determined by sandwich ELISA. Immulon-4 ELISA 
plates  (Corning)  were  coated  overnight  at  4°C  with  anti-IFN!  capture  antibody  diluted  in 
carbonate buffer (Sigma). Plates were washed a minimum of three times with PBS 0.05% 
Tween 20 (Sigma) before blocking with PBS 10% FCS for 1 hour at room temperature. Plates 
were washed and incubated with samples and recombinant IFN! standards (BD Biosciences) 
for 2 hours at room temperature before further washing and addition of biotinylated anti-IFN! 
detection antibody (BD Biosciences) for 1 hour at room temperature. Plates were then washed   64 
and  incubated  with  1:1000  extravidin-peroxidase  (Sigma)  for  1  hour  at  room  temperature 
before washing and being developed using tetramethylbenzidine (TMB) substrate (KPL) and 
read at 630nm or 450nm in the presence of stop solution (R&D Systems, Abingdon, UK). The 
optical density (OD) of each well at 450nm was determined using a MRX II microplate reader 
(Dynex) and sample cytokine concentrations calculated from the standard curve obtained. A 
list of the capture and detection antibodies used is shown in Table 2.1.  
 
2.27 Measurement of chemokine production by ELISA 
CCL21 protein levels were measured by ELISA according to the manufacturer’s instructions 
(R&D Systems). Capture antibody was coated onto plates overnight at 4°C. Plates were then 
washed with PBS 0.05% Tween 20 (Sigma) before being blocked with PBS 1% BSA (Sigma) 
for 3 hours at room temperature. Plates were washed again, samples and standards added for 2 
hours  and  after  washing,  detection  antibody  was  added  for  a  further  2  hours  at  room 
temperature. Plates were then washed and streptavidin-HRP was added at room temperature 
for 1 hour. Following washing, substrate solution (R&D Systems) was added for 20 minutes 
before stop solution (R&D Systems) was applied. The optical density (OD) of each well at 
450nm was determined using a MRX II microplate reader (Dynex) and sample chemokine 
concentrations calculated from the standard curve obtained. A list of the capture and detection 
antibodies used is shown in Table 2.1.  
 
2.28 Purification of PDCA-1
+ plasmacytoid DC  
Cells from the spleens of Flt3L treated CD45.1
+CD45.2
- C57Bl/6, WT and CCX-CKR KO 
mice were purified by negative selection using the plasmacytoid dendritic cell isolation kit II 
according  to  the  manufacturer’s  instructions  (Miltenyi  Biotec  Ltd).  Briefly,  single  cell 
suspensions of spleen cells were prepared as described and 10
8 cells were re-suspended per 
350µl MACS buffer (2mM EDTA, 0.5% BSA PBS). 50µ1 FcR blocking reagent and 100µl 
plasmacytoid  dendritic  cell  (pDC)  biotin  cocktail  were  added  per  10
8  cells  and  the  cells 
incubated for 10 minutes at 4°C.  Cells were then washed by centrifugation at 300g for 10 
minutes before 800µ1 MACS buffer and 200µ1 of anti-biotin microbeads per 10
8 cells were 
added. Cells were incubated for 10 minutes at 4°C, then washed by centrifugation at 300g for 
10 minutes and re-suspended in 500µl of MACS buffer per 10
8 cells.  Cells were then passed 
through  a  MACS  column  placed  within  the  magnetic  field  of  a  MACS  separator  and 
unlabelled PDCA-1
+ cells were collected in the effluent.   65 
2.29 Adoptive transfer of plasmacytoid DC 
Intact spleen cells from CD45.1
+CD45.2
- C57Bl/6 mice or enriched pDC from Flt3L treated 
CD45.1
+CD45.2
- C57Bl/6, WT C57Bl/6 or CCX-CKR KO mice were passed through Nitex 
and an aliquot of cells was stained with anti-PDCA-1 antibody (Miltenyi Biotec Ltd, Surrey, 
UK) to assess pDC numbers by flow cytometry. The proportion of PDCA-1 expressing cells 
was calculated and the equivalent of 1x10
6 PDCA-1
+ pDC were transferred in sterile PBS 
(Invitrogen) i.p. (in the case of intact spleen cells) or i.v. (in the case of enriched pDC) per 
recipient. 
 
2.30 Induction of dextran sulphate sodium mediated colitis 
To induce acute colitis, mice received 2% dextran sulphate sodium (DSS) (reagent grade; MW 
36,000-50,000 kDa; MP Biomedicals, Ohio) in sterile drinking water for 7 days. The amount 
of water consumed per animal was estimated by dividing the total water intake by the number 
of animals per cage. Mice were monitored for weight change, rectal bleeding and diarrhoea, 
which  were  scored  according  to  the  criteria  shown  in  Table  2.3.  Colon  shortening  was 
determined immediately after sacrifice by measuring colon length and histological analysis 
was performed on paraffin embedded sections stained with haematoxylin and eosin (H&E) 
processed by technical staff in the department of veterinary medicine at the University of 
Glasgow. 
 
2.31  Measurement  of  cytokine  and  chemokine  production  in  colon  explant 
cultures by Luminex 
Colons were opened longitudinally and 1cm long samples of proximal and distal colons were 
washed in PBS supplemented with 100µg/ml penicillin and streptomycin. Colon tissues were 
then cultured in RPMI-1640 with 100µg/ml penicillin and streptomycin for 24 hours at 37°C 
in 5% CO2 and supernatants removed and stored at -20°C. The supernatants were assayed for 
the presence of FGF, GM-CSF, IFN!, TNF", IL-1", IL-1#, IL-2, IL-4, IL-5, IL-6, IL-10, IL-
12 (p40 and p70), IL-13, IL-17, CCL2, CCL3, CCL4, CCL5, CXCL1, CXCL9 and CXCL10 
using the Multiplex Bead Assay (Biosource, Paisley, UK) according to the manufacturer’s 
guidelines. Briefly, supernatant samples were incubated with antibody coated microspheres 
expressing  distinct  fluorophores  specific  for  designated  chemokines/cytokines  in  96  well 
plates (Corning). After washing, biotinylated detection antibodies were added for 1 hour at 
room  temperature  before  the  addition  of  SA-PE  for  30  minutes  at  room  temperature.   66 
Following  washing,  the  fluorescence  intensity  bound  to  microspheres  was  detected  and 
measured using a Luminex XMAP system.  
 
2.32 Statistical analysis 
Results are shown as means +1 standard deviation (SD) unless stated otherwise and groups 
were compared using either a Student’s unpaired two-tailed t test, Mann-Whitney test, one-
way  Anova  or  two-way  Anova  with  Bonferroni  post  tests.  The  distribution  of  data  was 
assessed using a D’Agostino and Pearson omnibus normality test. Values of p<0.05 were 
considered to be statistically significant. 
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Table 2.1 Monoclonal antibodies used for ELISA. 
 
Antibody  Capture/ 
Detection  
Working 
Concentration 
Supplier 
Anti  mouse  IgG  (Fc  specific) 
Alkaline  phosphatase  antibody 
produced in goat 
Capture  1:40000 dilution  Sigma 
Purified rat anti-mouse IgA  Capture  1:500 dilution  BD Biosciences 
Biotin rat anti-mouse IgG2a  Detection  1:1000 dilution  BD Biosciences 
Biotin rat anti-mouse IgG1  Detection  1:16000 dilution  BD Biosciences 
Anti-mouse  IgG  (Fab  specific) 
biotin  antibody  produced  in 
goat 
Detection  1:200000 dilution  Sigma 
Biotin rat anti-mouse IgA  Detection  1:500 dilution  BD Biosciences 
Anti- mouse IFN!  Capture  1:250 dilution  BD Biosciences 
Biotin anti-mouse IFN!  Detection  1:250 dilution  BD Biosciences 
Rat anti-mouse CCL21  Capture  4 µg/ml  R&D Systems 
Biotin goat anti-mouse CCL21  Detection  50 ng/ml  R&D Systems 
Rat anti-mouse CCL21  Capture  4 µg/ml  R&D Systems 
Biotin goat anti-mouse CCL21  Detection  50 ng/ml  R&D Systems 
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Table 2.2 Monoclonal antibodies and isotype controls used for flow cytometry 
 
Antigen  Clone  Isotype  Supplier 
B220  RA3-6B2  Rat IgG2a  BD Biosciences 
CD3  145-2C11  Hamster IgG1  BD Biosciences 
CD4  GK1.5  Rat IgG2b  BD Biosciences 
CD8  53-6.7  Rat IgG2a  BD Biosciences 
CD11b  M1/70  Rat IgG2b  BD Biosciences 
CD11c  HL3  Hamster IgG1  BD Biosciences 
CD19  1D3  Rat IgG2a  BD Biosciences 
CD25  7D4  Rat IgG2b  BD Biosciences 
CD40  3/23  Rat IgG2a  BD Biosciences 
CD45  30-F11  Rat IgG2b  Ebioscience 
CD69  C9B7W  Rat IgG1  BD Biosciences 
CD80  16-10A1  Hamster IgG2a  BD Biosciences 
CD86  GL1  Rat IgG2a  BD Biosciences 
CD103  M290  Rat IgG2a  BD Biosciences 
DX5  DX5  Rat IgM  BD Biosciences 
IFN!  XMG1.2  Rat IgG1  BD Biosciences 
IL-4  11B11  Rat IgG1  BD Biosciences 
F4/80  BM8  Rat IgG2a  Ebioscience 
FoxP3  FJK-16s  Rat IgG2a  Ebioscience 
KJ  KJ1-26  Murine IgG2a  BD Biosciences 
CD45.1  A20  Murine IgG2a  BD Biosciences 
MHC class II (I-A
b)  25-9-17  Murine IgG2a  BD Biosciences 
PDCA-1  JF05-IC24.1  Rat IgG2b  Miltenyi-Biotec 
V"2 TCR  KB5-C20  Rat IgG2a  BD Biosciences 
CCR9  7E7  Rat IgG2b  Dr Oliver Pabst 
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Table 2.3 Disease score criteria for DSS induced colitis. 
 
Points  Weight Loss as % 
of  total  starting 
body weight 
Rectal Bleeding  Stools 
0  none  none  well-formed pellet 
1  1-5     
2  5-10  blood stain around anus  pasty soft pellets that do no adhere 
to the anus 
3  10-20     
4  > 20  gross bleeding  diarrhoea that adheres to anus 
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Chapter 3 
Characterisation of the Secondary Lymphoid Organs 
of CCX-CKR KO Mice 
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Introduction 
Chemokines  are  essential  for  inflammatory  processes,  as  well  as  the  maintenance  of 
homeostasis. CCR7 and CCR9 are examples of chemokine receptors that mediate leukocyte 
localisation within lymphoid organs and tissues (12, 82). Previous data from an earlier PhD 
student has indicated that CCX-CKR may function as a scavenger of the CCR7 ligand CCL19, 
suggesting a role for CCX-CKR in the regulation of the availability of its chemokine ligands. 
As  CCR7  is  the  principal  chemokine  receptor  involved  in  leukocyte  entry  into  secondary 
lymphoid  organs,  CCX-CKR  could  play  a  role  in  regulating  the  recruitment  of  CCR7 
expressing  DC  and  naïve  lymphocytes  from  tissues  and  the  bloodstream  into  secondary 
lymphoid organs. Therefore, I investigated the architecture and composition of the LN and 
spleen  in  CCX-CKR  KO  mice  and  assessed  the  proliferative  capacity  of  and  cytokine 
production by lymphocytes in response to a selection of stimuli.  
 
3.1 Analysis of CCX-CKR KO secondary lymphoid architecture  
To begin my characterisation of the secondary lymphoid organs of CCX-CKR KO mice, I 
carried out a histological analysis of ILN, MLN and spleens of CCX-CKR KO and WT mice. 
No gross abnormalities could be seen in CCX-CKR KO mice, with B cell follicles being 
apparent  along  the  outer  edge  of  LN,  as  well  as  densely  populated  T  cell  zones  in  the 
surrounding areas. Lymphoid white pulp areas also appeared normal in the spleens of CCX-
CKR KO mice (Fig 3.1).   
 
3.2  Analysis  of  CCX-CKR  KO  secondary  lymphoid  organ  cellularity  and 
lymphocyte composition 
At the time of starting my project, preliminary work had suggested there might be reduced size 
and  cellularity  of  secondary  lymphoid  organs  in  CCX-CKR  KO  FVB  mice.  I  therefore 
extended this work using large numbers of CCX-CKR KO mice backcrossed thoroughly onto 
the C57Bl/6 genetic background but I found no significant differences in the total cell numbers 
recovered from the MLN, ILN or spleens of CCX-CKR KO and WT mice (Fig 3.2).  
There were also no significant differences in the proportions or absolute numbers of CD4
+ and 
CD8
+ T cells, or of CD19
+ B cells in these tissues (Fig 3.3). As CCX-CKR expression could 
also potentially affect the availability of CCL25, a ligand recognised by CCR9, I assessed 
CCR9  expression  by  lymphocytes  within  secondary  lymphoid  organs.  As  expected,  most 
CD8
+ T cells in WT mice expressed CCR9, as did a proportion of CD4
+ T cells and B220
+ B   72 
cells,  but  there  were  no  significant  differences  in  the  proportions  of  CCR9  expressing 
lymphocytes between CCX-CKR KO and WT mice (Fig 3.4). Unfortunately attempts to assess 
CCR7  expression  by  lymphocytes  from  CCX-CKR  KO  mice  using  flow  cytometry  were 
unsuccessful.  
 
CD4
+CD25
+FoxP3
+ T regs are a further subset of lymphocytes that are dependent on CCR7 for 
efficient  migration  into  secondary  lymphoid  organs  (90).  Comparable  proportions  and 
absolute numbers of total CD4
+CD25
+FoxP3
+ cells, and of FoxP3
+ cells amongst CD4
+CD25
+ 
cells were present within the MLN and ILN of CCX-CKR KO and WT mice. However, the 
proportion of CD4
+CD25
+FoxP3
+ cells in the spleens of CCX-CKR KO mice was significantly 
increased  compared  with  controls,  although  this  did  not  translate  into  a  difference  in  the 
absolute numbers of T regs (Fig 3.5).  
 
3.3 Proliferative and cytokine responses of CCX-CKR KO lymphocytes in vitro 
Having determined that the lymphocyte composition of secondary lymphoid organs is not 
significantly different between CCX-CKR KO and WT mice, I went on to assess lymphocyte 
function, as measured by their proliferative capacity and cytokine responses in vitro.  
 
Cells isolated from the MLN, ILN and spleens of CCX-CKR KO and WT mice were cultured 
either in complete medium alone, or with 1µg/ml anti-CD3 and anti-CD28 antibodies. The 
proliferative responses of spleen and LN cells from WT and CCX-CKR KO mice were not 
significantly  different  at  any  time  point  after  stimulation  (Fig  3.6).  Similar  results  were 
observed when MLN and spleen cells were stimulated with 5µg/ml Con A  (Fig 3.7).  
 
In contrast, CCX-CKR KO MLN and spleen cells produced significantly lower levels of IFN! 
after 48 hours stimulation with anti-CD3 and anti-CD28 antibodies. A similar defect was seen 
when CCX-CKR KO MLN cells were stimulated with 5µg/ml Con A. The same trend was 
found with spleen cells, although the difference was not statistically significant in this case 
(Fig 3.8).  
 
To extend these studies, I analysed intracellular IFN! expression by MLN and spleen cells 
stimulated for 4 hours with PMA and ionomycin. This revealed a significant reduction of IFN! 
production  by  CCX-CKR  KO  CD4
+  cells  compared  with  WT  T  cells.  However,  IFN!   73 
production  by  CD8
+ c e l l s  was  comparable  between  CCX-CKR  KO  and  WT  (Fig  3.9). 
Unfortunately, I was unable to assess production of the Th2 associated cytokine, IL-4 using 
this approach. 
  
3.4  Analysis  of  DC  populations  in  secondary  lymphoid  organs  of  CCX-CKR  KO 
mice 
I next investigated whether the absence of CCX-CKR affected the composition of CD11c
+ DC 
subsets within the MLN, ILN and spleen from which there were no significant differences in 
the proportions or numbers of total CD11c
+ cells recovered (Fig 3.10). I also examined the 
presence of CD11c
hiclassIIMHC
hi and CD11c
hiclass11MHC
lo DC in the MLN, on the basis that 
these are believed to represent DC that have migrated from tissues into secondary lymphoid 
organs, or which are “resident” DC derived from the blood stream respectively. Again no 
differences were found in either of these populations between CCX-CKR KO and WT mice  
(Fig 3.11).  
 
I next assessed the abundance of conventional DC subsets in the MLN that are characterised 
by their expression of CD11c and CD4, CD8 or CD11b (98). The proportions of total live cells 
co-expressing CD11c and CD4 or CD8 were significantly reduced in CCX-CKR KO mice, 
although  the  proportion  co-expressing  CD11c  and  CD11b  were  unaffected  by  CCX-CKR 
deletion. When expression of these markers was examined directly on CD11c
+ cells, similar 
numbers and proportions of cells co-expressing CD11c and CD11b or CD4 were seen in the 
MLN of CCX-CKR KO and WT mice. However the proportion of CD11c
+ cells expressing 
CD8 was reduced significantly in the MLN of CCX-CKR KO mice, although this did not 
manifest as a difference in their absolute numbers (Fig 3.12). 
 
Finally, I assessed the prevalence of pDC, as they are reported to express both CCR7 and 
CCR9 (121, 122). pDC have been characterised as being CD11c
loB220
+PDCA-1
+ cells. On 
examining the total LN cells, I found populations of CD11c
lo cells which expressed B220 or 
PDCA-1 (Fig 3.13A) and when CD11c
lo cells were analysed directly I found two distinct 
subsets,  one  of  which  were  B220
+PDCA-1
+  and  the  other  B220
+PDCA-1
-  (Fig  3.13.B). 
Preliminary studies using these criteria showed an apparent decrease in the absolute numbers 
and proportions of the CD11c
loB220
+PDCA-1
+ cell subset in the MLN of CCX-CKR KO mice 
but there were no differences in the absolute numbers or proportions of the B220
+PDCA-1
-   74 
cell subset (Fig 3.13 C, D). Recent work suggests that only the PDCA-1
+ cell subset are bona 
fide pDC, whereas the CD11c
loB220
+PDCA-1
- cells may be DC precursors (243). As I found 
that all CD11c
loPDCA-1
+ cells co-expressed B220, I used CD11c
lo and PDCA-1 expression 
alone to identify pDC more simply in more extensive studies. This approach confirmed the 
virtual absence of pDC in the MLN of CCX-CKR KO mice, whereas around 10-20% of total 
CD11c
+ cells were of this phenotype in WT MLN (Figs 3.14 and 3.15) 
 
A similar, but somewhat smaller reduction was also seen in the proportions of pDC in the ILN 
of CCX-CKR KO mice, although the absolute numbers of pDC were not significantly reduced 
in this case. There were no differences in the proportions or numbers of pDC in the spleens of 
CCX-CKR KO mice compared with WT, where pDC were relatively scarce in both strains 
(Fig 3.15). 
 
Further analysis indicated that compared with WT, higher proportions of pDC from CCX-
CKR  KO  lymphoid  organs  expressed  class  II  MHC  and  that  the  level  of  class  II  MHC 
expression by pDC was also significantly higher in CCX-CKR KO mice as assessed by !MFI 
(Fig 3.16).  
 
I next assessed CCR9 expression by pDC in CCX-CKR KO mice. CCR9 expressing total 
CD11c
lo cells were identifiable in the MLN and spleens of both WT and CCX-CKR KO mice. 
Staining was absent in CCR9 KO mice, confirming the specificity of the CCR9 antibody used 
in  analysis.  There  were  no  significant  differences  in  the  proportions  or  numbers  of 
CD11c
loCCR9
+  cells  in  the  spleens  of  CCX-CKR  KO  and  WT  mice,  but  these  were 
significantly reduced by approximately 40% in the MLN of CCX-CKR KO mice compared 
with WT MLN (Fig 3.17). Because of staining difficulties, I was unable to use PDCA-1 to 
identify these CD11c
loCCR9
+ cells as pDC directly. Therefore I used the co-expression of 
CD11c
lo and B220, although as discussed earlier, this population will also contain additional 
cells. In agreement with this, the numbers of CD11c
loB220
+ cells in CCX-CKR KO tissues 
were not reduced as dramatically as I had found for the numbers of CD11c
loPDCA-1
+ cells 
(Figs  3.15  and  3.18B).  40-50%  of  CD11c
loB220
+  cells  expressed  CCR9  in  the  MLN  and 
spleens of WT mice and this proportion was significantly reduced in the MLN of CCX-CKR 
KO mice. In parallel there was a significant reduction in the total numbers and proportions of 
CD11c
loB220
+CCR9
+  pDC  in  CCX-CKR  KO  MLN.    This  contrasts  with  the  normal   75 
expression of CCR9 by lymphocytes in CCX-CKR KO tissues. Similar trends were observed 
in the spleen, but these were not statistically significant (Fig 3.18).   
 
3.5 Analysis of macrophages and NK cells in lymphoid tissues of CCX-CKR KO 
mice 
Having assessed the relative proportions and numbers of lymphocytes and DC in CCX-CKR 
KO secondary lymphoid organs, I decided to determine whether a deficiency of CCX-CKR 
affected  the  numbers  of  macrophages  and  NK  cells.  Macrophages  were  identified  by 
expression of F480, while NK cells were identified as CD3
-DX5
+ cells. No differences were 
seen in the proportions or numbers of either cell type in any tissues from CCX-CKR KO and 
WT mice (Figs 3.19 and 3.20). 
  
Summary 
In this chapter, I have characterised the cellular composition of secondary lymphoid organs 
from CCX-CKR KO mice. My results have indicated that there are no differences in the 
proportions and numbers of CD4
+ and CD8
+ T cells, CD19
+ B cells, macrophages or NK cells 
between WT and CCX-CKR KO mice. In addition, proliferative responses to mitogenic or 
TCR stimulation in vitro were comparable. However there was a decreased production of 
IFN! by CD4
+ T cells from CCX-CKR KO mice. 
 
In addition, most of the phenotypic subsets of conventional DC were comparable in CCX-
CKR KO and WT MLN, apart from a significant reduction in the proportion of CD11c
+CD8
+ 
DC. The numbers and proportions of “migratory” and “resident” DC were also normal in 
CCX-CKR KO MLN.  The most significant finding from my studies was a consistent and 
dramatic reduction in the numbers of pDC in the MLN of CCX-CKR KO mice, despite the 
fact that the proportions and numbers of total CD11c
+ cells were comparable with WT mice. 
In  parallel,  fewer  CD11c
loB220
+  cells  from  the  MLN  of  CCX-CKR  KO  mice  than  WT 
expressed CCR9, despite this marker being expressed normally by lymphocytes in these mice. 
Interestingly however, pDC from CCX-CKR KO mice appeared to express higher levels of 
class II MHC than WT pDC.  
   76 
Taken together, these data indicate that CCX-CKR plays an important and selective role in the 
recruitment and/or maintenance and/or function of pDC into/within MLN. CCX-CKR may 
also play a subtle role in regulating Th1 function in secondary lymphoid organs.  
 
In the next chapter I went on to examine the effects of CCX-CKR deletion on the cellular 
composition of the intestinal immune compartment, an environment in which all three CCX-
CKR ligands, CCL19, CCL21 and CCL25 are abundant.  A
B
C
Figure 3.1
Normal Architecture of Secondary Lymphoid Organs in Resting
CCX-CKR KO Mice
MLN (A), inguinal lymph nodes (ILN) (B) and spleens (C) from resting WT
and CCX-CKR KO mice were removed, fixed in 10% formalin, embedded in
paraffin and stained with haematoxylin and eosin for histological analysis.
Distinct B cell follicles, T cell areas and white pulp can be seen in both WT
and CCX-CKR KO tissue. Representative histology from 3 mice per group is
shown. (Final magnification x100).
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Figure 3.2
Total Cell Numbers in CCX-CKR KO and WT Secondary Lymphoid Organs
Cells were isolated from MLN (A), ILN (B) and spleens (C) of CCX-CKR KO
and WT mice and viable cells counted by phase contrast microscopy.
Results show means of between 25-113 mice per group used in 33
individual experiments.
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Figure 3.3
Lymphocyte Composition of CCX-CKR KO and WT Secondary Lymphoid
Organs
Cells were isolated from the MLN, ILN and spleens of CCX-CKR KO and
WT mice and analysed for cell surface expression of CD4 (A), CD8 (B)
and CD19 (C) by flow cytometry. Left hand graphs show the proportions
of each cell type within live cell gates, while right hand graphs show
absolute cell numbers. Results show means +1 SD of 3 mice per group.
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Figure 3.4
Expression of CCR9 by CCX-CKR KO and WT Lymphocytes
Cells isolated from MLN, ILN and spleens of WT and CCX-CKR KO mice were
analysed for surface expression of CCR9 on CD4+ (A) CD8+ (B) and B220+ (C)
cells. Results show the mean proportion of each subset expressing CCR9 +1
SD of 3 mice  per group. (D) Representative histograms show CCR9 isotype
(shaded) and CCR9 specific staining of CD8+ T cells from WT MLN.
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Figure 3.5
FoxP3+ Regulatory T Cells in the Secondary Lymphoid Organs of
CCX-CKR KO and WT mice
Intacellular expression of FoxP3 by CD4+CD25+ T cells from the MLN, ILN
and spleens of CCX-CKR KO and WT mice was determined by flow
cytometry. (A) A representative FACS plot (left) shows the gated
CD4+CD25+ population within total live WT MLN cells while the histogram
(right) shows FoxP3 isotype (shaded) and FoxP3 specific staining of
CD4+CD25+ cells from WT MLN. (B) The proportions of live cells
co-expressing CD4, CD25 and FoxP3 and of (C) CD4+CD25+ cells expressing
FoxP3 along with (D) their absolute numbers are shown.  Results show the
means of 3 mice per group.
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Figure 3.6
Proliferative Responses of CCX-CKR KO and WT T Cells to
anti-CD3/CD28 Antibodies In Vitro
Cells were isolated from MLN, ILN and spleens of CCX-CKR KO and WT
mice and cultured either in medium alone, or with anti-CD3 and anti-CD28
antibodies for 48 (A) 72 (B) 96 (C) and 120 hours (D). Proliferation was
assessed by 3H-TdR incorporation and results represent the mean cpm + 1
SD of 3 mice per group.
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Figure 3.7
Proliferative Responses of Lymphocytes from CCX-CKR KO and WT
Mice to Con A In Vitro
Cells were isolated from the MLN (A) and spleens (B) of CCX-CKR KO
and WT mice and cultured either in complete medium alone or with
5µg/ml Con A for 72 hours. Proliferation was assessed by 3H-TdR
incorporation and results represent the mean cpm  +1 SD of 3 mice per
group.
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Figure 3.8
IFN! Production by CCX-CKR KO and WT Lymphocytes In Vitro
Cells were isolated from the MLN, ILN and spleens of CCX-CKR KO and
WT mice and cultured either in medium alone or with (A) 1µg/ml
antiCD3/CD28 or (B) 5µg/ml ConA  for 48 hours. Cytokine production
was assessed by ELISA and results show the mean IFN! production in
pg/ml +1 SD of 3 mice per group.
**p<0.01 Unpaired t test
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Figure 3.9
Intracellular Cytokine Analysis of IFN! Production by CCX-CKR KO and
WT T Cells In Vitro
Cells were isolated from the MLN and spleens of CCX-CKR KO and WT
mice and cultured for 4 hours in complete medium with 0.1µM
PMA+1mM  ionomycin+10mg/ml Brefeldin A+1µM monesin. Cells were
then stained for surface expression of CD4 and CD8, fixed and
permeabilised to detect intracellular IFN!. (A) Representative FACS plots
of WT MLN CD8+ T cells show IFN! specific staining of stimulated cells
(left) unstimulated cells (middle) and isotype staining of stimulated cells
(right). Results show the mean proportions of live CD8+ (B) and CD4+ (C)
T cells expressing IFN! +1 SD of 5 mice per group.
*p<0.05 **p<0.01 Unpaired t test
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Figure 3.10
CD11c+ Cells in the Secondary Lymphoid Organs of CCX-CKR KO and
WT Mice
MLN, ILN and spleens from CCX-CKR KO and WT mice were digested with
1mg/ml collagenase D and 30µg/ml DNase I and cells analysed for surface
expression of CD11c by flow cytometry. (A) Representative FACS plots of
CD11c specific (left) and isotype staining (right) of WT MLN cells show
the CD11c+ cell population. (B), (C) and (D) show the proportions (left)
and numbers (right) of live cells expressing CD11c in MLN, ILN and spleens
respectively. Results show the mean cell numbers and proportions of
12-32 mice per group and are pooled from 8 individual experiments.
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Figure 3.11
Migratory and Resident DC in the MLN of CCX-CKR KO and WT Mice
Cells were isolated from the MLN of CCX-CKR KO and WT mice and
analysed for surface expression of CD11c and class II MHC by flow
cytometry. (A) Representative FACS plots show CD11c+ cells amongst live
WT MLN cells (left), sub-divided into CD11chiclass II MHChi "migratory DC"
and CD11chiclass II MHClo "LN resident DC" subsets (right). (B) The
proportions (left) and absolute numbers (right) of each CD11chi cell subset
were determined. Results show the means +1 SD of 3 mice  per group.
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Figure 3.12
DC Subsets in the MLN of CCX-CKR KO and WT Mice
Cells were isolated from the MLN of CCX-CKR KO and WT mice and
analysed for surface expression of CD11c and CD4, CD8 or CD11b by flow
cytometry. (A) Representative FACS plots of WT MLN cells show the
proportions of live cells expressing CD11c in the large gates and of those
co-expressing CD11c and CD4(left), CD8 (middle) or CD11b in smaller
gates.  The proportions of live cells co-expressing CD11c and CD4, CD8 or
CD11b are shown in (B).The proportions of CD11c+ cells expressing CD4,
CD8 and CD11b are shown in (C) and the absolute numbers of cells within
each CD11c+ cell subset in (D). Results show the means +1 SD of 3 mice per
group.
*p<0.05  **p<0.01 Unpaired t test
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Figure 3.13
pDC in CCX-CKR KO and WT Mice
Cells isolated from the MLN of WT and CCX-CKR KO mice were analysed
for surface expression of CD11c, B220 and PDCA-1 by flow cytometry. (A)
Representative FACS plots of live WT MLN cells show the proportion of
total live cells expressing CD11c in the large rectangular gates and
CD11cloB220+ (left) or CD11cloPDCA-1+ (right) populations in smaller oval
gates. (B) A representative FACS plot of live WT MLN CD11c+ cells shows
the proportions of CD11c+ cells in CD11cloB220+PDCA-1+ and
CD11cloB220+PDCA-1- populations. (C) and (D) show the mean proportions
and absolute numbers of CD11c+ cells in CD11cloB220+, CD11cloPDCA-1+,
CD11cloB220+PDCA-1+ and CD11cloB220+PDCA-1- cell subsets. Results show
the means of 3 mice per group.
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Figure 3.14
CD11cloPDCA-1+ pDC in the MLN of CCX-CKR KO and WT Mice
Cells isolated from the MLN of CCX-CKR KO and WT mice were
analysed for cell surface expression of CD11c and PDCA-1 by flow
cytometry to identify pDC. Representative FACS plots show the
proportion of total live cells expressing CD11c in large rectangular
gates and the CD11cloPDCA-1+ cell population in small oval gates (left).
Contour plots are shown to more clearly define the CD11cloPDCA-1+ cell
population  in small oval gates (right). (A) CD11c specific staining and
isotype staining for PDCA-1. (B) CD11c and PDCA-1 specific staining for
WT and CCX-CKR KO cells.
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Figure 3.15
pDC in the Secondary Lymphoid Organs of CCX-CKR KO and WT Mice
Cells from the MLN, ILN and spleens of CCX-CKR KO and WT mice were
analysed for cell surface expression of CD11c and PDCA-1. pDC were
identified as CD11cloPDCA-1+ cells.  Results show the mean proportions of
pDC amongst total live MLN cells (A) and CD11c+ cells (B) and the
absolute numbers of pDC (C) for 12-21 mice  per group, pooled from 7
individual experiments.
***p<0.001 *p<0.05 Mann-Whitney test
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Figure 3.16
Class II MHC Expression on pDC in Secondary Lymphoid Organs of
CCX-CKR KO and WT Mice
Cells isolated from the MLN, ILN and spleens of CCX-CKR KO and WT
mice were analysed for surface expression of CD11c, PDCA-1 and class II
MHC. (A) Representative histograms show class II MHC isotype (shaded)
and specific staining of CD11cloPDCA-1+ cells from CCX-CKR KO and WT
mice. The proportions of CD11cloPDCA-1+ pDC expressing class II MHC (B)
and the levels of class II MHC expression on pDC as determined by !MFI
(C) are shown. Results show means +1 SD of 3 mice per group.
***p<0.001 **p<0.01 *p<0.05 Unpaired t test
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Figure 3.17
CCR9 expression on CD11clo Cells in CCX-CKR KO and WT Mice
Cells isolated from the MLN and spleens of CCX-CKR KO and WT mice
were analysed for surface expression of CD11c and CCR9. (A)
Representative FACS plots show live MLN cells from WT, CCX-CKR KO
and CCR9 KO mice. The proportions of total live cells expressing CD11c
are shown in the large rectangular gates and the proportions of total live
cells (left) or CD11c+ cells (right) within the CD11cloCCR9+ cell population
are shown in the smaller oval gates.(B) Proportions and absolute
numbers of CD11cloCCR9+ cells in the MLN and spleens of CCX-CKR KO
and WT mice are shown. Results show the means +1SD of 3 mice per
group.
*p<0.05 Unpaired t test
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Figure 3.18
CCR9 expression on CD11cloB220+ Cells in CCX-CKR KO and WT Mice
Cells isolated from the MLN and spleens of CCX-CKR KO and WT mice were
analysed for surface expression of CD11c, B220 and CCR9. Specifically, a
CD11cloB220+ cell subset was identified and their CCR9 expression
determined. (A) Representative FACS plots show live MLN cells from WT,
CCX-CKR KO and CCR9 KO mice. The proportions of total live cells
expressing CD11c are shown in large rectangular gates (left). The
proportions of CD11cloB220+ cells amongst total live cells (left) and CD11c+
cells (middle) are shown in smaller oval gates. Histograms show the
proportion of CD11cloB220+ cells expressing CCR9 (right). (B) The
proportions and absolute numbers of CD11c+ cells that are CD11cloB220+ in
the MLN and spleens of CCX-CKR  KO and WT mice are shown as well as
(C) the proportions and absolute numbers of CD11cloB220+ cells expressing
CCR9.
**p<0.01 *p<0.05  Unpaired t test
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Figure 3.19
Macrophages in the Secondary Lymphoid Organs of CCX-CKR KO and
WT Mice
MLN, ILN and spleens from CCX-CKR KO and WT mice were digested with
1mg/ml collagenase D and 30µg/ml DNase I and cells analysed for surface
expression of F480 by flow cytometry.(A) Representative FACS plots of
F480 specific (left) and isotype staining (right) of WT spleen cells show
the F480+ cell population. The proportions (B) and absolute numbers (C)
of F480+ cells isolated from MLN, ILN and spleens are shown. Results
show means +1 SD of 3 mice per group.
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Figure 3.20
NK cells in the MLN of CCX-CKR KO and WT Mice
MLN from CCX-CKR KO and WT mice were digested with 1mg/ml
collagenase and 30µg/ml DNase I and cells analysed for surface expression
of CD3 and DX5 by flow cytometry. (A) Representative FACS plots of DX5
specific (left) and isotype staining (right) of WT MLN cells show the
CD3-DX5+ cell population. The proportions (B) and absolute numbers (C)
of CD3-DX5+ cell isolated from MLN are shown. Results show means +1 SD
of 3 mice per group.
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Chapter 4
Characterisation of the Small Intestinal Immune
Compartment of CCX-CKR KO Mice98
Introduction
In the previous chapter I described the effects of CCX-CKR deletion on the composition of
lymphocyte and DC subsets in secondary lymphoid organs where the CCX-CKR ligands,
CCL19 and CCL21 are abundant. In this chapter I have turned my attention to the small
intestine where the other ligand for CCX-CKR, CCL25, is expressed constitutively by small
intestinal epithelial cells and plays an important role in recruiting effector T cells to the small
intestine (82, 133). CCR9, the receptor for CCL25 is induced on effector lymphocytes during
priming by CD103
+ DC within the MLN and PP and is important for their gut tropism. CCL19
and CCL21 are also critical for cell positioning and immune responses in the intestine, as their
receptor, CCR7 controls the migration of CD103
+ DC from the mucosa to MLN. This is
required for the effective induction of tolerance and immunity to oral antigens (125, 133).
Therefore here, I carried out initial investigations into the composition of the small intestinal
immune compartment in CCX-CKR KO mice, examining lymphocytes and DC populations in
the mucosa, MLN and PP.
4.1 Small intestinal lamina propria cellularity of CCX-CKR KO mice
The small intestine hosts a multitude of CCR9 expressing cells including effector T cells, pDC
and plasma cells. Therefore, I first explored the leukocyte composition of the small intestinal
lamina propria of CCX-CKR KO mice. Histological examinations of the small intestine
revealed no obvious abnormalities in its architecture in CCX-CKR KO mice (Fig 4.1).
Leukocytes were present in normal numbers in the villus and lamina propria and IEL were
present in their normal position on the basement membrane. The numbers of IEL, however,
were significantly decreased in CCX-CKR KO mice compared with WT mice (Fig 4.2).
The total numbers of live leukocytes identified by their expression of CD45 and lack of 7-
AAD uptake in preparations obtained by collagenase and DNase digestion of small intestinal
mucosa were comparable in CCX-CKR KO and WT mice (Figs 4.3A and B). Leukocyte
populations were further analysed for the presence of T cells, B cells and DC (Fig 4.3A) and
revealed no differences between CCX-CKR KO and WT mice in the proportions or absolute
numbers of CD3
+, CD4
+ and CD8
+ T cells. However, the proportions of CD11c
+ and CD19
+
cells were significantly increased and decreased respectively in CCX-CKR KO lamina propria
compared with WT mice. Although a similar trend was observed in the absolute numbers of
these cells, this was not statistically significant (Figs 4.3C and D).99
Having previously observed a significant reduction of CD11c
loPDCA-1
+ pDC in the MLN of
CCX-CKR KO mice, I next went on to determine whether CCX-CKR deletion affected the
proportion  of  CD11c
+  cell  subsets  in  the  lamina  propria,  in  particular  that  of  pDC.
Unfortunately,  the  small  numbers  of  CD11c
+  cells  obtained  from  resting  mice  made
identification of individual DC subsets unreliable and I was unable to assess the numbers of
CD11b
+ and CD8!
+ DC. Attempts to identify a CD11c
loPDCA-1
+ population of pDC were
also inconclusive, although I was able to identify the CD11c
loB220
+ cell population that should
contain pDC (Fig 4.4A). No significant differences were seen in the proportions or absolute
numbers of CD11c
loB220
+ cells between CCX-CKR KO and WT mice, with approximately 7-
15% of CD11c expressing cells comprising this DC subset in both cases (Figs 4.4B and C).
I was also able to determine the proportions and absolute numbers of the CD103 expressing
DC which make up a substantial proportion of lamina propria DC (Fig 4.5A). There were no
differences in the absolute numbers of CD11c
+CD103
+ DC between CCX-CKR KO and WT
mice,  with  30-40%  of  CD11c
+  cells  expressing  CD103  in  both  strains  (Fig4.5B).
CD11c
+CD103
+ cells could be divided into CD11c
intCD103
lo and CD11c
hiCD103
hi subsets and
the proportions and absolute numbers of these subsets amongst CD11c
+CD103
+ DC were
identical in the lamina propria of CCX-CKR KO and WT mice (Fig 4.5B and C).
4.2 Analysis of CD103 expression on MLN DC in CCX-CKR KO mice
Because CD103
+ DC from the lamina propria are known to migrate to the MLN (133, 197,
209).  I  extended  my  studies  of  the  intestinal  immune  compartment  by  assessing  the
proportions and absolute numbers of CD11c
intCD103
lo and CD11c
hiCD103
hi subsets within the
MLN. This was particularly relevant, as CCR7 KO mice have reduced numbers of CD103
+
DC in their MLN resulting in a failure to generate CCR9 expressing gut tropic effector T cells
(125, 244). In agreement with published work (82), approximately 40% of CD11c
+ cells from
the MLN of WT mice expressed CD103. The proportions and absolute numbers of CD11c
+
cells expressing CD103 were comparable between CCX-CKR KO and WT mice, as were the
proportions and absolute numbers of CD11c
intCD103
lo and CD11c
hiCD103
hi cells amongst the
CD11c
+CD103
+ population (Fig 4.6).100
4.3 Peyer’s patch cellularity in CCX-CKR KO mice
As the Peyer’s patches (PP) are a major site of antigen presentation and T cell priming in the
gut, any disruption of CCL19 or CCL21 availability could potentially affect lymphocyte
and/or DC distribution there. Therefore I next assessed DC subsets and B cell abundance in
the PP of CCX-CKR KO and WT mice. There were no differences in the total numbers of live
leukocytes, or in the proportions and absolute numbers of B220
+ B cells between CCX-CKR
KO and WT mice. For both strains, approximately 75% of live cells comprised B cells.
However, there was a statistically significant increase in the proportions of CD11c
+ cells in
CCX-CKR KO PP compared to WT but although the absolute numbers of CD11c
+ cells in
CCX-CKR KO PP appeared increased compared to WT, this was not statistically significant
(Fig 4.7). As before, there were insufficient numbers of CD11c
+ cells in resting PP to allow a
detailed  assessment  of  most  individual  DC  subsets.  However,  the  proportion  of  pDC
identifiable as CD11c
loB220
+PDCA-1
+ cells was reduced in the PP of CCX-CKR KO mice
(Figs 4.8A, B and D). A similar reduction was seen in the absolute numbers of pDC, although
this did not attain statistical significance (Fig 4.8C).
4.4 Flt3L expanded CD11c
+ cell populations in CCX-CKR KO mice
Due to the difficulties I experienced in obtaining sufficient DC from lamina propria and PP to
conduct a detailed analysis of DC subsets in resting mice, I decided to expand DC numbers in
vivo using fms-like tyrosine kinase ligand (Flt3L). Flt3L is a growth factor for DC precursors
and is responsible for the homeostatic proliferation of DC in lymphoid tissues (245-247). By
administering an exogenous source of Flt3L I could expand DC in vivo with the aim of being
able to detect cell subsets more easily. In addition, it would allow me to determine whether the
defect in pDC numbers within the secondary lymphoid organs of CCX-CKR KO mice could
be overcome.
After 10 daily injections of Flt3L i.p, the total numbers of leukocytes were comparable in the
lamina propria of Flt3L treated mice and were elevated compared with resting mice (Figs 4.3B
and 4.9B). As expected, the proportion of live leukocytes expressing CD11c expanded
dramatically from approximately 15% of WT and 25% of CCX-CKR KO live leukocytes to
about 65% in both strains. In contrast to resting mice, there were no differences in the absolute
numbers or proportions of total CD11c expressing cells in CCX-CKR KO and WT lamina
propria after Flt3L treatment (Fig 4.9).101
The expansion of DC numbers allowed me to characterise individual DC subsets within the
lamina propria of Flt3L treated mice. The proportions and absolute numbers of CD11c
+ cells
co-expressing B220, CD4, CD8, CD11b, CD103 or PDCA-1 were identical in CCX-CKR KO
and WT mice (Fig 4.10). The proportions and absolute numbers of CD103
+ DC subsets
amongst total live cells were also expanded in Flt3L treated mice, with both CD11c
intCD103
lo
and CD11c
hiCD103
hi cell subsets being apparent. The proportions of CD11c
intCD103
lo and
CD11c
hi CD103
hi cells amongst CD11c
+CD103
+ cells in the lamina propria were significantly
decreased and increased respectively in Flt3L treated CCX-CKR KO mice compared to WT
however this did not translate into a significant difference in absolute numbers (Fig 4.11).
Next I investigated the effects of Flt3L mediated DC expansion in the PP of CCX-CKR KO
mice. The total numbers of leukocytes were comparable in CCX-CKR KO and WT mice as
was the proportion of CD11c
+ cells. The absolute numbers of CD11c
+ cells were elevated in
CCX-CKR KO mice, although this was not statistically significant (Fig 4.12). CD11c
+ cells
co-expressing B220, CD103 and PDCA-1 were readily definable in the PP of Flt3L treated
mice and there were no significant differences in the proportions of these CD11c
+ cell subsets
in the PP of CCX-CKR KO and WT mice (Fig 4.13A,B and D). However the absolute
numbers of pDC, defined as CD11c
loB220
+  or CD11c
loPDCA-1
+ cells were significantly
increased in CCX-CKR KO mice (Fig 4.13C). Perhaps reflecting the slightly elevated total
cell numbers, the absolute numbers of CD11c
hiCD103
hi DC were also significantly elevated in
CCX-CKR KO mice, although no significant difference was seen in the proportions of the
CD11c
hiCD103
hi or CD11c
intCD103
lo cell subsets amongst CD11c
+CD103
+ DC (Fig 4.14).
The total cell numbers obtained from the MLN of Flt3L treated CCX-CKR KO and WT mice
were similar, as were the proportions and absolute numbers of CD11c
+ cells (Fig 4.15A). In
both cases, the proportion of CD11c expressing cells rose dramatically from approximately
5% in resting mice to between 50 and 60% with Flt3L treatment (Figs 3.10B, 4.15B and C).
The relative proportions and absolute numbers of CD11c
+ cells co-expressing CD8, CD11b
and B220 in the MLN of Flt3L treated CCX-CKR KO mice were comparable with those in
WT MLN (Fig 4.16A and B). Approximately 40% of MLN cells in Flt3L treated WT mice
were CD11c
+CD103
+ and this proportion was significantly decreased in CCX-CKR KO mice,
where approximately 25% of cells were CD11c
+CD103
+ (Fig 4.16B). However, this did not102
translate into absolute numbers and the proportions of CD11c
+ cells co-expressing CD103
were the same in the MLN of Flt3L treated CCX-CKR KO and WT mice (Fig 4.16C and D).
As in the MLN of resting CCX-CKR KO mice, the proportion of CD11c
+ cells expressing
PDCA-1 was significantly reduced in Flt3L treated CCX-CKR KO mice compared to WT.
However, again this did not translate into absolute numbers or in differences in the proportions
of total cells co-expressing CD11c and PDCA-1 (Fig 4.16). As in resting mice, a CD103
+ DC
population was apparent, but there were no significant differences in the proportions or
absolute numbers of CD11c
hiCD103
hi or CD11c
intCD103
lo cells in Flt3L treated CCX-CKR KO
and WT mice (Fig 4.17).
Finally, I examined DC populations in the ILN and spleens of Flt3L treated mice. The total
numbers of ILN cells, as well as the proportions and absolute numbers of CD11c
+ cells were
similar in CCX-CKR KO and WT mice. As in the intestine, PP and MLN, CD11c
+ cells were
expanded in the ILN of both CCX-CKR KO and WT mice, increasing from approximately 2%
of total ILN cells in resting mice to 20-25% after Flt3L treatment (Fig 4.18).
The greater numbers of CD11c
+ cells recoverable from the ILN of Flt3L treated mice, allowed
me to analyse DC subsets. The proportions and absolute numbers of CD8
+ and CD11b
+ DC
subsets were similar in CCX-CKR KO and WT mice with CD8
+ DC predominating.   In
contrast to the resting ILN, the proportion of cells co-expressing CD11c and PDCA-1 was not
significantly reduced in the ILN of Flt3L treated CCX-CKR KO mice compared to WT (Figs
3.15 and 4.19).
There were no significant differences in the proportions or absolute numbers of CD11c
+ cells
in the spleens of Flt3L treated CCX-CKR KO and WT mice (Fig 4.20). Again, the proportion
of live spleen cells expressing CD11c rose substantially from around 5% to 30% after Flt3L
treatment (Figs 3.10 and 4.20). There were no differences in the proportions or absolute
numbers of splenic CD11c
+ cells, or of CD11c
+ cells co-expressing CD8, CD11b or PDCA-1
between CCX-CKR KO and WT mice (Fig 4.21).103
Summary
In this chapter I expanded on my finding of decreased pDC numbers in the MLN of resting
CCX-CKR KO mice by carrying out an extensive analysis of DC subsets in the small
intestinal lamina propria and its associated lymphoid tissues. I have also explored the effect of
the DC growth factor, Flt3L on DC subsets in the intestine and secondary lymphoid organs of
CCX-CKR KO mice.
Although CCX-CKR KO mice displayed no histological abnormalities in their small intestinal
architecture, they do have significantly fewer IEL than WT mice. However, the T cell
composition of the lamina propria of CCX-CKR KO appeared to be normal. The proportions
of CD19
+ and CD11c
+ cells were significantly decreased and increased respectively in the
lamina propria of resting CCX-CKR KO mice compared with WT and although my attempts
to  investigate  DC  subsets  in  the  resting  lamina  propria were largely unsuccessful, the
proportions and absolute numbers of CD11c
loB220
+ and CD103
+ DC subsets were comparable
between the strains. CD103
+ DC subsets in the MLN of resting CCX-CKR KO and WT mice
were also similar. Interestingly, however, CCX-CKR KO mice had a significantly decreased
proportion of pDC in PP compared with WT mice, although there were no differences in total
CD11c
+ DC or B cells.
As expected, in vivo treatment with Flt3L led to a large expansion of all DC subsets including
pDC in all the tissues I analysed. There were no differences in DC subsets including pDC in
the  ILN  or  spleen  of  CCX-CKR  KO  and  WT  mice  however  the  proportions  of
CD11c
hiCD103
hi and CD11c
intCD103
lo cells amongst total CD11c
+CD103
+ DC in the lamina
propria were significantly decreased and increased respectively. In addition, Flt3L overcame
the decreased numbers of pDC seen in the PP of resting CCX-CKR KO mice. Indeed, the
numbers of CD11c
+ cells expressing B220 or PDCA-1 in the PP of Flt3L treated CCX-CKR
KO mice were actually significantly increased compared with WT, as were the numbers of
CD11c
hiCD103
hi cells. In contrast, the numbers of pDC remained significantly decreased in
the MLN of CCX-CKR KO mice, despite the normal expansion of other DC subsets. The
proportion of total CD11c
+ cells co-expressing CD103 was also significantly decreased in the
MLN of Flt3L treated CCX-CKR KO mice compared with WT.104
Together, these results indicated that the principal finding of the previous chapter of decreased
pDC in the MLN in the absence of CCX-CKR was shared by PP. However this could be
rescued in PP and other tissues by Flt3L, but not in the MLN.
Having assessed the phenotypic effects of CCX-CKR deletion on the cellularity of secondary
lymphoid organs and the small intestinal lamina propria, in the next chapter I go on to explore
the functional consequences of CCX-CKR deletion in the development of antigen specific
immunity and tolerance.A
B
Figure 4.1
Histology of the Small Intestine of CCX-CKR KO and WT Mice
Sections of small intestine from WT (A) and CCX-CKR KO (B) mice were
fixed in 10% formalin, embedded in paraffin and stained with
haematoxylin and eosin for histolgical analysis.(Final magnification x
200)
105WT KO
5
10
15 *
 
I
E
L
/
1
0
0
 
e
p
i
t
h
e
l
i
a
l
 
c
e
l
l
s
Figure 4.2
Frequency of Small Intestinal IEL in CCX-CKR KO and WT Mice
Sections of small intestine from CCX-CKR KO and WT mice were fixed in
10% formalin, embedded in paraffin and stained with haematoxylin and
eosin to identify IEL (indicated by arrows) (A). The numbers of IEL per
100 epitheilal cells on sections were determined by counting (B).
*p<0.05 Unpaired t test
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Figure 4.3
Phenotypic Analysis of Small Intestine Lamina Propia Cells from
CCX-CKR KO and WT Mice
Small intestinal lamina propria cells from CCX-CKR KO and WT mice were
analysed for expression of CD45 and 7-AAD uptake to identify CD45+7-AAD-
cells as live leukocytes.(A) Representative FACS plots are shown of live
leukocytes and their expression of CD3, CD4, CD8, CD11c or CD19 with
respective isotype controls. (B) The total numbers of live leukocytes, the
(C) proportions of CD3+, CD4+, CD8+ T cells, CD11c+ DC and CD19+ B cells
and (D) their absolute numbers are shown. Results show the means of
5-14 mice per group and are pooled from 3 individual experiments.
*p<0.05 Unpaired t test
specific staining isotype
total cells
live 7-AAD- CD45+
leukocytes
107WT KO
0
5
10
15
 
%
 
l
i
v
e
 
C
D
4
5  
+  
C
D
1
1
c  
+  
 
c
e
l
l
s
 
e
x
p
r
e
s
s
i
n
g
 
B
2
2
0
WT KO
0
2
4
6
 
C
D
1
1
c  
l
o  
B
2
2
0  
+  
 
c
e
l
l
s
 
(
x
1
0  
5  
)
A
C
B
B220
CD11c
Figure 4.4
pDC in the Small Intestinal Lamina Propia of CCX-CKR KO and WT Mice
pDC were identified amongst live CD45+ cells based on CD11c and B220
expression. (A) Representative FACS plots show the proportion of
7-AAD-CD45+ live leukocytes expressing CD11c and the proportion of
CD11c+ cells expressing B220 (putatively termed pDC). The proportions of
live CD45+CD11c+ cells expressing B220 and the total numbers of
CD11cloB220+ cells are shown in (B) and (C) respectively. Results show the
means + 1 SD of 3 mice per group.
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Figure 4.5
CD103 Expressing DC in the Small Intestinal Lamina Propria of
CCX-CKR KO and WT Mice
(A) Representative FACS plots show the proportion of total 7-AAD-CD45+
live lamina propria leukocytes expressing CD11c (left), the proportions of
CD11c+ cells co-expressing CD103 (middle) and the proportions of
CD11chiCD103hi and CD11cintCD103lo cells amongst CD11c+CD103+ cells
(right). CD103 isotype staining is shown immediately below. (B) The
proportions of live CD11c+ cells expressing CD103 (left), and their
absolute numbers (right) are shown along with (C) the proportions (left)
and absolute numbers of cells (right) in CD11chiCD103hi and
CD11cintCD103lo cell subsets. Results show the means +1 SD of 3 mice per
group.
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Figure 4.6
CD103 Expressing DC in the MLN of CCX-CKR KO and WT Mice
(A) Representative FACS plots show the proportion of total live MLN cells
expressing CD11c (left), the proportions of CD11c+ cells co-expressing
CD103 (middle) and the proportions of CD11chiCD103hi and
CD11cintCD103lo cells amongst CD11c+CD103+ cells (right). (B) The
proportions of live CD11c+ cells expressing CD103 (left), and their
absolute numbers (right) are shown along with (C) the proportions (left)
and absolute numbers of cells (right) in CD11chiCD103hi and
CD11cintCD103lo cell subsets. Results show the means +1 SD of 3 mice
per group.
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Figure 4.7
DC and B Cells in the PP of CCX-CKR KO and WT Mice
(A)Total numbers of Peyer's patch (PP) cells were determined and
analysed for cell surface expression of CD11c and B220. (B)
Representative FACS plots show the proportions of total live cells
expressing CD11c and B220 (after excluding autofluorescent cells). CD11c
and B220 isotype staining is also shown. (C,E) The proportions and
absolute numbers (D,F) of live PP cells expressing B220 or CD11c are
shown. Results show means +1 SD of 5 mice per group.
**p<0.01 Unpaired t test
specific staining B220 isotype CD11c isotype
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Figure 4.8
pDC in the PP of CCX-CKR KO and WT Mice
(A) Representative FACS plots of total live PP cells show the proportions
expressing CD11c and co-expressing CD11c with PDCA-1 in rectangular
and oval gates respectively (left panels) in WT (upper panels) and
CCX-CKR KO (lower panels) mice. The proportions of CD11c+ cells
co-expressing B220 and PDCA-1 are also shown (right panels). (B) The
proportions and (C) absolute numbers of CD11cloPDCA-1+ pDC amongst live
cells are shown along with (D) the proportions of PDCA-1+ cells amongst
gated CD11c+ cells. Results show means +1 SD of 5 mice per group
***p<0.001 Unpaired t test
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Figure 4.9
DC in the Small Intestinal Lamina Propria of CCX-CKR KO and WT Mice
After Treatment With Flt3L
CCX-CKR KO and WT mice were injected daily with Flt3L for 10 days
after which small intestines were removed and live leukocytes were
analysed for CD11c expression. (A) Representative FACS plot showing the
proportion of total 7-AAD-CD45+ cells. (B) Total numbers of live leukocytes
in the lamina propria as well as (C) the proportions and (D) absolute
numbers of CD11c+ cells are shown.  Results show means +1 SD of 6 mice
per group.
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Figure 4.10
DC Subsets in the Small Intestinal Lamina Propria of Flt3L Treated
CCX-CKR KO and WT Mice
Live gated lamina propria cells from Flt3L treated CCX-CKR KO and WT
mice were analysed for surface expression of  B220, CD4, CD8, CD11b,
CD103 or PDCA-1 on CD11c+ cells. (A) Representative FACS plots show the
proportions of total live cells co-expressing CD11c and B220, CD4, CD8,
CD11b, CD103 or PDCA-1. Isotype staining for each CD11c+ cell subset is
shown in the top row. (B) The proportions and (C) absolute numbers of
live cells co-expressing CD11c and individual subset markers are shown.
(D) The proportions of CD11c+ cells expressing individual subset markers
are shown. Results show means +1 SD of 3-9 mice per group.
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Figure 4.11
CD103 Expressing DC in the Small Intestine Lamina Propria of CCX-CKR
KO and WT Mice After Treatment With Flt3L
Live gated cells from the small intestines of Flt3L treated CCX-CKR KO and
WT mice were analysed for co-expression of CD11c and CD103. (A)
Representative FACS plots show the proportion of total live leukocytes
expressing CD11c (left), the proportion of CD11c+ cells expressing CD103
(middle) and the proportions of CD11c+CD103+ cells that are
CD11chiCD103hi and CD11cintCD103lo cells (right). The proportion of
CD11c+CD103+ cells in CD11chiCD103hi and CD11cintCD103lo cell subsets and
their absolute numbers are shown in (B) and (C) respectively. Results show
the means +1 SD of 3 mice per group.
*p<0.05 **p<0.01 Unpaired t test
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Figure 4.12
DC in the PP of CCX-CKR KO and WT Mice After Treatment With Flt3L
CCX-CKR KO and WT mice were injected daily with Flt3L for 10 days and
the total numbers of live cells recovered from PP were determined (A).
The proportions (B) and absolute numbers (C) of  CD11c+ cells were
analysed by flow cytometry.  Results show means of 3 mice per group.
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Figure 4.13
DC Subsets in the PP of CCX-CKR KO and WT Mice After Treatment
With Flt3L
Live gated PP cells from Flt3L treated CCX-CKR KO and WT mice were
analysed for surface expression of  B220, CD103 or PDCA-1 on CD11c+ cells.
(A) Representative FACS plots show the proportions of total live cells
co-expressing CD11c and B220, CD103 or PDCA-1. (B) The proportions and
(C) absolute numbers of live cells co-expressing CD11c and individual subset
markers are shown. (D) The proportions of CD11c+ cells expressing
individual subset markers are shown. Results show means +1 SD of 3 mice
per group.
*p<0.05  ***p<0.001 Unpaired t test
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Figure 4.14
CD103 Expressing DC in the PP of CCX-CKR KO and WT Mice After
Treatment With Flt3L
Live gated cells from the PP of Flt3L treated CCX-CKR KO and WT mice
were analysed for co-expression of CD11c and CD103. (A) Representative
FACS plots show the proportion of total live leukocytes expressing CD11c
(left), the proportion of CD11c+ cells expressing CD103 (middle) and the
proportions of CD11c+CD103+ cells that are CD11chiCD103hi and
CD11cintCD103lo cells (right). The proportion of CD11c+CD103+ cells in
CD11chiCD103hi and CD11cintCD103lo cell subsets and their absolute numbers
are shown in (B) and (C) respectively. Results show the means +1 SD of 3
mice per group.
*p<0.05 Unpaired t test
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Figure 4.15
DC in the MLN of CCX-CKR KO and WT Mice After Treatment With Flt3L
CCX-CKR KO and WT mice were injected daily with Flt3L for 10 days and
the total numbers of live cells recovered from MLN were determined (A).
The proportions (B) and numbers (C) of CD11c+ cells were analysed by flow
cytometry.  Results show means of 9 mice per group and are pooled from
3 separate experiments.
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Figure 4.16
DC Subsets in the MLN of CCX-CKR KO and WT Mice After Treatment
With Flt3L
Live gated MLN cells from Flt3L treated CCX-CKR KO and WT mice were
analysed for surface expression of  B220, CD8, CD11b, CD103 or
PDCA-1 on CD11c+ cells. (A) Representative FACS plots show the
proportions of total live cells co-expressing CD11c and B220, CD8,
CD11b, CD103 or PDCA-1. Isotype staining for each CD11c+ cell subset is
shown in the top row (B) The proportions and (C) absolute numbers of
live cells co-expressing CD11c and individual subset markers are shown.
(D) The proportions of CD11c+ cells expressing individual subset markers
are shown in (D). Results show means +1 SD of between 3 and 9 mice
per group.
*p<0.05 Unpaired t test
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Figure 4.17
CD103 Expressing DC in the MLN of CCX-CKR KO and WT Mice
After Treatment With Flt3L
Live gated cells from the MLN of Flt3L treated CCX-CKR KO and WT
mice were analysed for co-expression of CD11c and CD103. (A)
Representative FACS plots show the proportion of total live leukocytes
expressing CD11c (left), the proportion of CD11c+ cells expressing
CD103 (middle) and the proportions of CD11c+CD103+ cells that are
CD11chiCD103hi and CD11cintCD103lo cells (right). The proportion of
CD11c+CD103+ cells in CD11chiCD103hi and CD11cintCD103lo cell subsets
and their absolute numbers are shown in (B) and (C) respectively.
Results show the means +1 SD of 3 mice per group.
live cells CD11c+CD103+ cells CD11c+ cells
CD11chiCD103hi cells
CD11cintCD103lo cells
121WT KO
0
5
10
15
 
I
L
N
 
c
e
l
l
s
 
(
x
1
0  
6  
)
WT KO
0
10
20
30
40
 
%
 
l
i
v
e
 
I
L
N
 
c
e
l
l
s
 
e
x
p
r
e
s
s
i
n
g
 
C
D
1
1
c
WT KO
0
2
4
6
 
C
D
1
1
c  
+  
 
c
e
l
l
s
 
(
x
1
0  
6  
)
A
B C
Figure 4.18
DC in the ILN of CCX-CKR KO and WT Mice After Treatment With Flt3L
CCX-CKR KO and WT mice were injected daily with Flt3L for 10 days and
the total numbers of live cells recovered from ILN were determined (A).
The proportions (B) and numbers (C) of CD11c+ cells were analysed by flow
cytometry.  Results show means of 3 mice per group.
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Figure 4.19
DC Subsets in the ILN of CCX-CKR KO and WT Mice After Treatment
With Flt3L
Live gated ILN cells from Flt3L treated CCX-CKR KO and WT mice were
analysed for surface expression of  CD8, CD11b or PDCA-1 on CD11c+
cells. (A) The proportions and (B) absolute numbers of live cells
co-expressing CD11c and individual subset markers are shown (C) The
proportions of CD11c+ cells expressing individual subset markers. Results
show means +1 SD of 3 mice per group.
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Figure 4.20
DC in the Spleens of CCX-CKR KO and WT Mice After Treatment With
Flt3L
CCX-CKR KO and WT mice were injected daily with Flt3L for 10 days and
the total numbers of live cells recovered from spleens were determined
(A). The proportions (B) and numbers (C) of CD11c+ cells were analysed
by flow cytometry.  Results show means of 3 mice per group.
124CD8+ CD11b+ PDCA-1+
0
2
4
6
8
10
12
 
%
 
t
o
t
a
l
 
l
i
v
e
 
c
e
l
l
s
 
c
o
-
e
x
p
r
e
s
s
i
n
g
 
C
D
1
1
c
CD8+ CD11b+ PDCA-1+
0
5
10
15 KO
WT
 
c
e
l
l
s
 
(
x
1
0  
6  
)
CD8+ CD11b+ PDCA-1+
0
10
20
30
40
50
 
%
 
C
D
1
1
c  
+  
 
c
e
l
l
s
A B
C
Figure 4.21
DC Subsets in the Spleens of CCX-CKR KO and WT Mice After
Treatment With Flt3L
Live gated spleen cells from Flt3L treated CCX-CKR KO and WT mice
were analysed for surface expression of  CD8, CD11b or PDCA-1 on
CD11c+ cells. (A) The proportions and (B) absolute numbers of live cells
co-expressing CD11c and individual subset markers are shown (C) The
proportions of CD11c+ cells expressing individual subset markers are
shown. Results show means +1 SD of 3 mice per group.
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Chapter 5
Analysis of Antigen Specific Immune Responses in
CCX-CKR KO Mice127
Introduction
The CCX-CKR ligands, CCL19 and CCL21 are crucial for co-ordinating liaisons between
CCR7 expressing antigen loaded DC and naïve T cells, as well as for regulating B cell
interactions with CCR7 expressing
 primed T cells within secondary lymphoid organs (22, 29,
67, 80). Such prominent roles in the development of adaptive immunity suggest that CCL19
and CCL21 bioavailability and activity must be tightly regulated to avoid the initiation of
aberrant and potentially damaging immune responses. As CCX-CKR has been proposed to
function as a regulator of CCL19 and CCL21 availability, I thought it would be of interest to
explore the effects of CCX-CKR deletion on antigen specific immunity.
The immune system generates active immunity to dangerous foreign antigens and just as
importantly, establishes immunological tolerance to innocuous and self-antigens. In the small
intestine, this phenomenon is known as oral tolerance and an important manifestation of this is
the suppression of antigen specific immune responses to a subsequent systemic challenge
(146, 227, 228). Recent work shows that oral tolerance requires CCR7 dependent migration of
DC from the gut wall to the draining MLN, indicating a central role for CCR7 and its ligands
in  regulating  homeostasis  within  the  gut  (125).  The  CCX-CKR  ligand  CCL25  is  also
important in co-ordinating mucosal immunity. CCR9 co-expression with the integrin !4"7
confers effector T cells with the ability to migrate to the mucosa from the blood in response to
CCL25 produced by small intestine epithelial cells (212, 221). CCR9 is also expressed on
pDC and plasma cells within the small intestinal lamina propria and both T cells and pDC are
decreased in numbers in the lamina propria of CCR9 KO mice (121).
For these reasons, I hypothesised that CCX-CKR may play an important role in co-ordinating
immune responses and tolerance, especially those originating in the intestine. I therefore
explored systemic immune responses to subcutaneous immunisation with OVA in adjuvant,
the generation of tolerance and immunity by feeding OVA and the induction of intestinal
inflammation by oral administration of DSS.
5.1 Assessment of antigen specific immune responses in CCX-CKR KO mice
WT and CCX-CKR KO mice were immunised subcutaneously in the hind footpad with OVA
emulsified in CFA. 3 weeks later, systemic DTH responses were measured by challenging the128
opposite hind footpad with heat aggregated OVA (HAO) and blood was taken to assess OVA
specific IgG1 and IgG2a antibody production (Fig 5.1A).
Both CCX-CKR KO and WT mice developed good DTH responses, as well as OVA specific
IgG1 and IgG2a antibodies after immunisation and there were no significant differences
between mouse strains (Fig 5.1B-D). In a separate experiment, mice received OVA emulsified
in CFA in the footpad as above and 2 weeks later the draining popliteal LN were removed, the
numbers of CD4
+, CD8
+ and CD19
+ lymphocytes were assessed by FACS and LN cells were
re-stimulated in vitro with OVA or anti-CD3/CD28 (Fig 5.2A). The draining popliteal LN of
immunised mice contained approximately 25% CD4
+ T cells, 20% CD8
+ T cells and 50%
CD19
+ B cells, with no significant differences between CCX-CKR KO and WT mice. The
absolute numbers of total cells and individual cell subsets were also identical (Figs 5.2B and
C). Both WT and CCX-CKR KO popliteal LN cells proliferated and produced IFN# robustly
in response to anti-CD3/CD28 with no significant differences between the strains. Lesser, but
still considerable proliferation and IFN# production occurred in a dose dependent manner after
re-stimulation of popliteal LN cells with OVA and again, these responses were not affected by
the absence of CCX-CKR (Figs 5.2D and E). Together these results indicate that CCX-CKR
does not have an essential role in priming of systemic T or B cell responses.
5.2 Assessment of oral tolerance induction in CCX-CKR KO mice using a single
high dose feed
I next decided to investigate whether oral tolerance induction is affected by CCX-CKR
deletion using a single high dose of protein.
WT and CCX-CKR KO mice were fed a single dose of 25mg OVA or PBS as a negative
control. 1 week later, mice were immunised in the footpad with OVA emulsified in CFA and 3
weeks later, systemic DTH and serum antibody responses were assessed as described above
(Fig 5.3A). As before, control CCX-CKR KO and WT mice that were fed PBS, developed
good OVA specific DTH, IgG1 and IgG2a responses that did not differ between the strains. In
each  of  the  3  experiments  performed,  WT  mice  that  received  OVA  orally  prior  to
immunisation showed a significantly reduced DTH response compared with PBS controls,
indicating the induction of oral tolerance (Fig 5.3B). OVA specific IgG2a antibody responses
were also lower in OVA fed WT mice than in PBS controls, although this was only significant129
in one experiment (Fig 5.4). In contrast, OVA fed CCX-CKR KO mice did not show
significant oral tolerance induction in any of the experiments, with identical OVA specific
DTH and IgG2a responses in OVA fed and PBS fed groups (Figs 5.3B, 5.4).  There was no
significant suppression of OVA specific IgG1 antibody responses in WT or CCX-CKR KO
OVA fed mice in any experiment.
In a further experiment, WT and CCX-CKR KO mice were fed PBS or 25mg OVA and 1
week later immunised in the hind footpad with OVA emulsified in CFA. 2 weeks after this,
the draining popliteal LN were removed, cells isolated and re-stimulated in vitro with different
doses of OVA to assess proliferation and IFN# production (Fig 5.5A). Both CCX-CKR KO
and WT cells from PBS fed mice proliferated in response to different doses of OVA. In both
strains, these responses were reduced in OVA fed mice compared with PBS fed mice,
although these effects were not statistically significant (Figs 5.5B and C). Similar results were
obtained when IFN# production was assessed, with OVA specific cytokine levels being
reduced to similar extents in OVA fed CCX-CKR KO and WT mice compared with PBS fed
controls. Again however these effects were not statistically significant (Fig 5.6).
5.3 Assessment of oral tolerance induction in CCX-CKR KO mice using multiple
low dose feeds
As it has been suggested that different mechanisms may cause oral tolerance depending on the
feeding regime employed, I went on to investigate if the apparent defect in oral tolerance
development I had observed in CCX-CKR KO mice could be reproduced using a different
protocol. CCX-CKR KO and WT mice were fed 1mg OVA daily over 5 consecutive days and
immunised in the footpad with OVA/CFA 1 week after the last feed. 3 weeks later, systemic
OVA specific DTH and antibody responses were assessed and as before, there were no
significant differences in these responses between PBS fed CCX-CKR KO and WT mice (Fig
5.7). As with feeding a single high dose of antigen, DTH responses were reduced in WT mice
fed multiple low doses of OVA compared with PBS controls, although this effect was not
statistically significant in this instance. In contrast, DTH responses were not reduced in CCX-
CKR KO mice fed multiple low doses of OVA compared with PBS controls and, if anything,
appeared slightly elevated, although this was not statistically significant (Fig 5.7B).130
As I found with high dose OVA feeding, WT mice fed multiple low doses of OVA had
significantly reduced OVA specific IgG2a antibody levels compared with PBS fed controls
whereas OVA specific IgG1 levels were identical in the two groups. OVA specific IgG1 and
IgG2a levels were not significantly different between CCX-CKR KO mice fed OVA or PBS
(Fig 5.8).
Together these findings indicate there is a defect in oral tolerance in CCX-CKR KO mice that
is not influenced by the feeding regime used.
5.4 Assessment of oral priming in CCX-CKR KO mice
In view of the apparent defect in oral tolerance in CCX-CKR KO mice, I decided to
investigate if there was also a difference in the ability of these mice to be primed by feeding
antigen with a mucosal adjuvant.
WT and CCX-CKR KO mice were fed PBS, 10mg OVA alone, or 10mg OVA together with
10µg CT on three occasions 10 days apart. 10 days after the last feed, all groups were
challenged in the footpad with HAO to assess priming of systemic DTH responses and serum
was taken for the measurement of OVA specific IgG, IgG1, IgG2a and IgA responses (Fig
5.9A). Both CCX-CKR KO and WT mice fed OVA+CT appeared to show priming of OVA
specific DTH responses, with increases in footpad thickness approximately twice or three
times those in the negative controls fed OVA or PBS alone for WT and CCX-CKR KO mice
respectively. However, this increase was only statistically significant for CCX-CKR KO mice
although, there were no significant differences in the OVA specific DTH responses between
primed CCX-CKR KO and WT mice (Fig 5.9B).
OVA specific antibody responses were assessed in 3 separate experiments (Figs 5.10-5.12). In
the first, CCX-CKR KO mice fed OVA+CT showed elevated levels of OVA specific serum
total IgG, IgG1, IgG2a and IgA antibodies compared with WT OVA+CT fed mice, which
showed little evidence of priming in this experiment, apart from slightly elevated levels of
IgG1 compared with OVA or PBS fed controls. However, levels of OVA specific total IgG
and IgG2a were significantly elevated in OVA+CT fed CCX-CKR KO mice compared to
primed WT mice and to OVA or PBS fed controls (Fig 5.10). In the second experiment,
virtually no OVA specific serum antibody was detectable in PBS fed mice for either strain,131
while OVA+CT fed CCX-CKR KO and WT mice showed some OVA specific IgG and IgG1
antibody production. CCX-CKR KO but not WT mice fed OVA alone also had detectable
OVA specific IgG, IgG1 and IgA antibodies. Again, CCX-CKR KO mice fed OVA+CT had
consistent levels of OVA specific antibody production of all kinds, which were much higher
than those of PBS or OVA fed CCX-CKR KO mice. The OVA specific total IgG, IgG2a and
IgA responses of OVA+CT fed CCX-CKR KO mice were higher than in OVA+CT fed WT,
although only their OVA specific IgA responses were significantly increased. Robust OVA
specific IgG1 responses were found in both OVA+CT fed CCX-CKR KO and WT mice (Fig
5.11). In the third experiment, there was also evidence of priming of OVA specific IgG
antibody in OVA+CT fed CCX-CKR KO and WT mice with the levels of OVA specific total
IgG and IgG1 being identical in both strains of mice. However, again, the levels of OVA
specific IgG2a and IgA were elevated in primed CCX-CKR KO mice compared with WT
mice fed OVA+CT although this was not statistically significant. WT mice fed OVA alone,
had little or no OVA specific antibodies but again OVA fed CCX-CKR KO mice showed
elevated levels of OVA specific total IgG and IgG1 compared with PBS fed controls, although
this was not statistically significant (Fig 5.12). Collectively these experiments indicated an
enhanced ability to prime systemic antibody production by feeding antigen with adjuvant to
CCX-CKR KO mice, especially with respect to serum IgG2a and IgA.
As my results suggested that antigen specific IgG antibody titres might be higher in CCX-
CKR KO mice, I thought it important to ensure that this did not reflect a generalised increase
in circulating immunoglobulin levels. Therefore I assessed total IgG levels in the CCX-CKR
KO and WT mice fed OVA+CT, OVA alone or PBS in the second of the oral priming
experiments described above. All these samples had identical levels of total serum IgG,
suggesting that the differences I observed were due to genuine variations in antigen specific
mucosal priming of immune responses (Fig 5.13).
To  examine  whether  the  susceptibility  of  CCX-CKR  KO  mice  to  priming  by  oral
administration of antigen extended to mucosal immune responses, I determined the levels of
OVA specific intestinal IgA in the faeces of CT primed CCX-CKR KO and WT mice. CCX-
CKR KO and WT mice fed OVA alone showed no OVA specific IgA antibody levels above
those of PBS fed controls. There was no significant production of OVA specific IgA in WT
mice fed OVA+CT, with only two mice showing any IgA above background. However, the132
majority of CCX-CKR KO mice fed OVA+CT had detectable OVA specific IgA antibodies,
with a significant difference between this group and all other groups (Fig 5.14A). Again, this
seemed to be due to priming of specific immunity, as there were no differences in total
intestinal IgA levels between any of the six groups (Fig 5.14B).
5.5 Assessment of DSS colitis in CCX-CKR KO mice
So far, I have addressed the induction of antigen specific mucosal immunity and tolerance in
CCX-CKR KO mice, responses that are induced predominantly via the small intestine. In the
next experiments, I decided to explore whether inflammatory effector responses in the large
intestine were also affected in these animals. To do this I used a model of colitis induced by
the oral administration of DSS.
Mice received 2% DSS in their drinking water for 7 days, while control mice received normal
drinking water. As expected, WT mice lost weight after administration of DSS from day 5
onwards, losing approximately 15% of their body weight by day 7. An identical pattern of
weight  loss  was  also  seen  in  CCX-CKR  KO  mice  (Fig  5.15A).  Clinical  disease  was
determined by monitoring weight loss, the presence of diarrhoea and rectal bleeding. The
combined clinical scores showed progressive disease in all mice and there were no significant
differences between CCX-CKR KO and WT mice (Fig 5.15B). Both groups also had similar
and significant reductions in colon length compared with controls when sacrificed on day 7
(Fig 5.15C).
Sections of distal colon segments from CCX-CKR KO and WT control and DSS treated mice
on day 7 were stained with haematoxylin and eosin (H&E) to visualise mucosal architecture
integrity and cellular infiltrates. The colons of CCX-CKR KO and WT mice given DSS both
showed gross disruption of colon crypts and loss of the surface epithelial layer, together with
extensive cellular infiltration of the mucosa (Fig 5.16). Thus there were no obvious differences
in the colon inflammation induced by oral administration of DSS between CCX-CKR KO and
WT mice.
To extend these findings, I used Luminex analysis to assess the production of cytokines and
chemokines from explants of distal and proximal colons of DSS treated CCX-CKR KO and
WT mice. As expected, this showed the presence of inflammatory cytokines such as IL-1!,133
IL-1", IL-6 and TNF! and VEGF in supernatants of distal colon explants, with no significant
differences between CCX-CKR KO and WT mice. Other cytokines such as IL-10 and IFN-#
(Fig 5.17) as well as GMCSF and FGF (Fig 5.18) were also detectable, but much less
consistently and generally at lower levels. In most cases, cytokines were produced at much
lower levels than from the proximal colon explants, confirming the pattern of disease
pathology in this model. Similar patterns of production of the chemokines CCL2, CCL3,
CCL4, CCL5, CXCL1, CXCL9 and CXCL10 were seen, with generally higher levels in
inflamed distal colon. Again, there were no significant differences between CCX-CKR KO
and WT mice (Fig 5.19).
Summary
In this chapter, I have begun to characterise the development of systemic and mucosal
immunity and tolerance in CCX-CKR KO mice.
There  were  no  significant  differences  in  systemic  immune  responses  to  subcutaneous
immunisation with OVA/CFA between CCX-CKR KO and WT mice when assessed in vivo or
in vitro. However, the development of oral tolerance in CCX-CKR KO mice was impaired,
with a lack of the suppression of OVA specific DTH responses seen in WT mice fed a single
high dose of OVA. In addition, IgG2a antibody responses were not suppressed in CCX-CKR
KO mice fed a single high dose or multiple low doses of OVA, but were tolerised in WT mice.
However, both groups of OVA fed mice showed similar suppression of T cell proliferation
and IFN# production following re-stimulation in vitro, while serum OVA specific IgG1
antibody responses were not significantly suppressed by feeding either CCX-CKR KO or WT
mice. Together these data suggest that the suppression of antigen specific Th1 responses by
oral tolerance may be dependent on CCX-CKR in vivo.
In parallel with defective systemic tolerance after feeding OVA, CCX-CKR KO mice
appeared much more susceptible to priming of systemic and local antibody responses after
feeding OVA with CT as a mucosal adjuvant. Although both CCX-CKR KO and WT mice
developed robust systemic OVA specific IgG1 responses after feeding OVA+CT, only CCX-
CKR KO mice showed evidence of systemic OVA specific IgG2a and IgA or intestinal OVA-
specific IgA. In addition, there was some evidence of priming of OVA specific antibody
responses in CCX-CKR KO mice fed OVA alone which was not seen in WT mice.134
Despite this evidence of abnormal mucosal immunity, CCX-CKR KO mice developed DSS
colitis normally, with all indices of disease being identical in CCX-CKR KO and WT animals.
Together these results indicate that there are selective defects in the regulation of mucosal
immune responses in CCX-CKR KO mice and in the next chapter I went on to investigate the
cellular basis of this, examining in particular the role of pDC function and migration. IgG1
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Figure 5.1
Priming of DTH and Antibody Responses by Systemic Immunisation of
CCX-CKR KO and WT Mice
(A) CCX-CKR KO and WT mice were immunised in the right hind footpad
(RHFP) with ovalbumin (OVA) emulsified in complete Freund's adjuvant
(CFA). 21 days later, mice were challenged in the contralateral footpad
with heat-aggregated OVA (HAO) and 24 hours later, OVA specific DTH
responses were assessed by measuring footpad swelling (B). OVA specific
serum IgG1 (C) and IgG2a antibodies (D) were determined by ELISA.
Results show the individual footpad increments and mean OD 630nm +/-
1 SEM of serially diluted sera of 5 mice per group.
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Figure 5.2
Priming of In Vitro Immune Responses by Systemic Immunisation of
CCX-CKR KO and WT Mice
(A) CCX-CKR KO and WT mice were immunised in the hind footpad with
OVA emulsified in CFA. 14 days later, the draining popliteal lymph nodes
were removed, cells isolated and restimulated with either !CD3/CD28,
different concentrations of OVA, or medium alone in vitro. Cells were
cultured for 120 hours and 3H-TdR was added for the final 18 hours of
culture. The proportions (B) and numbers (C) of CD4+, CD8+ and CD19+
cells from draining popliteal lymph nodes (dLN)  were determined by flow
cytometry. Proliferation was assessed by 3H-TdR incorporation (D) and
IFN" production was measured by ELISA (E). Results show means +1 SD of
4 mice per group.
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Figure 5.3
In Vivo Assessment of High Dose Oral Tolerance Induction in CCX-CKR
KO and WT Mice
(A) CCX-CKR KO and WT mice were fed a single dose of 25mg OVA or PBS
and immunised in the right hind footpad with OVA emulsified in CFA 7
days later. 21 days later, mice were challenged in the contralateral
footpad with HAO and 24 hours later, OVA specific DTH responses were
assessed. (B) OVA specific DTH responses are shown as the mean footpad
increments of 14-15 mice per group and are pooled from 3 individual
experiments.
Two way Anova with Bonferroni post tests ***p<0.001
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Figure 5.4
In Vivo Assessment of High Dose Oral Tolerance Induction in CCX-CKR
KO and WT Mice
CCX-CKR KO and WT mice were fed a single dose of 25mg OVA or PBS
and immunised in the hind footpad with OVA emulsified in CFA 7 days
later. 21 days later, mice were challenged in the contralateral footpad
with HAO and 24 hours later, OVA specific serum IgG1 (A) and IgG2a (B)
antibody responses were assessed by ELISA in 3 separate experiments.
Results show the mean OD 630nm +/- 1 SEM of serially diluted sera from
4-5 mice per group for each experiment.
**p<0.01 *p<0.05 Mann Whitney test comparing WT OVA and PBS fed
groups
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Figure 5.5
In Vitro Assessment of High Dose Oral Tolerance Induction in CCX-CKR
KO and WT Mice
(A) CCX-CKR KO and WT mice were fed a single high dose of 25mg OVA
or PBS and immunised in the right hind footpad with OVA emulsified in
CFA 7 days later. 14 days later, the draining popliteal lymph nodes were
removed, cells isolated and restimulated with either !CD3/CD28, different
concentrations of OVA, or with medium alone in vitro. WT (B) and
CCX-CKR KO (C) cells were cultured for 120 hours and 3H-TdR was added
for the final 18 hours of culture. Results show mean cpm  +1 SD of 4 mice
per group.
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Figure 5.6
In Vitro Assessment of High Dose Oral Tolerance Induction in CCX-CKR
KO and WT Mice
(A) CCX-CKR KO and WT mice were fed a single high dose of 25mg OVA
or PBS and immunised in the right hind footpad with OVA emulsified in
CFA 7 days later. 14 days later, the draining popliteal lymph nodes were
removed, cells isolated and restimulated with either !CD3/CD28,
different concentrations of OVA or with medium alone in vitro. (B) WT
and (C) KO cells were cultured for 48 hours before supernatants were
removed for analysis of IFN" production by ELISA. Results show means  +1
SD of 4 mice per group.
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Figure 5.7
In Vivo Assessment of Low Dose Oral Tolerance Induction in CCX-CKR
KO and WT Mice
(A) CCX-CKR KO and WT mice were fed a daily dose of 1mg OVA or PBS
over 5 consecutive days and immunised in the right hand footpad with
OVA emulsified in CFA 7 days after the final feed. 21 days later, mice
were challenged in the contralateral footpad with HAO and 24 hours
later, OVA specific DTH responses were assessed. (B) OVA specific DTH
responses are shown as the mean footpad increments of 5 mice per
group.
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Figure 5.8
In Vivo Assessment of Low Dose Oral Tolerance Induction in
CCX-CKR KO and WT Mice
(A) CCX-CKR KO and WT mice were fed a daily dose of 1mg OVA or PBS
over 5 consecutive days and immunised in the right hand footpad with
OVA emulsified in CFA 7 days later. 21 days later, mice were
challenged in the contralateral footpad and 24 hours later, OVA specific
serum IgG1 (A) and IgG2a (B) antibody responses were assessed by
ELISA. Results show the mean OD 630nm +/- 1 SEM of serially diluted
sera from 5 mice per group.
**p<0.01 *p<0.05 Mann Whitney test comparing WT OVA and PBS fed
groups
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Figure 5.9
Priming of CCX-CKR KO and WT Mice by Oral Administration of
Antigen
CCX-CKR KO and WT mice were fed 3 doses of 10mg OVA alone or
together with 10µg CT or PBS alone 10 days apart. 10 days after the final
feed, mice were challenged in the footpad with HAO and 24 hours later,
OVA specific DTH responses were assessed. (B) OVA specific increases in
footpad thickness are shown as the mean footpad increments of 11-14
mice per group and are pooled from 3 individual experiments.
Two way Anova with Bonferroni post tests **p<0.01
B
A
143 IgG1
 
1/500
 
1/1000
 
1/2000
 
1/4000
 
1/8000
 
1/16000
 
1/32000
 
1/64000
0.0
0.5
1.0
1.5
Serum Dilution
 
O
D
 
6
3
0
n
m
IgG2a
 
1/20
 
1/40
 
1/80
 
1/160
 
1/320
 
1/640
 
1/1280
 
1/2560
0
1
2
*
*
*
*
*
WT OVA+CT FED
KO OVA+CT FED
WT OVA FED
KO OVA FED
WT PBS FED
KO PBS FED
Serum Dilution
 
O
D
 
6
3
0
n
m
 IgG
 
1/500
 
1/1000
 
1/2000
 
1/4000
 
1/8000
 
1/16000
 
1/32000
 
1/64000
0.0
0.5
1.0
*
*
* * *
* *
*
Serum Dilution
 
O
D
 
6
3
0
n
m
IgA
 
1/20
 
1/40
 
1/80
 
1/160
 
1/320
 
1/640
 
1/1280
 
1/2560
0.0
0.2
0.4
0.6
Serum Dilution
 
O
D
 
6
3
0
n
m
C
B
D
A
Figure 5.10
Priming of CCX-CKR KO and WT Mice by Oral Administration of
Antigen
CCX-CKR KO and WT mice were fed 3 doses of 10mg OVA+10µg CT,
10mg OVA, or PBS alone 10 days apart. 11 days after the final feed,
OVA specific IgG (A), IgG1 (B), IgG2a (C) and IgA (D) levels in the
serum were determined by ELISA. Results show mean OD 630nm +/-
1 SEM of serially diluted sera from 4-5 mice per group.
*p<0.01 Mann Whitney test comparing WT OVA+CT FED and KO
OVA+CT FED groups
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Figure 5.11
Priming of CCX-CKR KO and WT Mice by Oral Administration of
Antigen
CCX-CKR KO and WT mice were fed 3 doses of 10mg OVA+10µg CT,
10mg OVA or, PBS alone 10 days apart. 11 days after the final feed,
OVA specific IgG (A), IgG1 (B), IgG2a (C) and IgA (D) levels in the serum
were determined by ELISA. Results show mean OD 630nm +/- 1 SEM of
serially diluted sera from 4-5 mice per group.
*p<0.01 Mann Whitney test comparing WT OVA+CT FED and KO OVA+CT
FED groups
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Figure 5.12
Priming of CCX-CKR KO and WT Mice by Oral Administration of
Antigen
CCX-CKR KO and WT mice were fed 3 doses of 10mg OVA+10µg CT,
10mg OVA, or PBS alone 10 days apart. 11 days after the final feed,
OVA specific IgG (A), IgG1 (B), IgG2a (C) and IgA (D) levels in the
serum were determined by ELISA. Results show mean OD 630nm +/- 1
SEM of serially diluted sera from 4-5 mice per group.
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Figure 5.13
Total Serum IgG Levels in in CCX-CKR KO and WT Mice
CCX-CKR KO and WT mice were fed 3 doses of 10mg OVA+10µg
CT, 10mg OVA, or PBS alone 10 days apart. 11 days after the final
feed, total IgG levels in the serum were determined by ELISA.
Results show mean OD 630nm +/- 1 SEM of serially diluted sera
from 4-5 mice per group.
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Figure 5.14
Priming of Local IgA Antibody Responses by Oral Administration of
OVA+CT in CCX-CKR KO and WT Mice
(A) OVA specific IgA levels in the faeces were measured 11 days after
the final feed of antigen, calculated as the fold increase in the ratio of
specific IgA:total protein relative to that of PBS fed mice. (B) Mean
IgA levels in faeces are shown, calculated as the ratio of OD 630nm of
specific IgA relative to the total protein levels of 9-10 mice per group.
Two way Anova with Bonferroni post tests  *** p<0.001
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Figure 5.15
Induction of DSS Colitis in CCX-CKR KO and WT Mice
WT and CCX-CKR KO mice received 2% DSS in their drinking water for 7
days to induce colitis. Control mice received normal drinking water
throughout. Body weight (A) and clinical disease (B) were assessed
daily. Clinical disease score was determined by monitoring diarrhoea
(score 0-4) and rectal bleeding (score 0-4). Colon lengths were
assessed after sacrifice on day 7 (C). Results show the mean +/- 1SD
of 4-5 mice per group.
** p<0.01 ***p<0.001 Unpaired t test
149Figure 5.16
Induction of DSS Colitis in CCX-CKR KO and WT Mice
WT and CCX-CKR KO mice received 2% DSS in their drinking water for 7
days to induce colitis.Control mice received normal drinking water
throughout. After 7 days, colons were excised and fixed in 10% formalin,
embedded in paraffin and sections stained with haematoxylin and eosin for
histological analysis. WT control (A), WT DSS treated (B), KO control (C)
and KO DSS treated (D) colon sections are shown. DSS treated mice show
crypt hyperplasia, goblet cell loss, ulceration and inflammatory cell
infiltrate. (Final magnification x100)
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Figure 5.17
Production of Cytokines by Colon Explants from CCX-CKR KO and WT
Mice with DSS Colitis
CCX-CKR KO and WT mice received 2% DSS in their drinking water for 7
days to induce colitis and explants of distal and proximal colon were
cultured for 24 hours in complete medium and the levels of IL-1!,
IL-1", IL-5, IL-6, IL-10, IFN# and TNF! were determined by Luminex
analysis. Results show the mean + 1 SD of 5 mice per group.
Two way Anova with Bonferroni post tests *p<0.05 ***p<0.001
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Figure 5.18
Production of Growth Factors by Colon Explants from CCX-CKR KO
and WT Mice with DSS Colitis
CCX-CKR KO and WT mice received 2% DSS in their drinking water for
7 days to induce colitis and explants of distal and proximal colon were
cultured for 24 hours in complete medium and the levels of FGF,
GMCSF and VEGF were determined by Luminex analysis. Results show
the mean + 1 SD of  5 mice per group.
Two way Anova with Bonferroni post tests *p<0.05
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Figure 5.19
Production of Chemokines by Colon Explants from CCX-CKR KO and
WT Mice with DSS Colitis
CCX-CKR KO and WT mice received 2% DSS in their drinking water for
7 days to induce colitis and explants of distal and proximal colon were
cultured for 24 hours in complete medium and the levels of CCL2,
CCL3, CCL4, CCL5, CXCL1, CXCL9 and CXCL10 were determined by
Luminex analysis. Results show the mean + 1 SD of  5 mice per group.
Two way Anova with Bonferroni post tests **p<0.01 ***p<0.001
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Chapter 6
Analysis of DC Function in CCX-CKR KO Mice155
Introduction
So far my data have shown that CCX-CKR deficiency causes a significant reduction in pDC
proportions and numbers in MLN. In addition, the induction of oral tolerance is defective in
CCX-CKR KO mice, while both local and systemic antibody production suggests enhanced
priming by oral administration of antigen and adjuvant. In this chapter, I have tried to connect
these findings by conducting preliminary studies of the function and distribution of DC in
CCX-CKR KO mice.
6.1 Intrinsic functions of CCX-CKR KO DC in vitro
In the first experiment, I examined the intrinsic functions of DC by comparing the responses
of GM-CSF derived bone marrow DC from CCX-CKR KO and WT mice to stimulation with
LPS in vitro. CD40, CD86 and class II MHC expression were moderately up-regulated in both
CCX-CKR KO and WT bone marrow derived DC (BMDC) after stimulation with 1µg/ml LPS
overnight compared with BMDC cultured in medium alone, and there were no differences
between the strains. CD80 expression was not altered by LPS stimulation of either CCX-CKR
KO or WT BMDC (Fig 6.1).
I next investigated the endocytic activity of CCX-CKR KO and WT BMDC by incubating
them with 1mg/ml FITC-dextran at 37°C for 10-60 minutes and analysing the uptake by flow
cytometry. Both CCX-CKR KO and WT BMDC showed time and temperature dependent
uptake of FITC dextran, with no consistent differences between the strains (Fig 6.2).
To assess the ability of CCX-CKR KO and WT BMDC to process and present antigen, BMDC
were pulsed with either OVA or OVA 323-339 peptide, irradiated and cultured with LN cells
from OT2 mice which have a transgenic TCR on CD4
+ cells specific for OVA 323-339
peptide. Both CCX-CKR KO and WT BMDC could present OVA peptide efficiently to OT2
cells at 1:5 and 1:10 ratios. Although CCX-CKR KO DC induced significantly more T cell
proliferation at the 1:5 ratio, no differences were seen at the 1:10 ratio. WT BMDC also
presented intact protein to OT2 cells with moderate efficiency, but CCX-CKR KO BMDC
were significantly less effective at presenting intact protein at both ratios (Fig 6.3). Taken
together, these data suggest that CCX-CKR KO BMDC can effectively present peptide bound
in class II MHC, but may be defective in their ability to process intact antigens.156
To extend these results, I examined the antigen presenting activity of tissue derived APC
obtained from the spleens of CCX-CKR KO and WT mice. Spleen cells were pulsed with
OVA protein or peptide, irradiated and cultured with LN cells or purified CD4
+ cells from
OT2 mice. Splenic APC from WT mice induced excellent proliferative responses by both
unpurified OT2 cells and purified CD4
+ T cells when either protein or peptide were used as
antigen. All these responses were markedly and significantly reduced when CCX-CKR KO
spleen cells were used as the APC (Fig 6.4). Overall these findings suggest there may be
defective APC activity in CCX-CKR KO mice.
6.2 Responses of DC from resting mice to TLR 7 stimulation in vitro
Having  explored  conventional  DC  activity,  I  next  attempted  to  examine  pDC  more
specifically, focussing particularly on the MLN where the most significant defect was found in
CCX-CKR KO mice. One of the most potent ways of stimulating pDC is via TLR7 which
recognises single stranded RNA (ssRNA) from viruses and induces the production of type 1
IFN. To mimic the effects of ssRNA on pDC, I used R848 as a synthetic agonist of TLR7 and
TLR8, which has been used widely to investigate pDC function (121, 248, 249).
Firstly, I examined the effects of R848 in vitro using MLN cells from resting mice which were
cultured for 20 hours with or without 5µg/ml R848. After culture, the cells were analysed by
flow cytometry for CD11c and PDCA-1 expression to identify DC subsets, and CD40 and
CD86  to  assess  activation  status.  CD11c
+  cells  were  divided  into  CD11c
+PDCA-1
-,
CD11c
loPDCA-1
+ and CD11c
hiPDCA-1
+ cell subsets to identify conventional DC, pDC and
PDCA-1 expressing conventional DC respectively (Fig 6.5).
Approximately 80% of CD11c
+  cells from resting CCX-CKR KO and WT MLN were
conventional CD11c
+PDCA-1
- DC, and there was only a small population of CD11c
loPDCA-
1
+ pDC. As I found previously, the numbers of pDC were drastically and significantly reduced
amongst CCX-CKR KO CD11c
+ MLN cells compared with WT MLN. The proportions of
conventional DC and pDC were not significantly altered by R848 stimulation in vitro.
However, the proportions of CD11c
hiPDCA-1
+ cells which I putatively defined as activated
conventional DC, were found rarely amongst CCX-CKR KO and WT MLN CD11c
+ cells
although were significantly increased in both strains of mice after R848 stimulation. This may157
reflect the effects of R848 induced type 1 IFN which has been shown to induce expression of
PDCA-1 on conventional DC (250) (Fig 6.6).
The expression of CD40 and CD86 on CD11c
hiPDCA-1
- conventional DC was low and
comparable in resting CCX-CKR KO and WT MLN, and these did not change after R848
stimulation. Similar results were obtained for CD11c
loPDCA-1
+ pDC in resting animals. CD40
and CD86 expression levels were higher on unstimulated CD11c
hiPDCA-1
+ cells compared
with the other two CD11c
+ cell subsets, suggesting this may represent a partially activated
subset. R848 stimulation did not alter the expression of CD40 by these DC amongst either
CCX-CKR KO or WT MLN cells. However R848 stimulation induced a significant increase
in CD86 expression by CCX-CKR CD11c
hiPDCA-1
+ DC. Although CD86 expression levels
also increased on WT CD11c
hiPDCA-1
+ cells stimulated with R848, this was not statistically
significant (Fig 6.7).
6.3 Responses of DC from Flt3L treated mice to TLR 7 stimulation in vitro
Due to the scarcity of the DC subsets in resting MLN, it was often difficult to determine
precisely the phenotypic changes in these DC after R848 stimulation in vitro. Therefore, I
extended these studies by expanding DC numbers in vivo using Flt3L. As I found previously
in Chapter 4, treatment with Flt3L produced a marked expansion of all DC subsets in the
MLN  of  CCX-CKR  KO  and  WT  mice  (Figs  6.6A  and  6.8A).  The  proportions  of
CD11c
+PDCA-1
- cells in the MLN of Flt3L treated mice were comparable in CCX-CKR KO
and WT mice, with approximately 80% of total CD11c
+ cells having this phenotype, as was
seen in resting MLN. However, in contrast to what I found in resting mice, stimulation of
Flt3L treated MLN cells with R848 in vitro reduced the proportion of CD11c
+PDCA-1
- DC by
about half (Fig 6.8B). As before, Flt3L treatment did not overcome the defect in the numbers
of CD11c
loPDCA-1
+ pDC in CCX-CKR KO MLN and although R848 stimulation in vitro led
to a significant increase in the proportion of pDC amongst CCX-CKR KO MLN cells, they
still did not attain the levels seen after R848 treatment of Flt3L expanded WT DC (Fig 6.8C).
As in resting mice, the proportions of CD11c
hiPDCA-1
+ conventional DC amongst total
CD11c
+ cells were dramatically elevated after R848 stimulation of MLN cells from Flt3L
treated CCX-CKR KO and WT mice, and this effect was much more clearly visible using
Flt3L treated animals (Fig 6.8D).158
In contrast to what I found in resting MLN, stimulation of Flt3L treated MLN cells with R848
in vitro reduced the expression of CD40 and CD86 on conventional CD11c
+PDCA-1
- DC in
both CCX-CKR KO and WT mice. Interestingly however, CD40 appeared to be expressed at
higher levels on unstimulated CD11c
+PDCA-1
- DC from CCX-CKR KO mice compared with
these DC in WT MLN (Fig 6.9A). R848 stimulation induced significant increases in CD40
expression by CD11c
loPDCA-1
+  pDC from Flt3L treated CCX-CKR KO and WT mice.
Similar effects were seen with CD86 expression by pDC, although this increase was only
statistically significant for CCX-CKR KO cells, which showed higher CD86 expression than
R848  stimulated  WT  pDC  (Fig  6.9B).  R848  also  induced  significant  increases  in  the
expression of CD40 and CD86 by CD11c
hiPDCA-1
+ MLN DC from Flt3L treated CCX-CKR
KO and WT mice, although again, CD86 was expressed at higher levels by CD11c
hiPDCA-1
+
DC from CCX-CKR KO MLN than WT MLN both before and after R848 stimulation (Fig
6.9C).
To try to expand on these phenotypic effects, I made several attempts to assess IFN!
production by MLN DC in response to R848 stimulation using ELISA. However, these
experiments were unsuccessful due to the ELISA being unreliable and due to time constraints,
I could not establish an intracellular staining protocol for this cytokine.
6.4 Effects of R848 on MLN DC in vivo
Previous studies have shown that feeding R848 induces the migration of conventional DC out
of the gut wall and that this is dependent on tissue resident pDC (121). I next examined the
effects of R848 on DC in CCX-CKR KO and WT mice in vivo. As well as assessing evidence
of activation, this allowed me to study how the pDC deficiency in CCX-CKR KO mice might
affect the migration of DC from the small intestinal lamina propria to the MLN. These
migratory,  tissue  derived  DC  can  be  identified  in  the  MLN  by  their
CD11c
hiclassIIMHC
hiCD103
+  phenotype,  whereas  resident  DC  are  characterised  as
CD11c
hiclassIIMHC
loCD103
- cells.
18 hours after oral administration of 100µg of R848, there were no changes in the overall
numbers of MLN cells in either CCX-CKR KO or WT mice compared with resting MLN.
However, there were significant increases in the proportions of CD11c expressing cells in the
MLN of both strains (Figs 6.10A and 6.10B). The absolute numbers of CD11c
+ cells in the159
MLN of CCX-CKR KO and WT mice also increased after R848 feeding, although this was
only statistically significant for WT mice. However, overall there were no major differences in
the proportions or absolute numbers of CD11c
+ cells in the MLN after feeding R848 to CCX-
CKR KO or WT mice (Fig 6.10C).
Clear populations of migratory and LN resident DC could be defined in the MLN of control
CCX-CKR KO and WT mice fed with PBS, with all CD11c
hiCD103
hi cells expressing high
levels of class II MHC (Fig 6.11). As the representative FACS profiles shown in Fig 6.11
illustrate, feeding 100µg R848 altered these proportions dramatically, with a large increase in
the proportion of migratory DC seen 18 hours after feeding. These effects were confirmed
when the overall results from groups of three mice were analysed, with significant increases in
the proportions of migratory CD11c
hiclassIIMHC
hi DC amongst CD11c
+ cells after R848
feeding in both strains. The absolute numbers of these cells in the MLN also increased with
R848 feeding in both strains, although this was only statistically significant for WT mice (Fig
6.12A). In parallel, the proportions of LN resident CD11c
hiclassIIMHC
lo DC amongst CD11c
+
cells in the MLN of CCX-CKR KO and WT mice were decreased significantly after R848
feeding, although this did not translate into significant changes in the absolute numbers of
these cells in either strain (Fig 6.12B). In addition, the proportions and absolute numbers of
CD103 expressing DC amongst CD11c
+ cells increased significantly in R848 fed CCX-CKR
KO and WT mice compared with PBS fed controls (Fig 6.12C).
As well as changes in the proportions of migratory and LN resident DC, the expression of
class II MHC and CD103 was significantly increased on CD11c
+ cells from the MLN of R848
fed CCX-CKR KO and WT mice compared with PBS fed controls (Fig 6.13). There were no
significant differences between CCX-CKR KO and WT mice in their responses to R848 in
vivo in any of these analyses. I also attempted to examine the effects of R848 feeding on pDC
numbers in the MLN, but this proved impossible, as although CD11c
loPDCA-1
+ pDC were
readily found in the MLN of PBS fed mice, this population was not clearly definable in R848
fed mice (Fig 6.14).
Thus both CCX-CKR KO and WT mice showed significant responses to R848 in vivo which
occurred identically in both strains. Next, I carried out a more extensive analysis of how160
widespread the defect in pDC numbers might be by examining the bone marrow (BM) and
non-lymphoid tissues such as the liver and blood of CCX-CKR KO mice.
6.5 Analysis of DC composition in the liver of CCX-CKR KO mice
There is considerable evidence that the liver may play an important role in oral tolerance and
recent studies have linked this specifically to pDC in the liver (226). Therefore, having
observed a defect in the establishment of oral tolerance coupled with a depletion of pDC in
CCX-CKR KO mice, I decided to analyse the pDC composition of the liver directly.
Live leukocytes were isolated from the livers of CCX-CKR KO and WT mice, and analysed
for CD11c and PDCA-1 expression to identify pDC. Total leukocyte numbers recovered from
livers were comparable in resting CCX-CKR KO and WT mice, as were the proportion and
absolute numbers of CD11c
+ cells. Although there seemed to be decreases in the proportions
and absolute numbers of CD11c
loPDCA-1
+ pDC in the liver of CCX-CKR KO mice, this was
not statistically significant (Fig 6.15). Similar results were obtained using liver cells from
Flt3L treated mice, suggesting there is no significant defect in total DC or pDC in the liver of
CCX-CKR KO mice (Fig 6.16).
6.6 Analysis of pDC from the bone marrow and blood of CCX-CKR KO mice
pDC begin life in the bone marrow (BM) and migrate to secondary lymphoid organs and other
tissues via the blood (106, 112). The reduction in pDC proportions and numbers I observed in
CCX-CKR KO MLN could be caused by an intrinsic deficiency in pDC differentiation or by
defective migration from the bone marrow into the blood or from the bloodstream into MLN.
To begin to examine these possibilities, I assessed the prevalence of pDC in the bone marrow
and blood of CCX-CKR KO mice.
The combined expression of B220 and PDCA-1 was used to identify pDC in the BM, as most
CD11c
+ cells in this tissue expressed PDCA-1 to some extent. There were no differences in the
proportions of CD11c
+ cells or B220
+PDCA-1
+ cells in resting CCX-CKR KO mice (Fig
6.17). I also examined the effects of Flt3L treatment on DC subsets in the BM, which showed
a dramatic expansion in the proportions of CD11c
+ cells and CD11c
loB220
+PDCA-1
+ pDC in
the BM of both CCX-CKR KO and WT mice. Again there were no differences between these
populations in the two strains (Fig 6.18). Live blood leukocytes were isolated from WT and161
CCX-CKR KO mice and analysed for CD11c, B220 and PDCA-1 surface expression by flow
cytometry. The concentrations of live leukocytes were comparable in the blood of CCX-CKR
KO and WT mice, as were the proportions of CD11c
+ cells. Although the absolute numbers of
CD11c
+ cells were significantly increased in CCX-CKR KO blood, there were no significant
differences in the proportions or absolute numbers of CD11c
loB220
+PDCA-1
+ pDC between
CCX-CKR KO and WT mice (Fig 6.19).
Flt3L treated WT mice had a significant increase in the total blood leukocyte count compared
with controls, with 25 fold and 60 fold increases in the numbers of CD11c
+ cells and pDC
respectively (Figs 6.19A,D,F and 6.20A,D,F). In comparison, although the total leukocyte
count increased in CCX-CKR KO mice treated with Flt3L, this was significantly less marked
than in Flt3L treated WT mice. In addition, Flt3L treatment had much less effect on the
numbers of CD11c
+ cells and pDC in the blood of CCX-CKR KO mice, with only 7 fold and
20 fold increases in these cells in Flt3L treated mice compared with controls. However, these
differences in CD11c
+ cell and pDC numbers in the blood of Flt3L treated CCX-CKR KO and
WT mice were not statistically significant (Figs 6.19D,F and 6.20D,F).
Thus despite normal numbers and proportions of pDC in the BM and blood of resting CCX-
CKR KO mice and a normal response of pDC precursors in the BM to Flt3L, there seems to
be a defect in the mobilisation of pDC into the bloodstream of CCX-CKR KO mice after
administration of Flt3L.
6.7 Adoptive transfer of pDC between CCX-CKR KO and WT mice
To try and determine whether the deficiency in pDC in CCX-CKR KO MLN was a property
of the lymphoid tissue environment, or if CCX-CKR KO pDC themselves are inherently
unable  to  migrate  effectively  into  WT  LN,  I  carried  out  reciprocal  adoptive  transfer
experiments using CCX-CKR KO and WT pDC (Table 6.1).162
Table 6.1: Donor and recipient combinations
Donor Recipient
CD45.1
+ WT CD45.2
+ WT
CD45.1
+ WT CD45.2
+ CCX-CKR KO
CD45.2
+ WT CD45.1
+ WT
CD45.2
+ CCX-CKR KO CD45.1
+ WT
In the first experiment, I followed a published protocol in which unseparated resting spleen
cells were used as a source of donor pDC (121) and used WT CD45.1
+ mice as donors so that
transferred cells could be identified in WT CD45.2
+ recipient mice. The equivalent of 1x10
6
CD11c
loPDCA-1
+ cells were transferred into recipients and 20 hours later, cells from the
MLN,  ILN  and  spleens  of  recipients  were  analysed  for  CD11c,  PDCA-1  and  CD45.1
expression to identify transferred pDC. However, very few donor derived pDC could be seen
in the spleens of recipient mice using this protocol and there were virtually none in the MLN
or ILN (Fig 6.21).
I therefore altered the protocol and purified pDC from the spleens of mice that had been
expanded in vivo with Flt3L. pDC were enriched by negative selection using magnetic beads,
yielding a purity of 50-70% (Fig 6.22). 1x10
6 pDC were then transferred into recipients and
the presence of donor cells within secondary lymphoid organs was assessed 20 hours later (Fig
6.23). This protocol also yielded sufficient pDC to allow a full transfer experiment in which
both WT and CCX-CKR KO pDC were transferred into each strain of recipients.
Donor pDC could be identified in all secondary lymphoid organs of recipients, irrespective of
which  donor/recipient  combination  was  used.  When  the  numbers  of  donor  pDC  were
expressed as a proportion of total pDC, WT CD45.1
+ or CD45.2
+ pDC appeared to re-populate
WT lymphoid tissues to similar extents. A similar difference was seen between the entry of
WT pDC into CCX-CKR KO ILN compared with WT ILN, although this was not statistically
significant. These differences did not translate into significant differences in the absolute
numbers of donor pDC suggesting that the proportional increase of donor pDC in CCX-CKR
KO tissues is likely to reflect the decreased numbers of pDC in CCX-CKR KO mice and
indicating that CCX-CKR KO tissues are permissive to the entry of normal pDC. CCX-CKR163
KO pDC were also able to migrate into the lymphoid organs of WT mice, although these pDC
did seem to show some decreased ability to enter WT MLN compared with WT pDC,
although this was not statistically significant (Fig 6.24).
6.8 Assesment of CCL21 protein levels in CCX-CKR KO tissues
As CCX-CKR has been proposed to regulate levels of its chemokine ligands in vivo, I decided
to assess the levels of CCL21 protein in CCX-CKR KO ILN, MLN, spleen, PP, lower small
intestine and upper small intestine by ELISA. The levels of CCL21 protein relative to total
protein across all tissues examined were not significantly altered by CCX-CKR deletion.
Summary
The results in this chapter suggest that CCX-CKR KO BMDC are activated by LPS and
endocytose FITC-dextran particles in a similar manner to WT BMDC. However, CCX-CKR
KO BMDC and splenic APC did not process and present antigen as effectively as WT cells.
MLN cells from resting and Flt3L treated CCX-CKR KO mice appeared to respond normally
to the synthetic TLR7 agonist, R848 with an expansion in the numbers of CD11c
hiPDCA-1
+
cells that nearly all expressed CD40 and CD86. In addition, R848 triggered identical migration
of CD11c
hiclassIIMHC
hiCD103
+ DC into the MLN of CCX-CKR KO and WT mice. There
were no differences in the proportions or absolute numbers of pDC in the liver or bone
marrow of resting or Flt3L treated CCX-CKR KO and WT mice. However, the expansion of
CD11c
+ cells and pDC found in the blood in response to Flt3L treatment appeared to be less
effective in CCX-CKR KO mice than WT. Experiments using the adoptive transfer of pDC
were somewhat inconclusive but suggested that WT pDC could enter the MLN and other
lymphoid tissues of CCX-CKR KO mice normally. However, pDC from CCX-CKR KO mice
may have a defective ability to enter WT MLN compared with WT pDC. In addition, the
levels of CCL21 protein in secondary lymphoid organs and the small intestine do not appear to
be affected by CCX-CKR deletion.CD40
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Figure 6.1
Activation of Bone Marrow Derived CCX-CKR KO and WT DC by LPS
Bone marrow (BM) DC from CCX-CKR KO and WT mice were cultured
overnight either in medium alone or with 1µg/ml LPS. The expression of
CD40, CD80, CD86 and class II MHC was then determined by flow
cytometry. (A) Representative histograms show CD40, CD80, CD86 and
class II MHC expression by WT BMDC and appropriate isotype controls after
culture in medium alone or with LPS. The !MFI of (B) CD40, (C) CD80, (D)
CD86 and (E) class II MHC expression on CD11c+ cells show the means +1
SD of 3 mice per group.
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Figure 6.2
Endocytic Activity of Bone Marrow Derived CCX-CKR KO and WT DC
Bone marrow (BM) DC from CCX-CKR KO and WT mice were cultured
with 1mg/ml FITC-dextran at 37
oC or 4
oC for 10-60 minutes. The
specific uptake of FITC dextran (!MFI) was calculated by subtracting the
MFI of control cells incubated at 4
oC from the MFI readings obtained
from cultures at 37
oC.
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Figure 6.3
Antigen Presenting Cell Activity of Bone Marrow Derived CCX-CKR KO
and WT DC
Bone marrow (BM) DC from CCX-CKR KO and WT mice were irradiated
and pulsed with 5mg/ml OVA for 2 hours before being cultured for 72
hours with OT2 LN cells at 1:5 (A) and 1:10 (B) responder cell:BMDC
ratios. OT2 LN cells were also cultured with unpulsed BMDC and OVA
323-339 peptide as a control. 3H-TdR was added for the last 18 hours of
culture and the results show means +1 SD of 3 mice per group.
*p<0.05 ***p<0.001 Unpaired t test
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Figure 6.4
Antigen Presenting Cell Activity of Tissue Derived CCX-CKR KO and WT
DC
Whole splenocytes from CCX-CKR KO and WT mice were irradiated and
pulsed with 5mg/ml OVA for 2 hours before being cultured for 72 hours
with OT2 LN cells (A) or purified OT2 CD4+ LN cells (B) at a 1:1 ratio. OT2
cells were also cultured with unpulsed splenocytes and OVA 323-339 as a
control. 3H-TdR was added for the last 18 hours of culture and the results
show means +1 SD of 3 mice per group.
*p<0.05 **p<0.01 Unpaired t test
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Figure 6.5
Effects of R848 on DC from CCX-CKR KO and WT MLN In Vitro
MLN cells were isolated from resting and Flt3L treated CCX-CKR KO and
WT mice and cultured either in medium alone, or with 5µg/ml R848 for 20
hours. DC subsets were identified by expression of CD11c and PDCA-1 and
their expression of co-stimulatory molecules assessed. Representative FACS
plots show the proportion of total MLN cells from Flt3L treated WT mice
expressing CD11c and the proportions of DC subsets within the CD11c+ cell
population. Histograms show isotype (shaded) and CD40 specific staining of
total CD11c+, CD11c+PDCA-1-, CD11cloPDCA-1+ and CD11chiPDCA-1+cell
populations after culture in medium alone (A) or with R848 (B).
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Figure 6.6
Effects of R848 on MLN DC from Resting CCX-CKR KO and WT Mice In
Vitro
MLN cells were isolated from resting CCX-CKR KO and WT mice and
cultured either in medium alone, or with 5µg/ml R848 and analysed 20
hours later for cell surface expression of CD11c and PDCA-1 to identify DC
subsets. (A) Representative FACS plot showing CD11c+PDCA-1-,
CD11cloPDCA-1+ and CD11chiPDCA-1+ DC subsets amongst WT CD11c+ MLN
cells  after stimulation with R848. The proportions of CD11c+ cells within
the CD11c+PDCA-1-(B), CD11cloPDCA-1+ (C)and CD11chiPDCA-1+ (D) cell
subsets for unstimulated and R848 stimulated cells are shown. Results
show means +1 SD of 3 mice per group.
Two way Anova with Bonferroni post tests *p<0.05 **p<0.01
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mice stimulated with 5µg/ml
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Figure 6.7
Effects of R848 on MLN DC from Resting CCX-CKR KO and WT Mice In
Vitro
MLN cells were isolated from resting CCX-CKR KO and WT mice and
cultured either in medium alone, or with 5µg/ml R848 and analysed 20
hours later for cell surface expression of CD11c and PDCA-1 to identify
DC subsets and CD40 and CD86. The expression of CD40 (left graphs) and
CD86 (right graphs) on (A) CD11c+PDCA-1-, (B) CD11cloPDCA-1+  and (C)
CD11chiPDCA-1+ cells is shown. Results show mean !MFI  +1 SD of 3 mice
per group.
Two way Anova with Bonferroni post tests  *p<0.05 **p<0.01
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Figure 6.8
Effects of R848 on MLN DC from Flt3L Treated CCX-CKR KO and WT
Mice In Vitro
MLN cells were isolated from Flt3L treated CCX-CKR KO and WT mice and
cultured either in medium alone, or with 5µg/ml R848 and analysed 20
hours later for cell surface expression of CD11c and PDCA-1 to identify
DC subsets. (A) Representative FACS plot showing CD11c+PDCA-1-,
CD11cloPDCA-1+ and CD11chiPDCA-1+ DC subsets amongst WT CD11c+ MLN
cells after stimulation with R848. The proportions of CD11c+PDCA-1-(B),
CD11cloPDCA-1+ (C)and CD11chiPDCA-1+ (D) cells within the CD11c+ cell
population for unstimulated and R848 stimulated cells are shown. Results
show means +1 SD of 3 mice per group.
Two way Anova with Bonferroni post tests *p<0.05 **p<0.01 ***p<0.001
WT MLN cells from Flt3L
treated mice stimulated
with 5µg/ml R848 in vitro
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Figure 6.9
Effects of R848 on MLN DC from Flt3L Treated CCX-CKR KO and WT
Mice In Vitro
MLN cells were isolated from Flt3L treated CCX-CKR KO and WT mice
and cultured either in medium alone, or with 5µg/ml R848 and analysed
20 hours later for cell surface expression of CD11c and PDCA-1 to
identify DC subsets and CD40 and CD86. The expression of CD40 (left
graphs) and CD86 (right graphs) on (A) CD11c+PDCA-1-, (B)
CD11cloPDCA-1+  and (C) CD11chiPDCA-1+ cells is shown. Results show
mean !MFI  +1 SD of 3 mice per group.
Two way Anova with Bonferroni post tests **p<0.01 ***p<0.001
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Figure 6.10
Effects of Oral Administration of R848 on DC Populations in the MLN
of CCX-CKR KO and WT Mice
CCX-CKR KO and WT mice were fed 100µg R848 or PBS, sacrificed 18
hours later and MLN cells analysed for cell surface expression of CD11c,
class II MHC and CD103 to identify DC subsets. (A) Total numbers of live
MLN cells and the (B) proportion and (C) absolute numbers of live cells
expressing CD11c are shown. Results show means +1 SD of 3 mice.
Two way Anova with Bonferroni post tests *p<0.05 **p<0.01
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Figure 6.11
Effects of Oral Administration of R848 on DC Populations in the MLN
of CCX-CKR KO and WT Mice
CCX-CKR KO and WT mice were fed 100µg R848 or PBS, sacrificed 18
hours later and MLN cells analysed for surface expression of CD11c, class
II MHC and CD103 by flow cytometry. Representative FACS plots show
the proportion of total live cells expressing CD11c from (A) PBS and (B)
R848 fed WT mice. CD11c+ cells were separated into class II MHChi and
class II MHClo sub-populations to identify migratory and lymph node
resident DC respectively. Histograms show isotype staining (shaded) and
specific CD103 expression by these DC subsets (top panels of each data
set). CD11c+CD103+ cells were also identifed amongst CD11c+ cells and
histograms show isotype staining (shaded) and specific class II MHC
expression on these cells (bottom panels of each data set).
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Figure 6.12
Effects of Oral Adminstration of R848 on DC Populations in the MLN of
CCX-CKR KO and WT Mice
CCX-CKR KO and WT mice were fed 100µg R848 or PBS, sacrificed 18
hours later and MLN cells analysed for cell surface expression of CD11c,
class II MHC and CD103 to identify DC subsets. The proportions (left) and
numbers (right) of (A) migratory DC (CD11chiclass II MHChi) and (B) LN
resident (CD11chiclass II MHClo) sub-populations are shown. The proportions
(left) and numbers (right) of CD11c+ cells expressing CD103 are also shown
(C). Results show means +1 SD of 3 mice.
Two way Anova with Bonferroni post tests *p<0.05 **p<0.01 ***p<0.001
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Figure 6.13
Effects of Oral Administration of R848 on Class II MHC and CD103
Expression by MLN DC from CCX-CKR  KO and WT Mice
CCX-CKR KO and WT mice were fed 100µg R848 and sacrificed 18 hours
later. MLN cells were isolated and analysed for cell surface expression of
CD11c, class II  MHC and CD103 by flow cytometry. The !MFI of (A) class II
MHC and (B) CD103 expression on CD11c+ cells is shown. The right panels
show representative histograms of isotype staining (shaded) and specific
class II MHC and CD103 expression by CD11c+ cells from PBS (red) and
R848 (blue) fed WT mice. Results show means +1 SD of 3 mice per group.
Two way Anova with Bonferroni post tests **p<0.01 ***p<0.001
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Figure 6.14
pDC from CCX-CKR KO and WT Mice MLN After Oral Administration
of R848
CCX-CKR KO and WT mice were fed 100µg R848 or PBS and sacrificed
18 hours later. MLN cells were isolated and analysed for cell surface
expression of CD11c and PDCA-1 by flow cytometry.  Representative
FACS plots of cells from the MLN of (A) PBS and (B) R848 fed WT mice
show the proportion of total live cells expressing CD11c (left) and the
proportion of CD11c+ cells co-expressing PDCA-1 (right).
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Figure 6.15
pDC in the Liver of Resting CCX-CKR KO and WT Mice
Liver cells from resting CCX-CKR KO and WT mice were analysed for
7-AAD uptake and expression of CD45 to identify 7-AAD-CD45+ live
leukocytes (A). The total numbers of live leukocytes were calculated (B)
and analysed for expression of CD11c and PDCA-1 to identify pDC. (C)
Representative FACS plots show the proportion of live leukocytes
expressing CD11c (left) and the proportion of CD11c+ cells expressing
PDCA-1 (right). The proportions and numbers of live leukocytes in
CCX-CKR KO and WT mice expressing CD11c (D) or CD11c and PDCA-1
(E) are shown. The proportions of CD11c+ cells which co-express PDCA-1
are shown in (F). Results show means +1 SD of 6 mice per group and
are pooled from 2 separate experiments.
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Figure 6.16
pDC in the Liver of Flt3L Treated CCX-CKR KO and WT Mice
Liver cells from Flt3L treated CCX-CKR KO and WT mice were analysed
for 7-AAD uptake and expression of CD45 to identify 7-AAD-CD45+ live
leukocytes (A). The total numbers of live leukocytes were calculated (B)
and analysed for expression of CD11c and PDCA-1 to identify pDC. (C)
Representative FACS plots show the proportion of live leukocytes
expressing CD11c (left) and the proportion of CD11c+ cells expressing
PDCA-1 (right). The proportions and numbers of live leukocytes in
CCX-CKR KO and WT expressing CD11c (D) or CD11c and PDCA-1 (E)
are shown. The proportions of CD11c+ cells which co-express PDCA-1
are shown in (F). Results show means +1 SD of 6 mice per group and
are pooled from 2 separate experiments.
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Figure 6.17
pDC in the Bone Marrow of Resting CCX-CKR KO and WT Mice
BM cells were isolated from the femurs of resting WT and CCX-CKR KO
mice and analysed for cell surface expression of CD11c, B220 and PDCA-1
to identify pDC. (A) Representative FACS plot of live WT BM cells showing
the CD11c+ cell gate and the proportions of live cells expressing CD11c.
(B) Representative FACS plot of live WT BM cells showing the
PDCA-1+B220+ cell gate and the proportions of live cells co-expressing
PDCA-1 and B220. (C) Representative FACS plot of live WT BM CD11c+
cells showing the PDCA-1+B220+ cell gate and the proportions of CD11c+
cells co-expressing PDCA-1 and B220. Results show means +1 SD of 3 mice
per group.
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Figure 6.18
pDC in the Bone Marrow of Flt3L Treated CCX-CKR KO and WT Mice
BM cells were isolated from the femurs of Flt3L treated WT and CCX-CKR
KO mice and analysed for cell surface expression of CD11c, B220 and
PDCA-1 to identify pDC. (A) Representative FACS plot of live WT BM cells
showing the CD11c+ cell gate and the proportions of live cells expressing
CD11c. (B) Representative FACS plot of live WT BM cells showing the
PDCA-1+B220+ cell gate and the proportions of live cells co-expressing
PDCA-1 and B220. (C) Representative FACS plot of live WT BM CD11c+ cells
showing the PDCA-1+B220+ cell gate and the proportions of CD11c+ cells
co-expressing PDCA-1 and B220. Results show means +1 SD of 3 mice per
group.
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Figure 6.19
pDC in the Peripheral Blood of Resting CCX-CKR KO and WT Mice
The concentration of leukocytes in the blood of resting CCX-CKR KO and
WT mice was calculated (A) and cells analysed for surface expression of
CD11c, B220 and PDCA-1 to identify pDC. Representative FACS plots of WT
and CCX-CKR KO blood leukocytes show the proportion of CD11c+ cells
within total live cells and the proportion of B220+PDCA-1+ cells in this
CD11c+ cell population (B). The proportions (C,E) and absolute numbers
(D,F) of total CD11c+ cells and CD11cloB220+ PDCA-1+ cells are shown as
well as the proportion of pDC within live CD11c+ cells (G). Results show
means + 1 SD of 4 or 5 mice per group.
*p<0.05 Unpaired t test
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Figure 6.20
pDC in the Peripheral Blood of Flt3L Treated CCX-CKR KO and WT
Mice
The concentration of leukocytes in the blood of Flt3L treated CCX-CKR
KO and WT mice was calculated (A) and cells analysed for surface
expression of CD11c, B220 and PDCA-1 to identify pDC. Representative
FACS plots of WT and CCX-CKR KO blood leukocytes show the proportion
of CD11c+ cells within total live cells and the proportion of
B220+PDCA-1+ cells in this CD11c+ cell population (B). The proportions
(C,E) and absolute numbers (D,F) of total CD11c+ cells and CD11cloB220+
PDCA-1+ cells are shown as well as the proportion of pDC within live
CD11c+ cells (G). Results show means + 1 SD of 4 or 5 mice per group.
*p<0.05 Unpaired t test
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Figure 6.21
Migration of Donor Derived pDC into Tissues of Recipient Mice
WT CD45.1+ splenocytes were stained for CD11c and PDCA-1 to identify
pDC as CD11cloPDCA-1+ cells. CD45.1 expression by all donor pDC was then
confirmed by flow cytometry (A). The equivalent of 1x106 pDC were
adoptively transferred i.p. into CD45.2+ WT mice and 20 hours later, the
MLN, ILN and spleens or recipient mice were removed, cells isolated and
stained for CD11c, PDCA-1 and CD45.1 to identify transferred pDC. (B)
Representative FACS plots show the proportions of total cells expressing
CD11c (left), the proportions of CD11c+ cells expressing PDCA-1 (middle)
and the proportions of CD11cloPDCA-1+ pDC expressing CD45.1 to identify
donor pDC in the MLN (top), ILN (middle) and spleens (bottom) of CD45.2+
recipient mice. 184CD45.1
PDCA-1
Figure 6.22
Purification of Splenic pDC from Flt3L Treated WT CD45.2+,
CCX-CKR KO CD45.2+ and WT CD45.1+ Mice
pDC were isolated from the spleens of Flt3L treated WT CD45.2+,
CCX-CKR KO CD45.2+ and WT CD45.1+ mice by negative selection using
magnetic beads. Cells were then analysed for surface expression of
CD45.1 and PDCA-1 by flow cytometry. Representative FACS plots
show the proportion of pDC within the negative fraction of splenocytes
from WT CD45.2+, CCX-CKR KO CD45.2+ and WT CD45.1+ donor mice.
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Figure 6.23
Adoptive Transfer of Flt3L Expanded WT and CCX-CKR KO pDC into WT
and CCX-CKR KO Recipients
1x106pDC from the spleens of Flt3L treated WT CD45.2+, CCX-CKR KO
CD45.2+ and WT CD45.1+ donor mice were transferred i.v. into WT
CD45.2+, CCX-CKR KO CD45.2+ and WT CD45.1+ recipient mice. 20 hours
later, the  MLN, ILN and spleens of recipient mice were removed, cells
isolated and stained for CD11c, PDCA-1 and CD45.1 to identify transferred
pDC. Representative FACS plots show the proportions of recipient live MLN
cells expressing CD11c (left panels) and the proportion of these live
CD11c+ cells expressing PDCA-1 to identify pDC (middle panels). The
proportion of donor pDC within the total MLN pDC population is shown as
the proportion of cells expressing CD45.1 or 2 as congenic markers (right
panels). Donor mice are indicated in green and recipients in orange
alongside plots.
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Figure 6.24
Migration of Adoptively Transferred pDC into Secondary Lymphoid
Organs of Recipient Mice
1x106pDC from the spleens of Flt3L treated WT CD45.2+, CCX-CKR KO
CD45.2+ and WT CD45.1+ donor mice were transferred i.v. into WT
CD45.2+, CCX-CKR KO CD45.2+ and WT CD45.1+ recipient mice. 20 hours
later, MLN, ILN and spleens of recipient mice were removed and cells
stained for CD11c, PDCA-1 and CD45.1 to identify transferred pDC. The
proportions of donor pDC within total pDC in the MLN, ILN and spleens of
recipient mice are shown in (A). The absolute numbers of (B) donor and
(C) recipient pDC are also shown. Donor mice are indicated in green and
recipients in orange. Results show means +1 SD of between 3 and 4 mice
per group.
One-way Anova with Bonferroni post tests *p<0.05 ***p<0.001 187ILN MLN SP PP lower SI upper SI
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Figure 6.25
CCL21 Protein Levels in CCX-CKR KO and WT Tissues
ILN, MLN, SP,PP and 3cm sections of lower and upper small intestine
were isolated from CCX-CKR KO and WT mice and homogenised in TPER
protein extraction solution with protease inhibitors. CCL21 levels were
determined by ELISA and total protein by BCA assay. Results show the
mean ratios + 1 SD of the CCL21 specific OD at 630nm relative to total
protein within tissue samples of 5 mice per group.
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Chapter 7
Discussion190
Introduction
The immune system is constantly interacting with our environment and reacting to the
bombardment of antigen it faces every day. The innate immune cells in peripheral tissues,
along with the naïve lymphocytes re-circulating throughout secondary lymphoid organs are
essential in the establishment of a targeted, antigen specific and efficient immune response
that can be re-deployed promptly during re-infection. The organisation of these cells is
crucially dependent on chemokines, which must be tightly regulated so that they in turn may
regulate leukocyte migration appropriately. Atypical chemokine receptors are proposed to
contribute to this organisation by scavenging and/or presenting chemokines and have been
studied extensively in recent years. However, the in vivo role of the atypical chemokine
receptor, CCX-CKR, has remained unclear and at the time of starting my project, there were
no publications on this subject. As CCX-CKR binds the homeostatic chemokines, CCL19,
CCL21 and CCL25, I aimed to characterise antigen specific immune responses in CCX-CKR
KO mice, paying particular attention to the intestinal immune compartment, where all three
ligands are involved in the regulation of immunity and tolerance.
7.1 The role of CCX-CKR in steady state lymphocyte trafficking
My initial experiments described in Chapter 3, examined the architecture and cellular
composition of secondary lymphoid organs in CCX-CKR KO mice, as CCL19 and CCL21
have important roles in the recruitment and organisation of the cells that initiate and occupy
these structures (47). The architecture of the MLN, ILN and spleens of CCX-CKR KO mice
appeared normal on H&E stained tissue sections. Secondary lymphoid organs were densely
populated and as expected, the LN appeared to be organised into T cell areas and B cell
follicles.  In  addition,  white  pulp  lymphoid  areas  were  also  obvious  in  the  spleen.
Immunofluorescence staining of tissue sections analysing the expression of T and B cell
markers  such  as  CD3  and  CD19  would  be  a  logical  next  step  to  assess  the
compartmentalisation of lymphocytes in CCX-CKR KO secondary lymphoid organs more
thoroughly.
The cellularity of secondary lymphoid organs appeared to be normal in the large cohort of
CCX-CKR KO mice that I examined. This contradicts reports by a previous PhD student
which suggested reduced LN cellularity and size in the absence of CCX-CKR. One possible
explanation for this discrepancy may be differences in the mouse strains examined, as I used191
CCX-CKR KO mice backcrossed on to the C57/Bl6 genetic background, whereas the previous
studies were carried out using CCX-CKR KO mice backcrossed on to the FVB genetic
background. I also found that the proportions and absolute numbers of CD4
+ or CD8
+ T and
CD19
+ B cells were completely normal in the MLN, ILN and spleens of CCX-CKR KO mice,
despite their dependence on CCR7 and its ligands for their entry and positioning (22, 66, 71,
76).
As increased concentrations of chemokine can potentially desensitize chemokine receptor
activity and CCX-CKR is hypothesised to scavenge excess CCL19, CCL21 and CCL25 (192),
I decided to assess lymphocyte expression of CCR7 and CCR9 in CCX-CKR KO mice. CCR9
expression by CD4
+ or CD8
+ T cells and B cells was not affected by CCX-CKR deletion,
suggesting that CCX-CKR does not regulate CCR9 expression directly, despite binding the
only known CCR9 ligand, CCL25. However, I did not assess whether or not CCR9 was
functional  on  these  cells,  for  instance,  by  assessing  chemotaxis  potential  in  vitro.
Unfortunately, my attempts to assess CCR7 expression on these lymphocytes by flow
cytometry were unsuccessful despite repeated efforts. Quantification of CCR7 mRNA presents
an alternative approach to investigate this and is currently being pursued by another PhD
student in the group, who has also developed an assay using biotinylated-CCL19 and flow
cytometry to detect CCR7 activity on primary lymphoid cells.  In addition, chemotaxis assays
could be used to assess CCR7 function in vitro.
T regs are essential mediators of peripheral tolerance and are dependent on their expression of
CCR7 for their effective function in vivo. The suppressive function of CCR7 deficient T regs
in vivo is profoundly perturbed due to their inability to access secondary lymphoid organs, the
T cell zones of which are the major site of T reg mediated suppression (12, 90, 251). There
were no differences in the proportions of CD4
+CD25
+FoxP3
+ T regs when calculated as a
proportion of CD4
+CD25
+ T cells that express FoxP3 in the MLN, ILN or spleens of resting
CCX-CKR KO mice. However, the absolute numbers and proportions of CD4
+CD25
+FoxP3
+
cells amongst total live spleen cells appeared to be slightly elevated in CCX-CKR KO mice
although only the increase in proportions attained statistical significance. This suggests that
although there is a normal frequency of FoxP3 expressing cells amongst CD4
+CD25
+ T cells
in the ILN, MLN and spleens of CCX-CKR KO mice, overall there is a greater proportion of
CD4
+CD25
+FoxP3
+ T regs in the CCX-CKR KO spleen. Perhaps, this reflects an aberrant re-192
circulation or distribution of T regs in CCX-CKR KO mice, a possibility that might be better
addressed using models of tolerance where the induction of T regs can be assessed, for
instance during the induction of oral tolerance.
The proliferative responses of T cells to anti-CD3/CD28 and to the mitogen, Con A, were
normal in the absence of CCX-CKR. However, IFN! production by cells from the MLN and
spleens of CCX-CKR KO mice was significantly reduced compared with WT cells when
stimulated with anti-CD3/CD28. Furthermore, CD4
+ T cells from the MLN and spleens of
CCX-CKR KO mice were less efficient than WT in their production of IFN! in response to
stimulation with PMA/ionomycin. IFN! production by MLN cells from CCX-CKR KO mice
stimulated with Con A was also significantly reduced compared with WT MLN cells. This
suggests that the in vitro production of the Th1 type cytokine, IFN! may be affected by CCX-
CKR deletion. It would be interesting therefore, to investigate Th2 or Th17 type responses in
CCX-CKR KO mice (252-256). Effector T cell functions in CCX-CKR KO mice have not
been examined in any detail but it has been published very recently that CCX-CKR KO mice
develop exaggerated Th17 responses during EAE (257).
Thus the lymphocyte composition of secondary lymphoid organs is normal in CCX-CKR KO
mice,  with  the  exception  of  slightly  but  significantly  elevated  proportions  of
CD4
+CD25
+FoxP3
+ T regs in the spleen. Proliferative responses of polyclonal T cells were
normal when stimulated with anti-CD3/CD28 or ConA, but the production of IFN! under such
circumstances and in response to PMA/ionomycin stimulation were impaired, suggesting that
T cells may be polarised differently in resting CCX-CKR KO mice.
7.2 Conventional DC in CCX-CKR KO mice
The CCR7 and CCX-CKR ligands CCL19 and CCL21 have crucial roles in the recruitment of
antigen loaded CCR7 expressing DC from peripheral tissues to secondary lymphoid organs
and are essential for the development of antigen specific adaptive immunity and tolerance (60,
62, 125, 258). All mouse DC express CD11c and class II MHC to varying extents, but class II
MHC is also highly expressed by B cells and activated macrophages, while CD11c may also
be present on some NK cells and even a few T cells in secondary lymphoid organs (259).
However during my project, only four colour flow cytometry was available in the department
and therefore I was limited in the number of parameters I could use to discriminate different193
cell populations. Therefore I decided to use CD11c expression as the consistent marker of DC
in all the tissues I examined. My initial results suggested there might be a significant reduction
of CD11c
+ cells in the MLN, but not the ILN or spleens of CCX-CKR KO mice compared
with WT. However this difference was not consistent when the experiments were repeated.
Overall, the proportions and absolute numbers of CD11c
+ cells in the MLN, ILN and spleens
of CCX-CKR KO mice were almost identical to those in WT mice. Despite this, I decided to
pursue a more thorough characterisation of the DC subsets in CCX-CKR KO mice, as some
DC subsets constitute a relatively minor fraction of total DC and so any differences in their
numbers may be very subtle and difficult to detect.
Due to my initial observations of reduced CD11c
+ cell numbers in the MLN of CCX-CKR KO
mice and difficulties in obtaining sufficient DC from other tissues for analysis, most of my
subsequent investigations were focussed on the MLN. Conventional DC can be broadly
divided into CD11c
+CD8
+ and CD11c
+CD11b
+ cell subsets, the latter of which also usually
expresses  CD4  (55).  Therefore  it  was  somewhat  surprising  that  although  I  found  the
proportions of CD11c
+CD11b
+ DC amongst total live cells to be normal in CCX-CKR KO
MLN, the proportion of CD11c
+CD4
+ DC were decreased under the same conditions. The
proportion of CD11c
+CD8
+ DC amongst total live cells was also reduced in CCX-CKR KO
MLN. I also assessed the prevalence of the individual DC subsets amongst CD11c
+ cells
themselves, so as to examine the relative contributions of any given DC subset to the total
CD11c
+ cell population. By doing this, I hoped to increase the accuracy and sensitivity of my
analyses as it meant that DC subsets that made up a relatively minor proportion of total live
cells would constitute a significant fraction of CD11c
+ cells. When I expressed the results in
this way, the proportion of CD8
+ DC amongst CD11c expressing cells was still significantly
reduced in CCX-CKR KO MLN, but the apparent defect in CD4
+ DC disappeared and
CD11b
+ DC remained normal. The absolute numbers of CD4
+, CD8
+ or CD11b
+ DC were not
significantly decreased in CCX-CKR KO MLN, although the absolute numbers of CD8
+ DC
did appear to be reduced. Further investigations using larger sample sizes and the nine colour
flow cytometry which became available in the department after my project finished would be
valuable in determining any affect of CCX-CKR deletion on the CD8
+ DC subset.
As CD8
+ DC gain access to LN via HEV, this suggests that CCX-CKR may play a role in
regulating trans-migration of DC into LN. Interestingly, an as yet unidentified receptor has194
been shown to transcytose CCL19 across the endothelial cells lining the HEV and in doing so,
regulates the recruitment of leukocytes into LN (72). The possibility that CCX-CKR may
serve such a purpose is intriguing. Adoptive transfer experiments using WT CD8
+ DC may
help to determine whether or not there is a defect in CD8
+ DC migration across HEV in CCX-
CKR KO mice.
In the experiments described in Chapter 6, I performed some preliminary investigations in to
the function of CCX-CKR KO DC. Firstly, I compared the intrinsic responses of CCX-CKR
KO and WT BMDC to stimulation with the TLR ligand, LPS. No differences were found
between the different sources of BMDC in this experiment, but these studies were only
partially successful as there were no statistically significant increases in the expression of co-
stimulatory molecules or class II MHC after LPS stimulation of either kind of BMDC.
Therefore these experiments need to be repeated and it would be important to assess other
responses to BMDC activation, such as CCR7 up-regulation and cytokine production, as well
as other TLR ligands. Although the endocytic capacity of CCX-CKR KO BMDC appeared to
be normal, their ability to process and present OVA to OT2 LN cells was significantly reduced
compared with WT BMDC. However, the capacity of BMDC to present OVA 323-339
peptide was not impaired by CCX-CKR deletion and in fact was significantly enhanced at a
1:5 DC:T cell ratio. Splenic DC from CCX-CKR KO mice also showed a significantly
reduced capacity to process and present either intact OVA or OVA peptide to T cells. These
findings of reduced APC activity by CCX-CKR KO DC are difficult to reconcile with the
apparently exaggerated susceptibility to oral priming that I observed. However, it should be
noted that immune responses to systemic immunisation were normal in CCX-CKR KO mice
and therefore any defect in antigen presentation may be restricted to the intestinal immune
compartment. As this may not be replicated by splenic DC or BMDC, it would be important to
assess APC activity of MLN or lamina propria derived DC directly. In addition, I would have
liked to examine the antigen presentation capacity of pDC from CCX-CKR KO mice by
generating BMDC in vitro using Flt3L as an alternative to GMCSF (279).
7.3 CCX-CKR KO mice have a selective defect in pDC in secondary lymphoid
organs
The most dramatic effect of CCX-CKR deletion I found on DC populations was a consistent
defect in pDC numbers in the MLN. I defined pDC as CD11c
loPDCA-1
+ cells, because195
although pDC are B220
+, a recent report has identified some CD11c
+B220
+ cells in LN as
being precursors of conventional DC rather than genuine pDC. The absolute numbers and
proportions of all CD11c
loB220
+ cells amongst CD11c
+ cells were reduced in the MLN of
CCX-CKR KO mice and closer examination showed that this was due to dramatic decreases in
the proportions and absolute numbers of pDC as defined by the CD11c
loPDCA-1
+  and
CD11c
loB220
+PDCA-1
+ phenotype. In contrast, the absolute numbers and proportions of the
CD11c
loB220
+PDCA-1
- putative precursor DC were not different between the strains.
This marked defect in pDC in CCX-CKR KO MLN was highly reproducible in repeated
experiments. The proportions of pDC amongst total live cells and CD11c
+ cells were also
significantly reduced in the ILN of CCX-CKR KO mice and the absolute numbers of pDC
were also reduced here, but this did not attain statistical significance. In addition, the
proportions and absolute numbers of pDC were normal in the spleen of CCX-CKR KO mice,
suggesting that the defect in pDC numbers is selective to lymphoid organs where pDC must
migrate across HEV to gain access (123, 124) and that this is particularly manifest in the
MLN. This is supported by the deficiency in the proportions of CD8
+ DC in CCX-CKR KO
MLN that I also observed. However, as some pDC are reported to express CD8 (55), it is
possible that the apparent decrease in CD11c
+CD8
+ cells I found in CCX-CKR KO MLN
could be accounted for by the large defect in pDC. It has been shown that pDC are found in
the  T  cell  zone  near  to  HEV  in  WT  LN  (117) and it would be important to perform
immunohistological analysis to determine the distribution of pDC in the lymphoid tissues of
CCX-CKR KO mice. Unfortunately, I did not have time to carry out studies of this kind.
PDCA-1, is also known as BST-2, CD317 or 120G8 (250, 260) and binds ILT7 which inhibits
type 1 IFN and pro-inflammatory cytokine production by pDC. The co-expression of PDCA-1
and ILT7 on human pDC is believed to co-operate in a negative feedback loop that limits their
cytokine production (261, 262). The apparent decrease in pDC numbers in CCX-CKR KO
MLN did not appear to be an artefact of decreased PDCA-1 expression, as the numbers of
pDC  were  similarly  altered  when  using  B220  and  CCR9  expression  as  pDC  markers.
Unfortunately, I was unable to examine the levels of CCR9 expression on PDCA-1
+ pDC, due
to technical difficulties and the lack of sufficient flow cytometry colours, but this would have
been interesting in view of the possibility that CCX-CKR may regulate the functional
expression of this receptor.196
Although macrophages and NK cells do not express CCR7 or CCR9 they do respond to the
cytokines that are secreted by activated pDC such as type 1 IFN (115). However, the
proportions and absolute numbers of F480
+ macrophages in the MLN, ILN and spleens of
CCX-CKR KO mice were entirely normal, as were the proportions and absolute numbers of
CD3
-DX5
+ NK cells in CCX-CKR KO MLN.
7.4 Composition of leukocytes in the intestinal immune compartment of CCX-
CKR KO mice
All three CCX-CKR ligands are expressed in the intestinal immune compartment and have
established roles in the development of mucosal immunity and tolerance. My experiments in
Chapter 4 indicated that the architecture of the small intestine and colon was normal in the
absence of CCX-CKR. One abnormality in the small intestine was that although IEL were
positioned normally in CCX-CKR KO mice, their numbers were significantly reduced in
comparison to WT mice. CCL25 secretion by the epithelial layer recruits CCR9 expressing
IEL and is thought to induce the CD103 mediated adhesion of IEL to the E-cadherin expressed
on the intestinal epithelium (199-201, 263). As CCL25 availability and/or distribution may be
affected  by  CCX-CKR  deletion,  it  would  therefore  be  of  interest  to  examine  CD103
expression on IEL in CCX-CKR KO mice. I did attempt to analyse IEL from CCX-CKR KO
and WT mice by flow cytometry, but was unable to produce consistent results and as this was
not a major aim of my work, I did not take this further.
CCR9 is expressed on most lamina propria lymphocytes (214, 264) and its expression is
imprinted by lamina propria derived CD103
+ DC that are dependent on CCR7 for their
migration to the MLN. Thus, the ligands of CCR7 and CCR9, CCL19, CCL21 and CCL25 all
have important roles in the induction and recruitment of gut homing effector lymphocytes to
the small intestinal lamina propria (125, 132, 133, 210). The proportions and numbers of T
cells in the lamina propria as defined by CD3, CD4 or CD8 expression were normal in the
absence of CCX-CKR suggesting that the migration of effector T cells to this site is not
dependent on CCX-CKR. Again, I was unable to confirm the expression levels of CCR9 on
these cells which would be important to determine. It would also be informative to assess the
levels of CCL25 protein in the mucosa of CCX-CKR KO mice to gain some insight into how
CCX-CKR might function as a chemokine scavenger. I did begin preliminary studies of this,
but other work going on in the laboratory at the same time showed that the commercially197
available ELISA kit was unreliable. As other reagents were not available, I did not pursue this
line of investigation and unfortunately as this was towards the end of my project, I did not
have time to assess CCL25 mRNA levels.
Interestingly, the proportions of CD11c
+ cells and CD19
+ B cells were significantly increased
and decreased respectively in CCX-CKR KO small intestinal lamina propria, although these
differences did not translate into differences in absolute numbers. As many CD11c
+ cells in
the lamina propria are likely to be macrophages rather than genuine DC (265), it was
important to determine if this finding might be related to the requirement for CCR7 ligands in
the migration of CD11c
+ DC from the lamina propria to the MLN. Therefore, I decided to
analyse the numbers of individual DC subsets in the lamina propria of CCX-CKR KO mice.
Assessing the numbers and phenotype of conventional DC in this tissue proved impossible due
to the limitations of four colour flow cytometry, but I was able to examine pDC in the CCX-
CKR KO lamina propria. This was important as pDC at this site express high levels of CCR9
and are absent from the small intestine of CCR9 KO mice, suggesting an essential role for
CCR9 and CCL25 in their accumulation at this site (121). I was unable to use CD11c and
PDCA-1 alone as markers of pDC in the mucosa as a significant proportion of CD45
+CD11c
-
cells in the lamina propria seemed to express PDCA-1, making gating difficult. I therefore
defined pDC as CD11c
loB220
+ cells. Although not a perfect strategy for the reasons discussed
above, a clear population of CD11c
loB220
+ cells was apparent in the small intestinal lamina
propria of both CCX-CKR KO and WT mice, with their proportions being identical between
strains. This requires confirmation using more sophisticated flow cytometry. I was able to
examine CD103 expression by CD11c
+ cells in the lamina propria and could distinguish two
subsets within this population, one CD11c
hiCD103
hi and the other, CD11c
intCD103
lo. The
proportions and absolute numbers of both subsets of CD103
+ DC were unaltered in the lamina
propria in the absence of CCX-CKR. As CD103
+ DC migrate from the lamina propria to
MLN, I also examined the numbers of these cells in CCX-CKR KO MLN.   Again, the
absolute numbers and proportions of CD103
+ DC were normal in the absence of CCX-CKR,
suggesting that CCX-CKR plays little or no role in regulating the constitutive migration of DC
from the lamina propria to MLN.
I also examined the numbers of migratory and LN resident DC in resting CCX-CKR KO MLN
using a phenotypic strategy that defined them on the basis of their levels of CD11c and class II198
MHC  expression.  I  found  that  the  proportions  and  absolute  numbers  of  DC  in
CD11c
hiclassIIMHC
lo LN resident and CD11c
hiclassII
hi migratory DC subsets in the MLN
were unaffected under resting conditions by CCX-CKR deletion, which was consistent with
the normal numbers of CD103
+ DC I observed in the small intestinal lamina propria of CCX-
CKR KO mice. While I was carrying out these investigations, it was reported that there was a
trend towards lower numbers of CD11c
hiclassIIMHC
hi migratory DC in the skin draining
brachial, axillary and inguinal LN of CCX-CKR KO mice. However, this trend vanished
following FITC sensitisation of the skin, when normal numbers of CD11c
hiclassIIMHC
hi
migratory DC accumulated in the draining LN with similar kinetics as those seen in WT mice
(191). These results suggest that any defect in DC migration via afferent lymphatics (a process
which is dependent on CCR7 and its ligands) in CCX-CKR KO mice is only subtle and
apparent under steady state conditions. One possible explanation for the discrepancy between
my findings and those published could be that the MLN are not draining a truly resting tissue
as the small intestine harbours a massive antigen load. Therefore, the normal proportions of
migratory DC I observed in the MLN in CCX-CKR KO mice would be consistent with the
normal proportions reported in the skin draining LN after FITC sensitisation. Although to
investigate the migratory responses of CCX-CKR KO small intestinal lamina propria DC
under inflammatory conditions, I used R848 as a synthetic TLR 7 agonist which I discuss
later.
The PP are a major inductive site of adaptive immunity in the small intestine and differ
significantly from MLN in being devoid of afferent lymphatics. Instead PP DC sample luminal
antigens that have been directly transcytosed across M cells into the SED, although naive
lymphocytes and pDC enter PP across HEV as they do in LN (197). Because of the significant
reduction of pDC in the MLN of CCX-CKR KO mice, I decided to focus on assessing pDC
numbers in the PP of these animals using the combination of CD11c, PDCA-1 and B220
expression to identify pDC. The proportions of total CD11c
+ cells in CCX-CKR KO PP were
significantly increased compared with WT PP and a similar but not statistically significant
trend was seen when absolute numbers were calculated. CD11c
loPDCA-1
+ cells in the PP all
expressed B220 and these were significantly reduced as both a proportion of total live cells
and of CD11c
+ cells in CCX-CKR KO PP compared with WT PP. The absolute numbers of
pDC appeared to be decreased in CCX-CKR KO PP, although this was not statistically199
significant, perhaps reflecting the overall increase in total CD11c
+ cells I found in CCX-CKR
KO PP.
7.5 Effects of Flt3L administration in CCX-CKR KO mice
Together these results suggested some selective defects in DC localisation in resting CCX-
CKR KO mice, particularly with regard to pDC. However several of the effects were subtle
and were compromised by difficulties in obtaining sufficient CD11c
+ cells to carry out a
detailed analysis of DC subsets across tissues. Therefore I decided to expand DC numbers in
vivo using the DC differentiation cytokine, Flt3L. Flt3L acts through the Flt3 receptor that is
expressed by DC committed precursors and drives the expansion of both cDC and pDC (246,
247, 266, 267). As well as expanding DC numbers, this also allowed me to investigate if the
pDC defect in CCX-CKR KO mice was apparent at the precursor level. In keeping with
published reports (245, 267), Flt3L caused a dramatic expansion of CD11c
+ DC in all the
tissues of WT and CCX-CKR KO mice that I examined. This protocol allowed the clear
identification  of  CD4,  CD8,  CD11b  or  CD103  expressing  DC  subsets,  as  well  as
CD11c
loB220
+  cells  and  CD11c
loPDCA-1
+  pDC  in  the  lamina  propria.  Although  the
proportions and absolute numbers of all these DC subsets were identical in CCX-CKR KO and
WT mice, the distribution of the CD11c
hiCD103
hi and CD11c
intCD103
lo subsets within the
CD103
+ DC population was different between the two strains, with a significant increase in
the proportion of CD11c
hiCD103
hi cells in CCX-CKR KO lamina propria compared with WT.
However, this did not translate into differences in the absolute numbers of these subsets and is
difficult to interpret, as I was unable to find previous literature on the functions of these
subsets. Recently, it has been shown in the laboratory that CD103
+ DC may contain CD11b
+
and CD8"
+ subsets and it would be interesting to assess these in CCX-CKR KO mice.
CD11c
+ DC were expanded to similar extents by Flt3L in CCX-CKR KO and WT PP,
although, as I had found in resting CCX-CKR KO PP, the absolute numbers of CD11c
+ cells
were slightly elevated in CCX-CKR KO PP compared to WT PP after administration of Flt3L.
Although this increase was not statistically significant, it may explain the statistically
significant increase I found in the absolute numbers of B220 or PDCA-1 expressing DC in the
PP of Flt3L treated CCX-CKR KO mice. Although the absolute numbers of CD103
+ DC were
also increased in the PP of CCX-CKR KO mice compared with WT PP, this did not attain
statistical significance. The absolute numbers of CD11c
loB220
+ cells and CD11c
loPDCA-1
+200
pDC were significantly increased in CCX-CKR KO PP compared to WT PP, which contrasts
with the decreased numbers of pDC I observed in resting CCX-CKR KO PP compared to WT.
Thus, Flt3L treatment can overcome the defects in pDC numbers in the PP of resting CCX-
CKR KO mice.
In contrast, the absolute numbers of CD11c
loPDCA-1
+ pDC in CCX-CKR KO MLN remained
significantly reduced despite Flt3L treatment, emphasising the extent of this defect. This was
particularly notable given that the numbers of B220, CD8 or CD11b expressing DC expanded
normally in response to Flt3L treatment in CCX-CKR KO MLN. However, CD11c
+CD103
+
“migratory” DC did not appear to expand in CCX-CKR KO MLN to the same extent as in WT
MLN, suggesting a defect in this population that was not apparent in resting mice as the
relative frequency of these cells amongst the total live cells in CCX-CKR KO MLN was
reduced significantly. However, caution must be exercised in interpreting these results as the
absolute numbers of CD11c
+CD103
+ DC and their proportions amongst CD11c
+ cells, were
not significantly different between CCX-CKR KO and WT MLN, suggesting that it is in fact
changes in other cell populations that are responsible for this apparent difference in the
proportions of CD11c
+CD103
+ DC after Flt3L treatment. In support of this, the proportions
and absolute numbers of CD11c
hiCD103
hi and CD11c
intCD103
lo cells amongst CD103
+ DC
subsets were expanded similarly in CCX-CKR KO and WT MLN in response to Flt3L
treatment.
The expansion of CD11c
+ DC in the ILN and spleens of Flt3L treated CCX-CKR KO and WT
mice allowed me to examine the proportions and absolute numbers of CD8
+, CD11b
+ and
PDCA-1
+ DC in these tissues, which were similar in the two strains. Thus, most CCX-CKR
KO DC subsets responded normally to Flt3L, except for pDC in the MLN, which retained
their defect in absolute numbers that was seen in resting CCX-CKR KO mice.
In a bid to address whether the reduced pDC numbers observed in CCX-CKR KO mice were
due to a defect in their generation and/or release from the bone marrow, I analysed CCX-CKR
KO bone marrow from resting and Flt3L treated mice for the presence of pDC. The pDC
marker, PDCA-1 is also known as bone marrow stromal cell antigen-2 (BST-2) and is thought
to be involved in the stromal cell interactions required for B cell development (268).
Interestingly, my first observation was that virtually all CD11c
+ cells in both CCX-CKR KO201
and WT bone marrow expressed PDCA-1. Because of this, I had to define bone marrow pDC
as CD11c
loB220
+PDCA-1
+ which were not different in their proportions in CCX-CKR KO and
WT mice. In addition, CD11c
loB220
+PDCA-1
+ pDC expanded normally in response to Flt3L
in vivo in both CCX-CKR KO and WT bone marrow indicating that pDC can develop in the
bone marrow in the absence of CCX-CKR and that the precursors respond normally to this
major growth factor.  Interestingly however, the absolute numbers of circulating pDC in the
blood of resting CCX-CKR KO mice appeared to be reduced compared with WT mice,
although this was not statistically significant perhaps because of the overall increase in the
numbers of total CD11c
+ cells in the blood of CCX-CKR KO mice. In addition, CCX-CKR
KO mice did not show the same expansion of total leukocytes, CD11c
+ cells or pDC in the
blood   in response to Flt3L as was found in WT mice. Although the differences in pDC
numbers between the blood of CCX-CKR KO and WT mice were not statistically significant,
it should be noted that there was only an approximate 25 fold increase in pDC numbers in the
blood of CCX-CKR KO mice after Flt3L treatment compared to a 60 fold increase in pDC
numbers in the blood of WT mice.  Together these results suggest that there may be a defect in
mobilisation of pDC precursors from the bone marrow into the blood stream in the resting
state and after Flt3L treatment in CCX-CKR KO mice. Alternatively, there may be a defect in
survival of pDC in the absence of CCX-CKR.
7.6 The role of CCX-CKR in antigen specific immune responses
CCR7 and its ligands, CCL19 and CCL21 are critical in organising lymphocytes and DC in
secondary lymphoid organs, driving the development of adaptive immune responses (22, 67,
80, 269). Thus any disruption in the distribution of CCL19 and CCL21 may perturb antigen
specific immune responses. The experiments described in Chapter 5 were designed to assess if
any such disruption could be seen in CCX-CKR KO mice. Systemic antigen specific DTH
responses  and  humoral  immunity  developed  normally  in  CCX-CKR  KO  mice  after
subcutaneous immunisation with OVA emulsified in CFA. In addition, the numbers and
proportions of lymphocyte subsets in the draining popliteal LN were normal in CCX-CKR KO
mice, as were antigen specific and DC dependent proliferative and IFN! responses after re-
stimulation of popliteal LN cells with OVA in vitro. This is in contrast to results described in
Chapter 3 that suggested a defect in IFN! production by polyclonally activated T cells from
CCX-CKR KO MLN, ILN and spleens. This evidence that CCX-CKR is not essential in the
priming of systemic antigen specific immune responses by subcutaneous immunisation, which202
is supported by other preliminary data from a previous PhD student and by the published
report of normal migration of DC from inflamed skin draining LN (191).
7.7 The role of CCX-CKR in oral tolerance
As CCR7 and its ligands are important in the development of oral tolerance (12, 125, 258) and
CCX-CKR also binds CCL25, the ligand for CCR9 which is induced on gut tropic effector
cells (82, 211, 212, 221), I decided to examine the development of oral tolerance in CCX-
CKR KO mice. In these experiments, I examined the effects of high and low doses of antigen
which have been proposed to induce clonal deletion/anergy of reactive T cells and the
induction of T regs respectively (227).
In WT mice, a single high dose feed of OVA resulted in the significant suppression of OVA
specific DTH responses and IgG2a antibody, confirming the induction of oral tolerance. This
suppression was not apparent in OVA fed CCX-CKR KO mice in any of the three experiments
I performed. In contrast, both strains seemed to show the same degree of oral tolerance of
proliferative and IFN! responses in vitro, while OVA specific IgG1 antibody production was
not suppressed in either CCX-CKR KO or WT mice in any of the three experiments I carried
out. A similar pattern of results were obtained when multiple low doses of antigen were used
to induce oral tolerance, with no suppression of either OVA specific DTH responses or IgG2a
seen in OVA fed mice. However, the suppression of DTH responses in WT mice was not
statistically significant in this experiment and I was unable to obtain successful antigen
specific T cell responses after re-stimulation of draining popliteal LN cells in vitro. I had
insufficient time to repeat this experiment and this would clearly be necessary before any
conclusions can be drawn regarding T cell tolerance in response to low dose antigen feeds in
CCX-CKR KO mice.
Shortly after I carried out these experiments, it was reported that pDC mediate the suppression
of antigen specific T cells during the induction of oral tolerance and that oral tolerance cannot
be induced after depleting pDC in vivo (226). Furthermore, these effects were attributed to
pDC in the gut associated lymphoid tissue, particularly the liver, which were shown to induce
CD4
+CD25
+ T regs capable of inhibiting systemic immune responses (225). However, I found
no differences in the absolute numbers or proportions of pDC in the livers of CCX-CKR KO
mice under resting conditions, or after Flt3L treatment. I therefore attempted to extend my203
studies by examining whether antigen specific FoxP3
+ T regs could be induced normally in the
MLN of CCX-CKR KO mice fed OVA after the adoptive transfer of OVA specific CD4
+ T
cells from OT2 mice. However, this experiment was unsuccessful and would be important to
repeat.
7.8 The role of CCX-CKR in priming mucosal immune responses
Having observed a defect in the development of oral tolerance in CCX-CKR KO mice I next
assessed the efficiency of mucosal priming in these animals using cholera toxin (CT), which
has  been  widely  used  as  a  mucosal  adjuvant  (270-276).  I  carried  out  three  separate
experiments to examine oral priming and although the results varied somewhat between each
study, CCX-CKR KO mice more consistently readily primed than WT mice. This affected
most kinds of responses, including OVA specific systemic DTH, serum IgG, IgG2a and IgA
antibodies, as well as intestinal OVA specific IgA production. CCX-CKR KO mice also
generated low levels of OVA specific serum antibody when fed OVA in the absence of CT. In
comparison, WT mice fed OVA+CT only appeared to show priming of Th2 dependent IgG1
antibody responses and had no evidence of responses to OVA alone. Importantly, CCX-CKR
KO mice had normal levels of total IgG in their serum and total IgA in secretions, ruling out
the possibility that these mice are inherently more prone to generating antibody in general.
Despite the evidence that CCX-CKR influences the induction of antigen specific immunity
and tolerance to protein antigens, CCX-CKR KO mice developed acute colitis normally after
oral  administration  of  DSS,  with  identical  weight  loss,  clinical  disease  scores,  colon
shortening and local production of inflammatory mediators seen in CCX-CKR KO and WT
mice. This is perhaps not surprising given that CCL25 is not produced in the colon and
suggests that antigen specific immune responses in the small intestine are selectively affected
by CCX-CKR deletion.
Together, these results suggest that in CCX-CKR KO mice, the environment of the CCX-CKR
KO MLN has unusual effects on the differentiation of T cells after oral administration of
antigen. Therefore it would be interesting to examine the phenotype of adoptively transferred
OVA transgenic CD4
+ and CD8
+ T cells in CCX-CKR KO mice to examine the development
of antigen specific effector or regulatory T cells cells directly, in particular their induction of
CCR9 and FoxP3 expression. This approach could also be used to assess the subsequent204
localisation of efector CD4
+ and CD8
+ T cells in the lamina propria. It would also be of interest
to compare the the numbers of plasma cells in the small intestines of primed CCX-CKR KO
and WT mice and examine their expression levels of CCR9 to determine if these correlate
with the elevated levels of OVA specific intestinal IgA in orally primed CCX-CKR KO mice.
7.9 pDC function in CCX-CKR KO mice
The tolerogenic properties of pDC have been described in several models in addition to the
work on oral tolerance described above. Specifically, pDC have been shown to induce
tolerance to cardiac grafts and suppress graft versus host disease, with the latter phenomenon
being associated with CCR9 expressing pDC in particular (118, 277).  Furthermore, pDC have
been linked to a spontaneous breach of self-tolerance in a model of autoimmune arthritis
(119). Together, these findings support my own observations that reduced pDC numbers in the
MLN of CCX-CKR KO mice correlates with abrogated oral tolerance and enhanced oral
priming.
Despite their relatively low expression of class II MHC, pDC have been reported to process
and present antigen to T cells directly in vivo, although not as effectively as conventional DC
(113, 116). Imaging studies have revealed that mature pDC maintain sustained contacts with T
cells while interactions between immature pDC and T cells are less stable. Consequently,
mature  pDC  were  found  to  induce  immunogenic  responses  whereas  their  immature
counterparts showed a very limited immunogenic capacity (278) and their low expression of
class II MHC and co-stimulatory molecules, induce T regs that control inflammatory immune
responses in EAE (117). Despite the decreased numbers, I found that pDC in the MLN, ILN
and spleens of resting CCX-CKR KO mice expressed significantly higher levels of class II
MHC than WT pDC. Thus pDC in the secondary lymphoid organs of resting CCX-CKR KO
mice may be of a more mature phenotype and this may be related to the functional defects in
oral tolerance I observed.
In an effort to investigate whether there was a causative relationship between reduced pDC
numbers and dysregulated immune responses to intestinal antigen in the mucosa, I began to
investigate pDC function in CCX-CKR KO mice. pDC are potent producers of type 1 IFN
which are important in the development of anti-viral immunity and DC activation (280-283).
Therefore I stimulated MLN cells or sorted pDC with  CpG or R848 as agonists of TLR9 and205
7 respectively, which are expressed by pDC and can induce their production of type 1 IFN
(248, 261, 281, 282, 284). I also stimulated cells in medium alone or with LPS or PolyI:C as
TLR4 and 3 ligands that are not reported to activate pDC. Unfortunately, I was unable to
detect any IFN" in supernatants from any of these cells by ELISA and it appears this may be a
general problem with immunoassays for this cytokine. At the end of my project, I was made
aware of a new antibody that is suitable for intracellular detection of type 1 IFN produced by
pDC that would provide a feasible alternative to ELISA (285).
To gain some insight into the functional potential of MLN pDC in CCX-CKR KO mice, I
analysed their phenotype after culture with R848 in vitro. MLN cells from resting mice
cultured in medium alone revealed CD11c
hiPDCA-1
- and CD11c
loPDCA-1
+ cell populations
and a minor CD11c
hi population of cells that expressed very low levels of PDCA-1, that I
termed CD11c
hiPDCA-1
+. The proportions of CD11c
hiPDCA-1
- cells amongst total CD11c
+
cells did not alter after R848 stimulation of either CCX-CKR KO or WT MLN cells. However
in  both  strains,  the  proportions  of  CD11c
loPDCA-1
+  cells  and  CD11c
hiPDCA-1
+  cells
significantly decreased and increased respectively after R848 stimulation. The CD11c
hiPDCA-
1
+ cell population was far more striking amongst cells from Flt3L treated mice stimulated with
R848 in vitro and was found to express high levels of CD40 and CD86 suggesting an activated
phenotype. The dramatic expansion of this population after R848 stimulation is indirect
evidence for the presence of type 1 IFN in these cultures as PDCA-1 has been shown to be
induced on conventional DC activated by type 1 IFN (250). Although the increase in the
proportions of CD11c
loPDCA-1
+ pDC after Flt3L expansion in vivo and stimulation with R848
in vitro occurred in both CCX-CKR KO and WT MLN cells, this was less marked amongst
CCX-CKR KO MLN cells, supporting my previous finding that the deficit in pDC in resting
CCX-CKR KO MLN could not be overcome with Flt3L treatment. Overall however, there
were no major differences between CCX-CKR KO and WT mice in their response to
stimulation with the synthetic TLR7 agonist, R848 in vitro.
Next I used R848 to explore pDC functions in vivo as previous work has shown that R848
drives a dramatic recruitment of lamina propria CD103
+ DC into the MLN, secondary to the
production of type 1 IFN and TNF" from lamina propria pDC (121, 223, 224). This effect is
not seen in CCR9 KO mice due to the lack of pDC in their lamina propria (121). Thus I hoped
this would give me some indirect information on the biological role of pDC in the lamina206
propria of CCX-CKR KO mice. As expected, feeding R848 to WT mice led to increased
proportions of migratory CD11c
hiclassIIMHC
hiCD103
+  DC  in  the  MLN,  consistent  with
mobilisation of lamina propria DC to the MLN and suggested that pDC function in the lamina
propria in response to R848 in vivo is normal in the absence of CCX-CKR. However, it would
be important to examine pDC function in the CCX-CKR KO small intestine more directly, as
well as assessing the antigen uptake and presentation ability of mucosal CD103
+ DC. Further
studies in the Nibbs group also plan to assess the migration of CD103
+ DC into pseudo-
afferent lymph of CCX-CKR KO and WT mice that have had their MLN surgically removed.
7.10 Transfer of pDC between CCX-CKR KO and WT mice
In my final experiments, I attempted to explore the in vivo behaviour of CCX-CKR KO pDC
more directly. Specifically, I attempted to determine whether the defective numbers of pDC in
CCX-CKR KO MLN were because the CCX-CKR KO pDC have an intrinsic failure to
migrate to MLN, or whether the environment of CCX-CKR KO MLN is not permissive to
pDC entry. To do this, I performed adoptive transfer experiments with pDC between CCX-
CKR KO and WT mice. Although I was able to detect transferred pDC in recipient tissues, the
results of my initial studies using resting mice were somewhat inconclusive and I went on to
use Flt3L treated mice as a source of pDC in order to obtain sufficient cells. The findings,
suggested that WT pDC could enter CCX-CKR KO MLN normally, but that CCX-CKR KO
pDC may not be as efficient at entering WT MLN as WT pDC. These experiments clearly
need to be repeated and should incorporate competitive co-transfers in which WT and CCX-
CKR KO  pDC are given together. In addition, time course studies should be used to
distinguish between failure of entry by pDC versus their failure to survive once there. The
generation of bone marrow chimera mice could give further insights into whether it is pDC,
stromal elements or both that is defective in CCX-CKR KO MLN. It would be particularly
interesting to conduct oral tolerance experiments in these bone marrow chimera mice to
determine if reconstitution with WT bone marrow would be sufficient to restore oral tolerance
in CCX-CKR KO mice and whether this is abrogated in WT mice receiving CCX-CKR KO
bone marrow.
Conclusions and future directions
These preliminary studies provide intriguing evidence that there may be a defect in the
environment of CCX-CKR KO MLN which limits entry and/or survival of pDC. An obvious207
candidate for this might be dysregulation of CCR7 and CCL19/CCL21 mediated pathways,
due to a lack of CCX-CKR mediated scavenging. Although my preliminary results suggested
there were no differences in the levels of CCL21 in the MLN, ILN, spleen, PP and small
intestine of CCX-CKR KO mice, it has been reported that the levels of CCL19 and CCL21
protein are significantly elevated in the LN of CCX-CKR KO mice, supporting the hypothesis
that CCX-CKR scavenges excess chemokine (257). It will be important to carry out more
detailed studies of CCL19, CCL21 and CCL25 in CCX-CKR KO mice. This is currently under
investigation by another PhD student in the group. In addition, recent work suggests that
chemerin on HEV may be a further mediator that recruits ChemR23 expressing pDC into LN
and it would be interesting to explore ChemR23 and chemerin expression in CCX-CKR KO
mice (286). It will also be essential to examine exactly where CCX-CKR is expressed in the
normal immune system. Despite several attempts, I was unable to obtain sufficient mRNA
from pDC to determine whether they themselves express CCX-CKR. However, preliminary
data from the Agace group in Lund (personal communication) suggest that CCX-CKR is
expressed only by the stromal compartment of organised lymphoid tissues and that no CCX-
CKR mRNA is detectable in CD45
+ cells, suggesting that pDC do not express this receptor.
Thus my studies have revealed a selective and robust defect in the numbers of pDC in the
MLN of CCX-CKR KO mice that cannot be overcome by the differentiation factor, Flt3L.
This was associated with an inability to induce oral tolerance and an abnormal susceptibility to
priming of systemic and mucosal immune responses after oral administration of antigen with
adjuvant. These abnormalities did not affect peripheral immune responses. Although I
obtained  some  evidence  that  CCX-CKR  KO  DC  had  a  defective  APC  capacity,  my
preliminary findings suggest that the dysregulation of small intestinal immune responses in
CCX-CKR KO mice was not due to a failure of CD103
+ DC to migrate to the MLN. However,
there may be a selective defect in the recruitment of pDC precursors from the bone marrow
and/or a failure of pDC to enter and/or survive in MLN. How this may relate to defective
tolerance remains to be determined. In conclusion, my project has revealed important roles for
the atypical chemokine receptor, CCX-CKR in the regulation of mucosal immune responses
and pDC positioning. In addition, it has also provided some insight into how pDC may
regulate immune responses in vivo.208
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